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Abstract 
Pluripotent stem cells (PSCs) possess the ability to differentiate to virtually any cell 
type whilst retaining the capacity to self-renew. There is an unmet need for an 
inexhaustible supply of hepatocytes to perform drug toxicity and metabolism screens 
on early stage drugs. PSCs therefore hold potential to generate mature hepatocytes 
for pharmaceutical testing. To realise this potential, there is a requirement to 
recapitulate hepatocyte specification in vitro. There are two main bottlenecks in 
generating metabolically relevant hepatocytes. The first is the specification of 
definitive endoderm (DE), where it is known that the TGFβ family member Nodal is 
the key driver in vivo. Currently the closely related TGFβ family member Activin A 
(AA) is universally used to mimic this process. However, it has been observed that 
AA results in off-target gene modulation that may be deleterious to the production of 
DE; from which the hepatic lineage arises. Preliminary data from the McKay group 
has shown that AA stimulates endogenous Nodal activity when applied to PSCs; 
leading to the hypothesis that Nodal is the true driver of DE specification in vitro. To 
address this avenue of investigation, tools to modulate Nodal signalling were 
assessed in different cell culture systems. Findings included the need to use an 
appropriate viral promotor to efficiently express lentiviral vectors in PSCs. The 
second major bottleneck concerns hepatic maturation where the signalling pathways 
and key regulators in vitro are not fully understood. Consequently, current derived 
hepatocyte-like cells (HLCs) show low functionality. Utilising Plasticell’s CombiCult® 
allowed thousands of growth factor and small molecule combinations to be screened 
to define efficient differentiation protocols. Protocols were derived containing novel 
differentiation factors that give rise to CYP450 inducible HLCs. Lentiviral reporters 
were then used to determine optimum concentrations of small molecules and to test 
ligands for the upregulation of hepatic master regulators. Findings gained from this 
thesis have contributed new insights into the differentiation of PSCs to hepatocytes. 
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Chapter 1: General Introduction 
1.1 Activin/Nodal Signalling in Pluripotency and Endoderm  
1.1.1 Mammalian Development and Pluripotency 
The development of a mammalian living organism is initiated by the fertilisation of an 
egg to form a zygote. The zygote then undergoes cleavage stages to form a four-
cell morula [1]. The ability of a cell to produce all the different cell types constituting 
an organism both somatic and germline, including the extra-embryonic tissue, is 
termed “totipotent” [2] [3] [4]. These transient unrestricted totipotent cells are found 
in the early embryo at the four-cell morula stage. As development proceeds to the 
blastocyst stage, the first cell specialisation events take place with the formation of 
two distinct cell populations. The first being in the outermost layer of the blastocyst 
called the trophoblast, from which the extra-embryonic endoderm develops [5]. The 
extra-embryonic tissue is required for implantation and in the support and 
maintenance of the developing embryo. As development progresses from the 
totipotent morula stage, the ability to contribute to extra-embryonic tissue is lost but 
the ability to differentiate into all cell types of the three embryonic germ layers, that 
being endoderm, mesoderm, ectoderm and also the germline is retained [6]. This 
ability to produce all cell types of both the embryo and associated germline cells is 
termed “pluripotent” [7] [8] [9]. Pluripotent cells are found at the sixteen-cell cleavage 
stage developing mammalian blastula in a subset of cells called the inner cell mass 
(ICM) (Figure 1).  
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Following differentiation of pluripotent stem cells down defined lineages, more 
restricted “multipotent” adult stem cell populations are found; named for their ability 
to produce a limited number of lineage specific cells types [10] [11]. Multipotent stem 
cells are retained in adulthood but are more restricted in their differentiation potential 
and have the capacity of replenishing cells types constituting defined lineages 
following injury or replacement of ageing cells.  
Figure 1: Overview of mammalian development 
Developmental progression from fertilised egg to the four-cell totipotent morula and 
subsequent progression to the blastocyst stage of mammalian development. Pluripotent 
cells found in the ICM of the cleavage stage blastocyst have the potential to differentiate 
down cellular lineages to produce all the cell types representing the three germ layers: 
endoderm, mesoderm and ectoderm. The endodermal lineage is highlighted in red as it 
is the focus of this thesis giving rise to definitive endoderm and subsequently 
hepatocytes. 
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1.1.2 Embryonic Stem Cells 
Pluripotent cells found in the ICM of the cleavage stage blastula can be isolated and 
cultured in vitro as embryonic stem cells (ESCs) [12] [13]. This was first achieved 
with mouse ESCs (mESCs) through the culture of the isolated ICM from pre-
implantation blastocysts [12] and subsequently with human ESCs (hESCs) [8]. In 
vitro cultured ESCs possess the ability to differentiate into any cell type constituting 
the three germ layers, whilst also retaining the capacity to self-renew and are 
therefore pluripotent [8] [14] [15] [16]. The ICM is separated from the trophectoderm 
by the process of immunosurgery. The first stage in this process is the acid 
digestion of the zona pellucida (ZP), the outermost layer of the developing embryo 
with Acid Tyrode’s solution. The isolated ICM can then be plated onto supportive 
feeder layers from which they expand to form established hESC colonies. 
Established hESC colonies are characterised by a high nuclear to cytoplasmic ratio 
and their ability to be cultured for extended periods of time, possibly indefinitely [8]. 
To support the growth of hESCs in vitro, mitotically inactivated mouse embryonic 
fibroblast (MEF) feeder layers are largely utilised [17]. MEFs secrete an undefined 
cocktail of growth factors whilst also laying down an extracellular matrix (ECM), 
supporting cell maintenance and proliferation whilst crucially maintaining 
pluripotency of hESC colonies (Figure 2A). The secreted MEF cocktail of factors 
maintain hESC pluripotency through the regulation of pluripotency transcriptional 
networks. This is in conjunction with exogenously supplemented basic fibroblast 
growth factor (bFGF/FGF2) to cell culture media to suppress BMP signalling, which 
promotes the differentiation of hESCs [18]. The co-operation of Activin/Nodal 
signalling in conjunction with FGF signalling has been shown to be sufficient to 
maintain pluripotency of hESCs [19]. 
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The culture of mESCs relies on the addition of leukemia inhibitory factor (LIF) to cell 
culture media. This promotes pluripotency through the activation of the signal 
transducer and activator of transcription 3 (STAT3) pathway to maintain an 
undifferentiated state; withdrawal of LIF causes mESC differentiation [20]. However, 
the culture of hESCs does not require the addition of LIF and STAT3 activation to 
maintain pluripotency and studies have found these pathways to be inactive in 
hESCs [21], [22]. Instead hESCs require activation of the Activin/Nodal signalling 
pathway to promote pluripotency in vitro [19] [23] [24].  
Xu et al. (2001) amongst others have shown it is possible to grow and maintain 
pluripotent hESCs without supportive MEF feeder cells [15] [25] [26] [27]. This is 
termed “feeder-free” culture and is achieved using a defined culture medium with 
supplemented growth factors accompanied by the use of an appropriate synthetic 
ECM [15] [28] [29] (Figure 2B). The feeder-free growth of hESCs is advantageous 
for a number of reasons. Firstly, the use of defined culture conditions removes 
complicating variables associated with the use of an undefined cocktail of secreted 
growth factors in MEF conditioned culture media [30]. Secondly, the translational 
application of hESCs in regenerative medicine would require the absence of 
contaminating xenogenic components to achieve clinical grade Good Manufacturing 
Practice (cGMP) [29]. 
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It is of fundamental importance to confirm pluripotency in newly derived or long-term 
maintained ES cell lines by showing the capacity to differentiate to cells 
representative of the three germ layers [8] [16] [31]. There are two common 
methodologies for confirming the pluripotent capabilities of ES cell lines. Firstly, in 
vivo teratoma formation; a tumor representing cell types of all three germ layers 
upon transplantation of ESCs, which is used as a test of pluripotency [32] [33] [34]. 
In vitro cultured pluripotent hESCs can be injected into immunocompromised mice 
which do not reject human cells and can indeed produce teratomas and contribute 
to cell lineages comprising the three germ layers [35], [12] [36] [37]. Secondly, in 
vitro embryoid body (EB) formation where 3D aggregates have the ability to 
spontaneously differentiate into the three germ layers in the absence of 
pluripotency-maintaining culture media [12] [38] [39].  
 
Figure 2: In vitro methods for hESC culture 
(A) Pluripotent Shef-3 hESC colonies cultured on mitotically inactivated MEF feeder 
layers to support proliferation and maintenance of pluripotency in vitro. Established hESC 
cultures can be maintained and propagated indefinitely. (B) Feeder-free adapted Shef-3 
hESCs grown in chemically defined media on fibronectin coated plates. Cell cultures 
were imaged at x10 magnification.  
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1.1.3 Pluripotency Regulatory Networks 
The pluripotent state has been well characterised and the expression of a specific 
set of pluripotency-associated markers including genes and cell-surface antigens 
has been defined and mechanistically interrogated [8]. A core transcriptional 
network involving octamer-binding transcription factor 4 (OCT4), sex determining 
region Y-box 2 (SOX2) and NANOG have been shown to be key regulators that 
cooperate in the maintenance of hESC pluripotency [24] [40] [41] [42] [43] [44] [45] 
[46]. Core pluripotency factors are responsible for supressing genes involved in the 
differentiation of hESCs whilst also maintaining the expression of other downstream 
genes involved in the maintenance of pluripotency [47]. This is evident in the OCT4 
regulation of REX1 [48], a key regulator of pluripotency found to be expressed at 
high levels in hESCs then rapidly decreased upon differentiation [49]. OCT4 has 
been shown to have a regulatory role on the status of the REX1 promoter [48]. 
When OCT4 is expressed at high levels, the REX1 promoter is repressed by OCT4 
and conversely when OCT4 is not actively expressed, REX1 is upregulated through 
the activation of the REX1 promoter. The interaction of NANOG and REX1 is also 
evident through the ability of NANOG to activate the REX1 promoter and prevent 
differentiation [50]. However, high levels of variability are evident amongst the core 
pluripotency transcriptional network including NANOG and REX1 [51] [52] in 
pluripotent stem cells. It has been shown that NANOG expression levels fluctuate 
transiently in sub populations of pluripotent stem cells without losing an 
undifferentiated state [46]. Purified populations of pluripotent stem cells expressing 
either high or low levels of NANOG expression were observed to eventually revert to 
a heterogeneously expressing population despite previous purification.  
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Extensive mapping of the epigenetic state of CpG promoter regions reveals that 
genes associated with differentiation are repressed and highly methylated in 
pluripotent stem cells and subsequently become demethylated upon lineage 
committed differentiation [47].  
Pluripotent hESCs display a unique set of surface antigen markers which can be 
used to distinguish them from their differentiated progeny. The characterisation of 
hESCs is also important to ensure that differentiation studies are carried out on high 
quality, undifferentiated starting populations. The most commonly utilised antigens 
to identify pluripotent stem cells include the glycolipid stage specific embryonic 
antigen 3/4 (SSEA3/4) and the keratin sulphates TRA-1-60 and TRA-1-81 [8] [31] 
[53] [54] .  
 
1.1.4 TGFβ Signalling Pathway 
Members of the transforming growth factor beta (TGFβ) superfamily including 
TGFβ1, TGFβ2, TGFβ3, bone morphogenetic proteins (BMPs), Nodal, Activins and 
growth and differentiation factors (GDFs) and their corresponding antagonists play a 
central role in a wide range of biological processes including the regulation of cell 
growth, stem cell maintenance and cellular differentiation [55], [56] [57]. There are 
three known classes of TGFβ cell-surface receptors with which TGFβ family 
member ligands interact, TGFRI (also known as Activin-like kinases (ALKs)), 
TGFRII and TGFRIII [58]. The difference between the three classes of TGFβ 
receptors is concerned with their affinity for different TGFβ family ligands. It has 
been suggested that there is a large degree of overlap between TGFβ family ligand 
binding to TGFβ receptors due to the large number of ligands compared to 
prospective receptors [58].  
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TGFβ family members signal through the binding of ligands to cell surface type I and 
II serine-threonine kinase receptors [59] [60]. Downstream of the TGFβ receptors, 
intracellular mothers against decapentaplegic (SMAD) proteins are then involved in 
the mediation of TGFβ signalling. This involves the targeted phosphorylation of the 
C-terminal MHII domain of SMAD proteins by corresponding TGFβ serine-threonine 
kinase receptors [60] [61] [62]. There are eight SMAD proteins encoded by the 
human genome, however only five function as signalling substrates for the TGFβ 
family of receptors. SMAD proteins that interact with TGFβ receptors as referred to 
as receptor-regulated SMADS (R-SMADs). R-SMADS include SMAD1, SMAD2, 
SMAD3, SMAD5 and SMAD8. TGFβ, Activin and Nodal receptors are associated 
with signalling through SMAD3 and the less common isoform SMAD2, whilst the 
BMP signalling pathway is associated with SMAD1, SMAD5 and SMAD8 [63]. The 
other two SMAD proteins, SMAD6 and SMAD7, serve as inhibitory SMADS (I-
SMADs) involved in the interference of SMAD-receptor and SMAD-SMAD 
dimerization [63]. 
Upon phosphorylation, R-SMADs are released from SMAD anchor for receptor 
activation (SARA) which function to regulate the availability of R-SMADs to interact 
with activated TGFβ receptors [64]. Phosphorylation of the R-SMAD proteins is then 
followed by the association with the common signal transducer SMAD4 (Co-SMAD) 
and subsequent translocation to the nucleus, where the SMAD complexes 
accumulate and bind transcription factors to regulate the transcription of target 
genes [65]. SMAD proteins undergo a constant process of cytoplasmic to nuclear 
shuttling in response to TGFβ mediated receptor activation. In this way, SMAD 
signalling allows cells to respond to external TGFβ signals and mediates 
transcriptional responses [66].  
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Co-SMAD4 contains a nuclear export signal (NES), which is typically a cluster of 
basic residues recognised by nuclear importation factors [67] [68]. The presence of 
the NES on SMAD4 facilitates the shuttling of SMAD protein complexes between the 
nucleus and cytoplasm [67]. In this way SMAD mediators localised in the cytoplasm 
are able to efficiently respond to TGFβ signalling and regulate transcription of target 
genes [69]. TGFβ signalling elicits very different responses in a cell-type specific 
manor through the interaction with master regulators of particular cell types [66]. 
SMAD binding elements (SBEs) have been found in the promoter regions of cell-
type specific master regulators [66]. SBEs consist of a CAGACA sequence that 
directs the binding of SMAD protein complexes to the promoter regions in TGFβ 
target genes [70].   
R-SMADS and Co-SMAD4 share highly conserved N-terminal MHI domains in 
contrast to the I-SMADs which show diversity in the N-terminal region [71] [72]. The 
R-SMADs are distinct in their linker region amino acid sequences whereas the C-
terminal region is conserved amongst all the SMAD proteins [73]. The linker region 
of the SMAD protein contains binding sites for SMAD-associated factors including 
SMAD ubiquitination-related factor (SMURF) as well as sites for phosphorylation 
through interactions with protein kinases. SMURF functions to selectively regulate 
the levels of SMAD proteins through proteasomal degradation via ubiquitination [74]. 
This allows for SMAD protein levels in both unstimulated and activated cells to be 
tightly controlled [75] [76].  
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1.1.5 TGFβ Signalling in Pluripotency  
TGFβ signalling is known to be active in pluripotent stem cells, cooperating with 
exogenously supplemented bFGF/FGF2 in vitro to exert control on elements of the 
pluripotency network, although the precise mechanisms remain unclear [18] [19] 
[24]. It has been shown that NANOG is a direct target of Nodal/Activin signalling with 
SBEs, responsible for recruitment and binding of SMAD complexes, found in the 
NANOG promoter [59] [65]. TGFβ signalling has also been shown to cooperate with 
OCT4 to maintain pluripotency, similarly to NANOG, SBEs have been found in the 
promotor of the OCT4 gene [66].  
SMAD2/3, the effectors of Activin/Nodal signalling, have been shown to control 
pluripotency-associated factors in hESCs such as OCT4, NANOG, REX1, forkhead 
box D3 (FOXD3), developmental pluripotency-associated 4 (DPPA4), telomerase 
reverse transcriptase (TERT), MYC and undifferentiated embryonic UTF1 [66]. The 
SMAD2/3 regulation of NANOG has been demonstrated to block FGF signalling 
which would otherwise promote a neuroectodermal fate, the default differentiation 
pathway of primed hESCs [19] [77] [78] [79] [80]. In pluripotent hESCs, NANOG 
limits the transcriptional activity of the SMAD2/3 pathway which in turn suppresses 
endodermal specification and maintains a pluripotent state. BMP signalling  
promotes differentiation of hESCs; consequently the active inhibition of BMP 
signalling in hESC cultures has been found to be beneficial for the maintenance of 
self-renewal and maintenance of pluripotency [23] [81].  
Activin/Nodal signalling has also been shown to play a critical role in endodermal 
development [23] [82] [83]. Endodermal cells are regulated upstream of SMAD2/3 
demonstrating the divergent transcriptional networks that are controlled by 
Activin/Nodal signalling.  
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The mechanisms by which Activin/Nodal signalling control this divergent range of 
responses is yet to be fully understood, however, could explained through the 
interactions of SMAD2/3 with tissue specific binding partners [66].  
 
1.1.6 TGFβ Signalling During In Vivo Endoderm Development 
During early embryogenesis, a structure known as the Primitive Streak (PS) is 
formed, into which uncommitted epiblast cells migrate and subsequently leave as 
either committed mesoderm or definitive endoderm (DE) [55] [84]. The PS has been 
shown to possess varying developmental potential achieved through differential 
gene expression and signalling gradients [85] [86]. A tightly regulated interplay of 
signalling factors controls the development of multipotent precursors, termed 
mesendoderm [87]. It has been shown that during development, a population of bi-
potent mesendoderm precursors arise from the anterior PS possessing the ability to 
give rise to either mesoderm or endoderm depending on Nodal signalling cues [88] 
[87].  
Nodal has been shown to be critical in DE specification and subsequent lineage fate 
choice between endoderm and mesoderm [89] [90] [91] [92]. Nodal signalling is 
controlled extracellularly through its EGF-CFC partner cofactor, Cripto/TDGF-1 
(epidermal growth factor-Cripto-1/FRL-1/Cryptic). Nodal signalling is further 
regulated through the Nodal antagonists Lefty and Cerberus [91] [93] [94]. The co-
activator FoxHI is also involved in Nodal signalling through the binding of SMAD2 
and regulation of target gene activation [95] [96] [97]. The modulation of Nodal 
signalling allows for both endoderm and mesoderm specification from mesendoderm 
precursors [88] [87] [96].  
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It has been shown that high levels of Nodal signalling specify cells to an endodermal 
fate, whereas lower levels of Nodal signalling lend to a mesodermal fate [87] (Figure 
3). These findings have also been confirmed in vitro by the derivation of pancreatic 
cells, which arise from mesendoderm, through low levels of Nodal-like signalling [98] 
and hepatocyte-like cells (HLCs) being derived through endodermal precursors 
utilising high levels of Nodal signalling mimicked through the exogenous addition of 
Activin A [99] [83]. 
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Figure 3: TGFβ signalling in pluripotency and differentiation 
(A) Activin signalling in conjunction with exogenously added FGF maintains pluripotency 
provided BMP signalling is inhibited. (B) Sole FGF signalling promotes neuroectoderm 
differentiation in the absence of BMP and Activin signalling. (C) Sole BMP signalling in 
the absence of Activin and FGF signalling leads to an extraembryonic fate. (D) When 
BMP, FGF signalling are active in a high Activin environment mesodermal differentiation 
is initiated.  
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1.1.7 In Vitro Definitive Endoderm Specification 
The in vitro specification of endoderm is of particular interest for regenerative 
medicine as both the hepatic and pancreatic cell lineages arise from DE [98]. 
Despite the large interest in endodermal progenitor cells, progress in deriving the 
cells in vitro has been hampered partly due to the lack of distinctive markers that are 
currently available to identify cell types of interest. Currently, combinations of 
markers are used to distinguish differentiated cell populations but this is made 
difficult by the significant overlap of expressed markers in different cell types [100] 
[101] [102]. 
Progression to DE is associated with the co-expression of chemokine (C-X-C Motif) 
receptor 4 (CXCR4), sex determining region Y box 17 (SOX17) and forkhead box 
protein A2 (FOXA2/HNF3β) [77] [103] [104] [105]. These markers are often used to 
discriminate DE from visceral endoderm (VE); the latter being distinguished by the 
lack of GSC expression coupled with robust hepatocyte nuclear factor-α (HNF4α) 
expression [106] [103]. High levels of HNF4α expression at this stage are 
characteristic of extra embryonic endoderm, which would indicate that VE had been 
specified [106]. VE can also be identified from DE by the extra-embryonic endoderm 
markers sex determining region Y box 7 (SOX7) and caudal type homeobox 2 
(CDX2) [107]. Specification to DE from mesendoderm can therefore be monitored in 
vitro by the expression of FOXA2+, GSC+, CXCR4+ in populations of differentiated 
cells, [87] [103] [108].   
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TGF-β Signalling 
It is known that the TGFβ family member Nodal is a key regulator for the 
establishment of DE specification in vivo [92] [109]. To this end Activin A, another 
related TGFβ family member to Nodal, is routinely used in vitro to induce DE 
specification from pluripotent stem cells [87] [110] [111] [84] [106] [83]. Activin A 
binds to the same Activin type I/II receptors as Nodal and activates similar signalling 
pathways in vitro. There are however distinct differences in the signalling of Activin 
A and Nodal. Nodal is dependent on its co-factor Cripto to bind Activin type II 
receptors and initiate SMAD signalling through the recruitment and phosphorylation 
of SMAD2/3. This is followed by the association with the common signal transducer 
SMAD4 and subsequent translocation to the nucleus to modulate gene expression; 
whilst Activin A is not reliant on Cripto to bind Activin type II receptors [91].  
Using high levels of exogenous Activin A, typically 100ng/ml for five to six days, 
specifies DE from pluripotent stem cells through mesendodermal precursors, [87] 
[99] [110] [84] [106] [112] [107] [83]. Differentiation to a cell-type synonymous with  
mesendoderm in vivo can be identified through the expression of markers such as 
Brachyury (T) and Goosecoid (Gsc) [87]. It is thought that the specification of 
endoderm by Activin A is dependent on the inhibition of the phosphoinositide-3-
kinase (PI3K) signalling in low concentrations of knock-out serum replacement 
(KSR) [83]. McLean et al. (2007) proposed that factors present in serum drive PI3K 
signalling and block the differentiation of hESCs [83].  
There has been evidence uncovered showing that there are significant off-target 
effects caused by the utilisation of Activin A to induce DE specification in vitro 
(McKay et al., unpublished data). Expression of the visceral endoderm marker OTX2 
and mesodermal markers Brachyury (T) and BMP2 were found to be increased 
upon the exogenous addition of Activin A over the course of six days.  
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Activin A is hypothesised to stimulate the transcriptional up-regulation of Nodal 
which then promotes DE specification from this study. The differences in signalling 
networks between Activin A and Nodal are hypothesised to account for the 
heterogeneous populations of DE produced through this procedure. Work is 
therefore required to dissect the underlying mechanisms involved in Nodal signalling 
during the specification of DE. 
 
WNT Signalling 
Wnt signalling has been shown to have a key role during early embryogenesis and 
in the self-renewal and maintenance of hESCs [87] [113] [114] [115] [116] [117]. The 
canonical Wnt signalling pathway that involves binding of the Wnt family ligands 
WNT1, WNT3A and WNT8 to the trans-membrane protein Frizzled (Fzd) and low 
density receptor-related protein 5/6 (LDRRP5/6) which activates Wnt/β-catenin 
signalling [118] [119]. Fzd is then involved in the recruitment of the intracellular 
protein Dishevelled (Dvl) which subsequently localises the axin-glycogen synthase 
kinase 3 (GSK3) to the cell membrane initiating two rounds of LDRRP5/6 
phosphorylation firstly by Axin-GSK3 and finally by casein kinase 1 (CK1). This 
series of events leads to the inactivation of the β-catenin destruction complex and 
allows the accumulation and translocation of β-catenin to the nucleus where it binds 
to TCF/LEF transcription factors [120] (Figure 4). The abolition of WNT3 signalling 
results in the lack of PS formation during embryogenesis [113]. In vitro hepatocyte 
differentiation has also provided evidence for the importance of canonical WNT3A 
signalling during early DE specification steps [99] [121].  
29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Canonical Wnt signalling pathway 
Overview of the canonical Wnt signalling pathway in both the activated or repressed 
states. During the inactive state, β-catenin is sequentially phosphorylated leading to 
ubiquitination and subsequent proteasomal degradation; preventing β-catenin from 
reaching the nucleus. Upon Wnt ligand binding the β-catenin destruction complex 
disassociates and β-catenin accumulates and subsequently translocate to the nucleus 
where it binds to TCF/LEF transcription factors and activates downstream targets of Wnt 
signalling. 
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Recent studies utilising small molecules to mimic WNT3A signalling through the 
inhibition of the GSK3 pathway have provided evidence for the requirement in DE 
specification [121]. Bone et. al (2011) showed that a chemically synthesised 
selective GSK3 inhibitor, 1M, when used in defined culture conditions efficiently 
promote the differentiation of hESCs towards DE through mesendoderm precursors 
[121]. These findings conclude that the inhibition of GSK3 signalling does not 
support pluripotency, when assayed in hESCs through the loss of the pluripotency-
associated surface markers SSEA-4 and TRA-1-60. It was found that 1M mediated 
differentiation of hESCs resulted in a transient increase in Nodal expression. A 
further non-structurally related GSK3 inhibitor, BIO, was also used in parallel in the 
same study and showed a similar trend in promoting the differentiation of hESCs 
towards an endodermal fate [121]. Further evidence of the importance of WNT 
signalling has previously been shown by Tahamtini et al. (2013) where the small 
bioactive molecule CHIR99021, a GSK-3β inhibitor, was used to prime pluripotent 
stem cells before differentiation to DE using Activin A. Specified DE cells exhibited 
stronger expression of both SOX17 and FOXA2 with CHIR99021 priming followed 
by Activin A differentiation than populations of DE produced without initial Wnt 
signalling priming [122].   
 
Other signalling pathways active during DE differentiation 
The role of FGF signalling in the specification of anterior definitive endoderm (ADE) 
has been examined by studying the expression of the early ADE and 
mesendodermal marker, homeodomain protein (Hex) [77]. Morrison et al. (2008) 
utilised a fluorescent reporter gene under the control of Hex along with the DE 
marker, CCXR4 to examine the role of FGF during hESC differentiation to DE [77].  
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Results from this study showed that FGF signalling promoted the specification of 
ADE from hESCs. Previous studies showed that if FGF signalling is abolished by the 
knock-out of the corresponding receptor FGFR1, there is an inability to contribute to 
endoderm [123].  
 
1.2 Hepatocyte Differentiation In Vitro 
1.2.1 Application of Embryonic Stem Cells to Drug Discovery 
There is a demand from the biotechnology industry for an inexhaustible supply of 
hepatocytes to be used in regenerative medicine to help to repair, augment or 
replace damaged tissues and with which to perform drug toxicity screens [124] 
[125]. As the liver is the primary organ to metabolise drug compounds, it is 
susceptible to damage through drug toxicity. The pharmaceutical industry has a 
current unmet need for hepatocytes to carry out drug safety testing and this is 
further compounded by the fact that isolated primary hepatocytes quickly lose their 
proliferative potential when cultured in vitro and dedifferentiate; losing their 
functional activity [126]. Phenotypic and genotypic variability is also a significant 
problem amongst isolated donor primary hepatocyte samples [127]. The use of 
current in vitro HLC models for pre-clinical drug development is also of limited value, 
as it is not directly translatable to the predictive drug toxicity and metabolism in 
humans [4]. HepG2 and Huh7 hepatocarcinoma cell lines are widely used as a 
model for hepatocytes, however they show limited metabolic activity so are 
unsuitable for drug induction assays [124] [128] [129] [130].  
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HepaRG cells are a bi-potent progenitor hepatocarcinoma cell line which possesses 
the potential to differentiate towards either biliary-like cells or hepatocytes-like cells 
[128] [129] [131] [132]. The differentiation to more differentiated cell type is achieved 
through the application of DMSO, a HDAC inhibitor, to cell culture media to promote 
terminal differentiation [133]. HepaRG cells have been shown to possess 
metabolically significant drug induction levels, albeit at lower levels than seen in 
primary hepatocytes.  It is also of note that HepaRG cells serve as a poor model for 
hepatotoxicity studies [124] [128].  
Pluripotent stem cells therefore hold immense promise to produce an unlimited 
amount of fully differentiated hepatocytes through the directed step-wise 
differentiation in vitro using chemically defined culture conditions. To realise this 
potential, there is a need to understand the cell fate specification with a view to 
efficiently and reproducibly differentiate pluripotent stem cells to hepatocytes. 
Studies have shown that in vitro derived HLCs to date show some degree of hepatic 
maturation [107] [99] [106] [134] [135]. Functional characteristics of primary 
hepatocytes include ureagenesis and gluconeogenesis [110] [99], albumin 
production [110] [111], indocyanine green (ICG) secretion [110] [111] and CYP450 
activity [110] [136]. Differentiated HLCs produced so far have been assessed to 
show some degree of functional capability albeit at significantly lower levels than 
seen in isolated primary hepatocytes. This leads to the conclusion that the HLCs 
that have been derived so far in these in vitro studies resemble immature, foetal 
hepatocytes [137] [138] [139]. 
The CYP450 family play a critical role in metabolism and detoxification of drug 
compounds and other xenobiotics [140] [141] [142] [143]. Therefore, it is important 
to elucidate the mechanisms underlying hepatic maturation to produce fully 
functional and mature HLCs for application in pre-clinical drug toxicity screening.  
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Proof of principle studies have shown that these derived HLCs can be transplanted 
in vivo and have the potential to contribute to liver function in recipient rat models 
demonstrating the potential for regeneration of damaged livers through 
transplantation of differentiated HLCs [106]. 
 
1.2.2 Hepatic Specification In Vitro 
The process of liver specification in vivo is complex, relying on a number of factors 
involving secreted growth factors along with cell-cell interactions and ECM 
microenvironment [144] [145] [146] [147]. Although the fundamental signalling 
pathways involved in DE differentiation are well characterised the more complex 
regulatory networks involved in these processes are still not yet fully understood. 
The in vitro differentiation of pluripotent stem cells down the hepatic cell lineage to 
ultimately form mature hepatocytes can be broken down into four distinct stages of 
mammalian development (Figure 5A). The first step is the specification of DE from 
pluripotent stem cells, followed by hepatic specification and finally hepatic 
maturation to produce mature, functional cells. In vitro hepatocyte differentiation 
strategies attempt to mimic the tightly regulated signalling pathways involved in DE 
formation, hepatic specification and maturation in vivo using key stage-specific 
markers to assess the progression [83, 84, 87, 99, 106, 107, 110, 112] (Figure 5B).  
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HLCs have been induced from populations of pluripotent stem cells in vitro firstly 
through the utilisation of Activin A or prolonged 1M/BIO/GSK3β inhibitor use, 
mimicking canonical WNT3A signalling [148] [121]. After DE specification hepatic 
induction is carried out to produce bi-potent liver precursors, termed hepatoblasts. 
Hepatoblasts have the ability to produce both metabolically active hepatocytes or 
biliary epithelial cells constituting two of the cell types of the liver [149] [150].  
The presence of alpha fetoprotein (AFP) and HNF4α, characteristic of hepatoblast 
progenitor cells at this stage, can be detected demonstrating the capacity of growth 
factors and small molecule inhibitors to modulate signalling pathways, allowing the 
differentiation of hESCs to a DE and a subsequent hepatic fate [151] [152] [153] 
[111] [106]. 
B 
Figure 5: In vitro stages of hepatocyte differentiation from pluripotent hESCs 
(A) Overview of the four main developmental stages of differentiation from pluripotent stem 
cells to definitive endoderm, hepatic progenitors and finally mature, functional hepatocytes. 
(B) Table highlighting the Key stage-specific gene and cell surface markers associated with 
the progression through distinct phases of hepatic lineage development.   
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A reduction in serum concentration to between 0.5–2% has also been shown to 
increase the expression of hepatic markers although the precise mechanism is 
unclear [148] [135]. An increase in Albumin (ALB), AFP, alpha 1-anti trypsin (α1AT), 
HNF4α and FOXA2 was seen after the reduction of the serum concentration in 
culture media [135]. FGF4 and BMP2 have been shown to be critical in the 
specification to the hepatic lineage in studies of mouse embryos [154] [155] [135] 
and are frequently used during hepatic lineage specification steps. In vivo studies 
have also shown that BMP and FGF signalling are involved in hepatic progenitor 
proliferation stages upon liver injury [156] [157]. 
As well as the characterised role of the canonical WNT3A in DE specification, the 
related non-canonical Wnt family member WNT5A has been implicated in 
differentiation along the hepatic lineage. It has been proposed that WNT5A could act 
as an antagonist to repress canonical Wnt signalling dependant on the 
differentiation status of the hepatic cells [158] [159]. In this way, differential Wnt 
signalling is active during the different developmental stages from canonical Wnt 
signalling in early differentiation stages to non-canonical signal activation upon the 
maturation of hepatic cells.  
It has been shown by Cai et al. (2007) that the combination of both FGF4 and BMP2 
has an increased effect on the expression on ALB, a hepatoblast marker, indicating 
a role in hepatic specification in vitro [110]. The addition of either FGF4 or BMP2 
alone in the same study however was shown to have had no effect, demonstrating 
the cooperative effect. These results were demonstrated using the FGF inhibitor 
SU5402 and the BMP inhibitor Noggin. In a separate study Song et al. (2009) used 
FGF4 and BMP2 to induce hepatic specification in cultures of DE, differentiated from 
induced pluripotent stem cells (iPS) lines [107].  
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After culture with FGF4 and BMP2 for a period of four days, expression of hepatic 
markers and liver-enriched transcription factors were detected when analysed 
through qPCR. The hepatic markers AFP, ALB, Cytokeratin-8 (CK-8), CK-18, 
HNF4α, Hex and GATA binding protein 4 (GATA4) were all found to be expressed in 
cells treated with FGF4 and BMP2  [107].  
Hepatocyte growth factor (HGF) has been used in studies after DE has been 
specified, to induce differentiation towards the hepatic lineage and expand the 
population of hepatic-like cells [99], [107], [106]. Addition of HGF was shown to up-
regulate AFP and FOXA2 expression levels, whilst immunostaining showed that the 
cells were double positive for AFP and FOXA2, indicating that the cells had been 
induced to a hepatoblast fate [106].  
There has been support from studies that dimethyl sulfoxide (DMSO), a histone 
deacetylase (HDAC) inhibitor, provides an inductive effect towards differentiation to 
the hepatic lineage from primed DE [99]. Because DMSO alters the epigenetic state 
of cells, it is thought that exposure of cells to DMSO provides inductive effects 
towards certain cell fates by altering methylation and epigenetic modifications and 
promoting terminal differentiation [160]. Typically, 2% DMSO is used in specified DE 
cultures alongside both FGF4 and BMP2 to induce hepatic specification and 
promote proliferation. The addition of 2% DMSO to Huh7 cells, a liver carcinoma cell 
line used as an in vitro model for studying hepatocytes, resulted in terminal 
differentiation and consequently elevated levels of late stage hepatic markers [161]. 
Another HDAC inhibitor, sodium butyrate (NaB), has also been used to induce 
hepatic specification from hESCs in a similar manner as DMSO [162].  
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The second stage of in vitro hepatocyte differentiation is concerned with the 
expansion of the specified hepatic progenitor cells. For this reason, FGF4 and HGF 
are commonly used as they are known to be involved in cell proliferation and 
expansion of the hepatic progenitor pool. FGF signalling has a number of roles in 
determining cell fate in embryogenesis and in differentiation [78]. FGF/MAPK 
signalling is also known to be involved in the regulation of hepatic gene expression 
whilst HGF has been seen to be highly upregulated upon hepatectomy [163] [164]. 
As well as the addition of FGF2 to maintain hESCs in a proliferating and pluripotent 
state, the related family member FGF4 is involved in the proliferation and 
maintenance of hepatic progenitors [165].  
Vascular endothelial growth factor (VEGF) is known to play a role in the proliferation 
of hepatocytes and has been documented to induce proliferation and function in EBs 
[166] and also to play a role in liver regeneration in coordination with HGF [167]. 
Along with VEGF, FGF and HGF the cytokine GDF15, a divergent member of the 
TGFβ superfamily, has been shown to be upregulated following liver injury. It has 
been found that the mRNA expression and protein secretion levels of GDF15 were 
increased after acute Hepatitis C virus (HCV) infection, surgical and chemical liver 
injury [168], [169].  
Upregulation of GDF15 following liver injury was seen to induce the activation of Akt 
signalling, which is involved in a wide variety of cellular processes including glucose 
metabolism, cell proliferation and transcriptional modulation. Activation of Akt 
signalling leads to the downstream target phosphorylation of this pathway which 
includes GSK3β, E-cadherin and β-catenin. Inhibition of GSK3β through Akt 
activation could therefore increase glycogen synthesis and lead to Wnt signalling 
activation which has been shown to be important in hepatic organogenesis [170]. 
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It has been previously reported that the inhibition of TGFβ1/SMAD signalling 
through the overexpression of the I-SMAD7 improves liver regeneration through 
suppression of TGFβ1 signalling  [171] [172]. SB-431542 selectively inhibits Alk4, 
Alk5 and Alk7 which are responsible for the transmission of TGFβ1 signalling. 
Specific inhibitor of SMAD3 (SIS3), a selective inhibitor of the SMAD3 pathway, has 
been shown to attenuate TGFβ1 mediated transcriptional activity without exhibiting 
inhibitory action on SMAD2 [173]. Consequently, after DE specification where 
TGFβ/SMAD signalling is of critical importance, SIS3 and SB-431542 could be 
utilised to expand the hepatic progenitor cell population.   
 
 
1.2.3 Hepatic Maturation 
The CYP450 family of mono-oxygenases are key players in the removal of 
xenobiotic compounds from the body; mainly involved in phase I and II of metabolic 
reactions which includes oxidation, hydrolysis and reduction reactions  [140] [141] 
[142] [143]. The inductive level of CYP450 metabolic activity is therefore of critical 
importance if the promise of the application of pluripotent stem cell derived HLCs to 
drug toxicity screens is to be fulfilled. Targeting the regulatory mechanisms that 
underlie CYP450 expression is used as an approach in the production of more 
mature hepatocytes [174] [175]. There is a wide diversity on the specificity of 
interactions of the CYP450 family members; some being very selective in substrate 
interactions whilst some having a more generalised association with xenobiotic 
targets [176] [177]. Diversity amongst the CYP450 family members is also seen in 
the expression of different isoforms that are induced by the presence of xenobiotic 
compounds [178].  
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Members of the CYP3A family have been found to be the most abundant CYP450 
family member present in the liver and also display the widest range of xenobiotic 
substrate interaction [179] [180]. CYP3A4 can be induced through the addition of the 
drug rifampicin [181]. CYP1 is another key member of the CYP450 family involved in 
phase I metabolic reactions and activated by some polycyclic aromatic 
hydrocarbons (PAH) [182]. CYP1 can be experimentally induced through the 
addition of the proton pump inhibitor drug omeprazole [183]. 
Oncostatin M (OSM) has been identified as a potent extra-cellular inducer of hepatic 
development in vivo [146]. OSM has been shown to up-regulate the expression of 
the hepatic markers HNF4 and ccaat-enhancer binding proteins (C/EBPα) [184] and 
promote morphological changes as well as functional characteristics of primary 
hepatocytes [146]. Consequently, OSM is added to cultures for a period of seven to 
ten days after hepatic specification to induce the maturation of differentiated HLCs in 
vitro [185] [99] [135] [106] [186]. Dexamethasone (Dex) is routinely added to 
cultures along with OSM to improve hepatic cell viability, through the ability of Dex to 
suppress apoptosis through the upregulation of anti-apoptotic factors [187]. In 
separate studies, Dex has been shown to be sufficient to induce a reprogramming 
switch from pancreatic cells to a hepatic fate, identified by the upregulation of 
hepatic markers [188]. Insulin has also been used utilised in the maturation process 
of differentiated HLCs because of its ability to regulate glycogen synthesis  [135] 
[99].   
It is known that HNF4α, a transcription factor of the steroid hormone receptor 
superfamily and plays a key role in the development of the liver [189] [190] [191] 
[192] [193] [194] [195]. HNF4α regulates a wide variety of liver specific factors 
including hepatocyte proliferation [196] and the CYP450 superfamily of metabolic 
enzymes, which play a central role in drug metabolism [197] [198] [199].  
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The importance of HNF4α in the regulation of members of the CYP450 family was 
demonstrated in primary human hepatocytes through the expression of HNF4α 
antisense RNA resulting in a 50% reduction of CYP3A4 mRNA expression levels 
[198]. Further evidence was shown by reduction in the mRNA of phase II enzymes 
and xenobiotic transporters in Hnf4α-null mice [200].  
However, the HNF4α ligand has remained elusive despite a number of possible 
candidates including the essential fatty acid, linoleic acid [201]. HNF4α contains 
both DNA and ligand binding domains [202] and can regulate discrete targets 
through the association with coactivators [203] [204]. It is known that nuclear 
receptor ligand binding domains exist in two forms; the active and inactive bound 
conformations [205] [206]. Differences between these two states of activity depends 
on the conformation of the helix α12, also known as AF-2. In the inactive state, the 
ligand binding pocket is accessible and “open” which prevents the binding of 
coactivators. In the active state, the ligand binding pocket is in the “closed” 
conformation and allows the association and binding of coactivators. The process of 
conformational change to transition between the active and inactive states of other 
nuclear hormone receptors has led to the theory that ligand binding is required for 
the activation of HNF4α [205] [206] [207] [202]. This theory is challenged however 
by the fact that not all fatty acids can bind and induce a conformational change in 
HNF4α from the inactive to active states; being necessary for HNF4α activation but 
not sufficient on their own [208]. Previous studies have suggested that HNF4α is 
constitutively bound to fatty acids [207] and possesses a binding pocket that is 
different than other nuclear receptors including peroxisome proliferator-activated 
receptor (PPAR) and retinoid x-receptor (RXR) [209].  
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The binding pocket of HNF4α has previously been shown through the x-ray crystal 
structure analysis to contain fatty acids; therefore suggesting that fatty acids are in 
fact the endogenous ligands [202]. Despite the evidence that fatty acids can indeed 
bind to the ligand binding pocket of HNF4α, there is limited evidence to show the 
subsequent modulation and effects on activity [210] [208]. Progress in 
understanding and identifying potential ligands that modulate HNF4α activity is 
particularly hampered by the discovery that ligand exchange in the ligand binding 
pocket is very poor in vitro; meaning changes in HNF4α activity upon addition of 
fatty acids is difficult to study  [202] [207]. The lack of definitive answers has raised 
the question of whether ligands do indeed bind and modulate HNF4 activity or rather 
ligand binding results in a conformational change [210]. 
Due to the key role played by HNF4α in the regulation of the CYP450 family 
members, targeting the upregulation of HNF4α during the hepatic maturation 
phases of differentiation is critical in producing more metabolically active 
hepatocytes [211] [212]. In vitro studies have further shown that Hnf4α is critical for 
the maintenance of differentiated hepatocyte functions [213]. Nuclear hormone 
receptor (NHR) proteins are key regulators of liver metabolism and in the 
detoxification and removal of xenobiotic compounds from the body [214]. There is a 
growing body of evidence that another function of the nuclear hormone receptors is 
the protection of cells from the accumulation of toxic metabolic intermediates [215]. 
Toxic intermediates activate nuclear hormone sensors which in turn upregulate 
members of the CYP450 family with a view to eliminate them. Xenobiotic-mediated 
activation of the nuclear hormone receptors results in the activation of a battery of 
the phase I and II metabolic enzymes. There are several nuclear receptor families 
that are involved in these processes and are therefore targeted for manipulation with 
a view to produce more metabolically relevant HLCs for use in drug toxicity screens 
[216].  
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HNF4α has been shown to important in the nuclear hormone receptor-mediated 
activation of CYP3A4 through binding to the enhancer region of CYP3A4 and 
allowing subsequent nuclear hormone receptor-mediated transcriptional activation of 
CYP3A4 [217]. In the same study, it was demonstrated that the deletion of Hnf4α 
resulted in the abolition of CYP3A in fetal mice and conditional deletion in adult mice 
resulted in the lack of CYP3A inducibility and a reduction in basal levels [217].  
 
PXR Family 
The pregnane X receptor (PXR) family of nuclear hormone receptors are activated 
by many xenobiotic compounds including steroids and antibiotics as well as 
hyperforin, a component of St. John’s Wort [218] [219]. The PXR family function as 
generalised sensors of hydrophobic toxins; in contrast to other nuclear receptor 
family members which act more specifically and recognise a smaller number of 
ligands [220] [221]. Hyperforin has been shown to have an inductive effect of the 
CYP450 family members, in particular, CYP3A4 and CYP2C9 through the activation 
of PXR [222] [174] [220] [175] [223].  
Upon sensing of xenobiotic compounds, PXR binds to DNA regulatory elements of 
CYP3A4 along with other factors involved in the metabolic process, resulting in the 
removal of the compound from the body. This system of PXR activation of CYP3A 
has been previously established in vivo [224] [225]. Since the CYP3A family is 
involved in a large proportion of xenobiotic drug metabolism and PXR has been 
shown to play a regulatory role in all stages of metabolic process, PXR activation 
would seem to be a key target in trying to induce CYP450 family members to levels 
of activity seen in primary hepatocytes.  
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CAR Family 
The constitutive androstane receptor (CAR) family of nuclear hormone receptors 
function as sensors and regulators for the metabolism of endobiotic and xenobiotic 
compounds in conjunction with PXR [226] [227]. CARs regulate transcription of 
genes including members of the CYP450 family of enzymes involved in drug 
metabolism [221]. CITCO, a small biologically active molecule, has been 
demonstrated to be an agonist of the CAR [228]. In a similar manor clofibrate, an 
organic compound found to be an activator of lipoprotein lipase, has been shown to 
have an inductive effect on members of the CYP450 family of enzymes, particularly 
CYP4A in rat hepatocyte cultures in vitro [229]. However, the effects have been 
seen to be transient and the underlying molecular mechanisms remain largely 
unknown.   
 
LXR Family 
The liver X receptor (LXR) family of transcription factors are closely related to 
nuclear factors such as peroxisome proliferator activated receptor-α (PPARα) and 
function to regulate cholesterol, fatty acid and glucose homeostasis and sense the 
presence of xenobiotics [230]. In addition, LXR has been shown to upregulate the 
expression of CYP3A [231] and is of interest during hepatocyte maturation.  
The small molecule agonist T0901317 has been shown to upregulate LXR and 
consequently ATP-binding cassette transporter 1 (ABC1) which has been shown to 
be a major regulator of both cholesterol and phospholipid homeostasis [232]. Whilst 
LXR functions to regulate the homeostasis of cholesterol, fatty acids and glucose 
the role of LXR in promoting hepatocyte differentiation was examined as a method 
of increasing metabolic activity in pluripotent-derived HLCs in this thesis.  
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In vitro studies using HepaRG cell cultures have shown that the overexpression of 
LXR corresponds with an increase in hepatic functions associated with mature 
hepatocytes including CYP450 family member upregulation [233]. Interestingly, it 
was seen that the overexpression of LXR and the corresponding maturation of 
hepatocytes was dependant on cooperative HNF4α signalling.  
 
1.3 CombiCult®  
The primary challenge of in vitro stem cell differentiation is recapitulating the 
complex set of signalling cues in normal in vivo mammalian development. The ability 
to target key lineage specific signalling pathways with growth factors and small 
molecules to direct stem cell differentiation toward desired cell lineages is a major 
challenge in research and threatens to create a bottleneck in an otherwise rapidly 
advancing field [234] [235] [236]. Trial and error methods for the determination of 
revised stem cell differentiation protocols and the associated titration optimisation 
steps are both costly and time-consuming procedures resulting in slow progress. 
The ability to grow cell lines long-term in vitro relies on delineating the precise 
culture conditions allowing the retention of cell line integrity in terms of cell viability, 
morphology, and proliferative potential.  
Plasticell, a biotechnology company specialising in stem cell differentiation, has 
developed combinatorial cell culture, (CombiCult®), a powerful multiplexed 
screening platform, for the establishment of new stem cell differentiation protocols 
[237] [238] [239]. The CombiCult® platform achieves this through step-wise 
assessment of the application of growth factors and/or small bioactive molecules to 
stem cells to direct differentiation towards cell types of interest (Figure 6).  
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CombiCult® allows for the multiplexing of a large range of variable cell culture 
media combinations through a process known as split-pooling; currently allowing for 
up to 20,000 possible culture media permutations to assess differentiation potential 
[239]. This enables not only for the trial of new growth factors and bioactive small 
molecules but also the temporal sampling and titration so that the optimal 
combination of cell culture media variables can be delineated to faithfully 
recapitulate normal developmental cues.  
Advantages of the CombiCult® platform include the ability to carry out vast 
multiplexed combinatorial cell culture in small scale, greatly reducing the cost 
associated with discovering new differentiation protocols [239]. The elimination of 
serum from cell culture and the use of defined culture conditions enables the precise 
combination of signalling cues involved in cell lineage fate to be identified [240]. 
Other advantages of CombiCult® include the plasticity of cell lines that can be 
seeded onto the polymer beads. Different hESC lines are known to be better suited 
and more capable of differentiating to certain cell lineages than others [241] [242] 
[243]. It is therefore possible to identify the optimal hESC line to be used in 
conjunction with the optimal culture conditions for the step-wise differentiation to 
hepatocytes. The ability to screen small molecule libraries to direct cell 
differentiation is advantageous as it reduces the costs associated with the use of 
growth factors in culture media.  
The CombiCult® screening platform is therefore a powerful tool to identify critical 
factors important in the differentiation of hepatocytes from pluripotent stem cells. 
This will be of great value in identifying new and novel differentiation protocols and 
overcoming the major bottlenecks associated with the early differentiation and 
subsequent maturation of hepatocytes.  
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Figure 6: CombiCult® split pooling workflow overview 
Overview of the CombiCult® split-pooling procedure for shuffling microcarriers seeded with 
hESCs through sequential media combinations. Each media condition is spiked with a 
unique fluorescent tag to allow tracking of cell culture history to identify new and novel 
differentiation protocols by assessing the cell culture history of “hits”. Credit: Plasticell 
Limited. 
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1.4 Aims of Thesis 
There has been great progress in the understanding of liver development and 
consequently protocols have been developed for the in vitro differentiation of 
pluripotent stem cells to hepatocyte-like cells (HLCs). However, there remains two 
major bottlenecks in the efficient differentiation of functional hepatocytes with which 
to apply to early stage drug toxicity screens. The research questions addressed in 
this thesis were aimed to contribute to the overall understanding and knowledge of 
the hepatic differentiation process in vitro and shed new light on further avenues of 
investigation.  
The first bottleneck in this process is in the homogenous differentiation of DE from 
cultures of pluripotent stem cells. To date, hepatic differentiation protocols almost 
exclusively use Activin A, used as a substitute of Nodal signalling, in the first stage 
of pluripotent stem cell differentiation to specify DE. Tools to investigate these early 
developmental steps are therefore required to better assess the populations of DE 
produced through the manipulation of Nodal/Cripto signalling; with a view to more 
efficiently and homogenously differentiate pluripotent stem cells as a starting point 
for subsequent hepatic lineage specification. Consequently, gene modulation tools 
and cell differentiation systems to investigate these early developmental processes 
were assessed in this thesis. The working hypothesis would be that Nodal is in fact 
the driver for DE specification in vitro and the absence of Nodal signalling would 
produce a more heterogeneous population of cells compared to a cell differentiation 
environment with high levels of Nodal signalling. To investigate this hypothesis, 
lentiviral vectors to knock down or overexpress Nodal/Critpo signalling were 
assessed with a view to create tools with which to compare DE homogeneity in 
future studies.  
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The second bottleneck concerns the maturation of differentiated hepatic cells to 
possess the functional capabilities that are characteristic of mature hepatocytes. 
The incorporation of novel hepatic maturation factors at appropriate concentrations 
to in vitro differentiation protocols is therefore required with a view to induce terminal 
differentiation to functional hepatocytes. To address this research problem in this thesis, 
a CombiCult® differentiation screen was conducted to identify combinations of hepatic 
differentiation factors that promote the most mature HLCs in vitro. Growth factors and small 
molecule inhibitors/agonists which have not previously been applied to hepatic in vitro 
differentiation protocols were incorporated into the CombiCult® differentiation screen to 
identify and define novel differentiation protocols. Lentiviral reporter vectors were then further 
used to determine optimum concentrations of small molecule agonists and to validate 
potential ligands for master hepatic regulators.  
To investigate these research problems, this thesis will address the following aims: 
• Validate lentiviral vectors to overexpress or knock down Nodal and/or Cripto.  
• Compare different Nodal/Cripto conditioned media systems to differentiate 
pluripotent cells to DE. 
• Design and conduct a CombiCult® screen to identify novel factors for the 
optimal hepatic differentiation of pluripotent stem cells to HLCs. 
• Isolate top CombiCult® hepatic differentiation protocols for further analysis of 
maturation in monolayer culture. 
• Optimise in vitro hepatic differentiation differentiation procedure using 
CombiCult®-derived protocols over the 28-day time course. 
• Create a hepatic reporter applicable to the CombiCult® platform to replace 
ICC staining as a readout for mature HLCs. 
• Validate hepatic reporters for the in vitro titration of hepatic maturation 
inducing factors identified through CombiCult®. 
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• Identify optimal concentration ranges for small molecule agonists for in vitro 
studies of HLC maturation. 
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Chapter 2: Methods 
2.1 Cell Culture Techniques 
2.1.1 Cell Lines 
All cell lines were cultured at 37⁰C in humidified incubators supplemented with 5% 
CO2. Human Embryonic Kidney (HEK) 293T cells (originally obtained from 
European Collection of Authenticated Cell Cultures (ECACC): 12022001)) were 
used at passage 10 (P10) to produce lentivirus. The hepatocarcinoma cell lines 
Huh7 (originally obtained from ECACC: 01042712), HepG2 at P15 (originally 
obtained from ECACC: 85011430) and HepaRG at P5 (Invitrogen, Loughborough, 
UK) were used as in vitro hepatocyte models. The human colon adenocarcinoma 
cell line LS174T (originally obtained from ECACC: 87060401) was used to validate 
levels of LGR5 knockdown using shRNA clones at P11. HeLa cells (originally 
obtained from ECACC: 93021013) were used to validate Nodal/Cripto shRNA 
knockdown clones at P15. The mouse fibroblast cell line NIH-3T3 (originally 
obtained from ECACC: 93061524) was used as a non-hepatic control to validate 
hepatic lentiviral reporters at P3.  Mouse Embryonic Fibroblasts (MEFs) were 
obtained from Dr. Simon Waddington at University College London (UCL) and used 
as feeder cells for human Embryonic Stem Cells (hESC) culture upto P4. 
Karyotypically normal 46, XY Sheffield (Shef)-3 hESCs were obtained from Dr. 
Diana Hernandez of Plasticell Ltd. (Stevenage, UK) at P28. Feeder-free conditioned 
huES1-OCT4-eGFP hESCs were grown at The University of Manchester and 
obtained from Dr. Tristan McKay at P7 post conditioning to feeder-free conditions. 
Mycoplasma PCR testing was routinely carried out on cells lines to ensure there 
was no contamination.   
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2.1.2 Cell Culture 
The cell lines 293T, HepG2, Huh7 and HeLa adherent were plated onto cell culture 
treated flasks (Greiner Bio-One, Stonehouse, UK) in Dulbecco’s Modified Eagles 
Medium (DMEM) (Sigma-Aldrich, Dorset, UK), 10% heat inactivated (HI) fetal bovine 
serum (HI-FBS) (Life Technologies, Loughborough, UK), 1% non-essential amino 
acids (NEAA) (Life Technologies), 1% GlutaMAX (Life Technologies) and 1% 
penicillin/streptomycin (P/S) (Life Technologies), termed “DMEM-complete media”. 
Cells were cultured to 70% confluence before passaging which consisted of 
removing DMEM-complete media and washing cells twice with phosphate buffered 
saline (PBS) (Sigma-Aldrich). Cells were then incubated with 0.25% Trypsin (Sigma-
Aldrich) at 37⁰C until cells detached from the culture flask surface. Trypsin was 
neutralised with the addition of DMEM-complete at a 2:1 ratio of serum containing 
media to trypsin to neutralise enzymatic activity before pelleting cells at 300xg for 
five minutes. Cells were split at a 1:10 ratio which resulted in cells being passaged 
twice weekly. Freezing media consisting of 90% HI-FBS supplemented with 10% 
DMSO (Sigma-Aldrich) to -80⁰C in a slow freezing vessel filled with 100% 
isopropanol (NALGENE, Loughborough, UK) before being transferred to liquid 
nitrogen for long-term storage.  
 
2.1.3 LS174T Culture 
Human colon adenocarcinoma LS174T cells were cultured in RPMI-complete media 
consisting of RPMI 1640 (Sigma-Aldrich) containing 20% HI-FBS, 1% NEAA, 1% 
GlutaMAX and 1% P/S. Cells were cultured to 80% confluence before passaging as 
previously described (see Methods 2.1.2). Cells were replated at a 1:10 seeding 
density resulting in cell passaging being carried out twice weekly.  
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Cryopreservation of LS174T cells was carried out using freezing media consisting of 
90% HI-FBS supplemented with 10% DMSO. Cell vials were frozen at -80⁰C in a 
slow freezing vessel filled with 100% isopropanol before being transferred to liquid 
nitrogen for long-term cryopreservation. 
 
2.1.4 HepaRG Culture 
HepaRG cells were plated onto collagen I (Corning, Flintshire, UK) coated tissue 
culture surfaces in hepatocyte basal media (HBM) (Lonza, Slough, UK) 
supplemented with the provided SingleQuots. HepaRG cells were grown to 
confluence and then passaged by washing the cells with PBS and incubated with 
Accutase (EMD Millipore, Watford, UK) at 37⁰C until the cells detached from the 
plastic culture surface. Cells were replated at a 1:10 seeding density resulting in cell 
passaging being carried out twice weekly. Cryopreservation of HepaRG cells was 
carried out by pelleting HepaRG cells pelleting cells at 300xg for five minutes and 
resuspending in ProFreeze serum free freezing media (Lonza). Cell vials were 
frozen at -80⁰C in a slow freezing vessel filled with 100% isopropanol before being 
transferred to liquid nitrogen for long-term cryopreservation. 
 
2.1.5 DE Basal Differentiation Media 
DE basal differentiation media consisted of William’s E media (Lonza), 1x B27 (Life 
Technologies), 1% NEAA, 1% GlutaMAX, 1% Sodium Pyruvate (Life Technologies) 
and 1% P/S.  
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To produce conditioned overexpression differentiation media, basal media was 
applied to overexpression cell lines and allowed to be conditioned for a period of 24 
hours by before being filtered using a .22µm syringe. Conditioned media was 
refreshed every 24 hours unless stated otherwise.  
 
2.1.6 Isolation of MEFs  
Wild type CD1 mouse embryos were obtained at E12.5 from pregnant female mice. 
Embryos were isolated by cutting between individual implantation sites along the 
uterine wall to isolate individual embryos. Enclosed embryos were dissected out and 
internal organs and heads were removed using a scalpel and tweezers. Dissected 
embryos were sequentially washed in PBS until all blood was removed.  
Prepared embryos were then incubated in 0.25% Trypsin/EDTA or 1 µg/ml 
Collagenase I (Sigma-Aldrich) at 37⁰C to digest the dissected embryos for 
approximately fifteen minutes until visible dissociation could be observed. 
Dissociation enzyme was then neutralised with the addition of complete DMEM-
complete media and then cells then were plated at a density of three embryos per 
0.1% gelatin (Sigma-Aldrich) coated T175 flask and the adherent fraction of cells 
amplified. MEFs were expanded in culture and passaged at 70% confluence until 
they reached P4.  
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2.1.7 Mitotic Inactivation of MEF Feeder Layers   
MEFs were mitotically inactivated through the supplementation of DMEM-complete 
cell culture media containing Mitomycin C (Sigma-Aldrich) at 10µg/ml for three 
hours. Inactivation media was then removed, cells washed three times with PBS 
before being passaged with 0.25% Trypsin at 37⁰C until cells detached from the 
culture flask surface. MEFs were plated at a density of 200,000 cells/6cm diameter 
tissue culture dish which had previously been pre-coated coated with 0.1% gelatin. 
 
2.1.8 Feeder-Based hESC Culture 
Pluripotent hESCs were grown on mitotically inactivated MEF feeder layers 
supplemented with hESC culture media. Pluripotent hESC media consisted of 
KnockOut DMEM (Life Technologies), 20% KnockOut Serum Replacement (KSR) 
(Life Technologies), 1% Non-Essential Amino Acids (NEAA) (Life Technologies), 1% 
GlutaMAX, 1% P/S, 0.1M 2-Mercaptoethanol (Life Technologies) and 10ng/ml 
bFGF/FGF2 (R and D Systems, UK).  
Every two days differentiated areas of cells were removed by manual scraping and 
media was refreshed until approximately 70% confluence was reached. At this 
stage, hESC colonies were manually passaged by cutting into equal sized small 
colony pieces and replated on to fresh MEF feeder layers. Cryopreservation of 
feeder-based hESCs was achieved by freezing colonies in mFreSR (Stem Cell 
Technologies, Cambridge, UK) to -80⁰C in a slow freezing vessel (NALGENE) 
containing 100% isopropanol before being transferred to liquid nitrogen for long-term 
cryopreservation. Karyotypically normal 46, XY Shef-3 hESCs were used for a 
maximum of 10 passages from the point of obtaining them at P28. 
55 
 
2.1.9 Feeder-Free hESC Culture 
Feeder supported hESC colonies were grown on MEF feeder layers and then 
enzymatically passaged with TrypLE (Life Technologies) and replated onto 50µg/ml 
fibronectin coated dishes (EMD Millipore). Initially enzymatically passaged hESCs 
were cultured in pre-conditioned MEF hESC media supplemented with 10ng/ml 
bFGF and 10µM ROCK inhibitor (Y27632) (EMD Millipore) immediately following 
plating to support single cell passaging. After a period of two days, media was 
replaced with a 50:50 split of MEF conditioned hESC media supplemented with 
10ng/ml bFGF and mTeSR (Stem Cell Technologies). The proportion of mTeSR 
was subsequently increased until hESCs were adapted to grow in fully feeder-free 
conditions. Subsequent passaging of feeder-free hESCs was carried out by 
incubation with TrypLE for five minutes at 37⁰C before replating on fibronectin 
coated plates supplemented for two days of 10µM ROCK inhibitor treatment. 
Cryopreservation of hESCs was achieved by freezing colonies in mFreSR to -80⁰C 
in a slow freezing vessel. 
 
2.1.10 Mammalian Cell Transfection 
Cells to be transfected were grown in six well plates and allowed to reach 70% 
confluence. To produce the cell transfection mix, 2.75µg of plasmid DNA was mixed 
with 327.25µl of OptiMEM (Life Technologies) and left to incubate for five minutes at 
room temperature. In parallel, 2.75µl of 0.1mM Polyethylenimine (PEI) (Sigma-
Aldrich) was mixed with 327.25µl of OptiMEM and incubated for five minutes at 
room temperature. After five minutes of incubation the DNA-OptiMEM and PEI-
OptiMEM mixtures were mixed in a final volume of 660µl and left to incubate for a 
further 20 minutes at room temperature.  
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This was carried out for every well of a six well plate to be transfected and the 
volume of transfection mix was scaled up accordingly based on lentiviral preparation 
size.  Cells to be transfected were then washed with PBS to remove serum-
containing culture media and the transfection mix added for three hours at 37⁰C. 
Transfection mix was then removed and cells washed with PBS before addition of 
DMEM-complete to transfected cells.  
 
2.1.11 Production of Lentivirus 
Lentivirus was created by transfecting plasmid DNA along with pCMVR8.74 
packaging and pMD2.G envelope plasmids (Plasmid Factory, Bielefeld, Germany) 
into 293T viral producing cells. The following day, transfection media was removed 
and refreshed with DMEM-complete media. Lentivirus was collected in media 
supernatant at 48 and 72 hours post transfection.  Viral supernatant was 
subsequently filtered using a 0.22µM syringe filter and centrifuged at 4500xg 
overnight at 4⁰C to pellet lentivirus particles. The supernatant was aspirated and 
viral particles re-suspended in OptiMEM containing no serum, aliquoted and 
cryopreserved at -80⁰C.  
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2.1.12 Lentiviral Titering  
Lentiviral titering was carried out using a p24 antigen capture ELISA assay 
(ZeptoMetrix, New York, US) as per the manufacturer’s instructions. The p24 assay 
allows the detection of the number of lentiviral envelope particles with a view to be 
able to determine an appropriate multiplicity of infection (MOI) with which to 
transduce cells. Briefly, 96 well plates were coated with a monoclonal antibody 
specific for the p24 gag gene product of the HIV-1 virus. Viral antigen in test 
samples were subsequently applied to wells and captured with the monoclonal 
antibody specific for the p24 gag gene product. The captured antigen was then 
reacted with a high titered human anti-HIV-1 antibody conjugated to biotin. The 
assay then relies on a subsequent incubation with a streptavidin-peroxidase enzyme 
resulting in a colour change resulting from bound enzyme reacting with the 
substrate. The colorimetric reaction was then analysed at 595nM wavelength using 
the GloMax® Multi+ machine (Promega, Southampton, UK).  
 
2.1.13 Mammalian Cell Transduction 
For lentiviral transduction, cells were cultured to 70% confluence and lentiviral 
particles suspended in OptiMEM were added to fresh cell culture media at the 
desired MOI concentration. Typically, this was done at 20MOI unless stated 
otherwise along with the addition of polybrene (EMD Millipore) at a concentration of 
5µg/ml to increase lentiviral transduction efficiency. Lentiviral transduction was 
carried out for a period of 48 hours after which transduction media was removed and 
replaced with the appropriate fresh culture media. 
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2.2 Molecular Biology 
2.2.1 Isolation of Plasmid DNA 
To isolate plasmid DNA, 8ml lysogeny broth (LB) was supplemented with 
appropriate selection antibiotics. Antibiotics used was either ampicillin or kanamycin 
(Sigma-Aldrich) at 100mg/ml which allowed the selection of plasmid DNA containing 
antibiotic-resistant bacteria. LB selection media was inoculated with a single 
bacterial colony and incubated overnight at 37°C on a shaking platform. Bacterial 
cultures were centrifuged at 300xg for 10 minutes. Plasmid DNA was isolated using 
the Plasmid Mini Kit (Qiagen, Manchester, UK), which is based on a modified 
alkaline lysis procedure followed by binding of plasmid DNA to an anion resin under 
appropriate low salt and pH conditions using the manufacturer’s instructions. The 
isolated DNA was then eluted in 30µl of nuclease-free water. 
 
2.2.2 Gel Extraction 
To isolate DNA fragments from agarose gels a commercially obtained Gel Extraction 
Kit (Qiagen) was used according to the manufacturer’s instructions. Isolated DNA 
captured in the anion resin of the gel extraction column was eluted in 30µl of 
nuclease-free water. Additional steps in the extraction process using RNase 
(Qiagen) was used degrade contaminating RNA to further purify DNA samples. 
 
59 
 
2.2.3 Restriction Digests 
Restriction digests of plasmid DNA were carried out using restriction enzymes 
obtained from NEB (Hitchin, UK). In a reaction volume of 50µl, 500ng of plasmid 
DNA was digested using the appropriate restriction digest buffer and incubation 
temperature according to the manufacturer’s instructions. Restriction digests were 
carried out for one hour unless otherwise stated.  
 
2.2.4 Ligation Reactions 
Ligation reactions were carried out using 50ng of lentiviral backbone vector using a 
1:3 molecular ratio of backbone vector to insert. Reactions were carried out in a total 
volume of 20µl using the Quick Ligase kit (NEB) and incubated at 25ºC for five 
minutes as per manufacturer’s instructions. Reactions were carried out as follows: 
Backbone vector 50ng 
Insert  (1:3 molecular ratio) 
2x Quick Ligation buffer 10µl 
Quick Ligase 1µl 
Nuclease-free water       to a total of 20µl 
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2.2.5 Gateway Cloning 
Gateway cloning (Invitrogen) was carried out to shuffle genes of interest from a 
donor vector, pENTR-1A, into a lentiviral vector. The pENTR-1A donor vector 
contains aatL sites flanking the gene of interest and the destination vector contains 
corresponding attR sites. The use of the clonase™ enzyme (Invitrogen) allows 
recombination of the gene of interest from the donor clone into the destination vector 
at high efficiency and in a specific orientation. To carry out LR clonase™ 
recombination the following reaction was carried out: and left to incubate at 25ºC for 
sixty minutes before 2µl of Proteinase K solution (Invitrogen) was added to stop the 
reaction:  
Entry clone (100-300ng) 1-10µl 
Destination vector (150ng/ml) 2µl 
5x LR clonase™ reaction buffer  4µl 
TE buffer (pH 8.0)     to a total of 16µl 
 
2.2.6 Plasmid DNA Transformation 
Plasmid DNA was transformed into stable competent DH5α bacterial cells (NEB) to 
amplify and extract clones of interest. 50µl aliquots of competent cells were thawed 
on ice and mixed with 100ng of plasmid DNA by carefully flicking the transformation 
mix tube. The transformation mix was then incubated on ice for 30 minutes before 
being heat shocked at 42ºC for 30 seconds. The transformation mix was again 
incubated on ice for five minutes before 500µl of super optimal broth with catabolite 
repression (SOC) media was added and incubated for sixty minutes. Transformation 
mix was then plated onto appropriate antibiotic containing agar petri dishes under 
sterile conditions and left to incubate overnight at 37ºC.  
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2.3 Gene Expression Analysis 
2.3.1 Agarose Gel Electrophoresis 
Agarose gels were prepared depending on the DNA fragment size by dissolving 
agarose (Sigma-Aldrich) in 1x Tris-acetate-EDTA (TAE) buffer (Thermo Scientific, 
Loughborough, UK). Agarose gels were mixed with SYBR Safe (Invitrogen) to 
visualise DNA bands. Sample DNA was mixed with gel loading buffer at a 1:5 ratio 
before being loaded into cast wells. Appropriate sized DNA HyperLadder™ 
(Invitrogen) was selected depending on the size of the DNA band in question.  
 
2.3.2 RNA Extraction  
Total RNA was isolated from monolayer cell cultures using an RNeasy Kit (Qiagen) 
as per manufacturer’s instructions. Briefly, cells were washed three times with PBS 
before being subjected to lysis using RLT buffer (containing 1:100 concentration 2-
Mercaptoethanol to inhibit RNases). Cell lysate was homogenised to shear high 
molecular weight DNA and other cellular components by passing samples through a 
QIAshredder Column (Qiagen) followed by RNA isolation from cell lysate using an 
RNeasy kit. On column DNase I treatment (NEB) was carried out to remove 
contaminating genomic DNA from individual samples. RNA integrity was checked by 
denaturing RNA secondary structure by heating to 70ºC for 5 minutes followed by 
running the sample on a 1.5% agarose gel to check the relative quantities of 18S 
and 28S subunits. Quantitative measurements were calculated using a NanoDrop™ 
spectrophotometer (Thermo Scientific) and a 260/280 ratio assessed. A ratio of ~2.0 
is indicative of pure RNA and a cut off was established which excluded RNA from 
being further assessed if a score of less than 1.9 or greater than 2.1 was achieved. 
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2.3.3 cDNA Synthesis 
First strand cDNA synthesis was subsequently carried out on high purity RNA 
samples using a cDNA synthesis kit (Agilent, Craven Arms, UK) using 2µg of 
purified RNA following manufacturer’s instructions. Confirmation of successful 
synthesis of cDNA was carried out through the amplification with housekeeper 
genes β-Actin and GAPDH by RT-PCR followed by visualisation through agarose 
gel electrophoresis.  
 
2.3.4  RT-PCR 
RT-PCR reactions were carried out on synthesised cDNA using a Taq DNA 
polymerase kit (NEB) as per manufacturer’s instructions. RT-PCR reactions were 
carried out for 30 cycles using appropriate annealing temperatures for the primer set 
depending on nucleotide length and composition. PCR reactions for each primer set 
containing no reverse transcriptase (noRT) controls were carried out to check for 
genomic DNA contamination in the RNA samples. Further no template controls 
(NTC) were carried out by omitting template cDNA to check for additional nucleic 
acid contamination and for primer dimer formation. NoRT and NTC control samples 
were ran on agarose gels along with test samples to check for the absence of PCR 
product bands which would be indicative of DNA contamination from RNA samples. 
The following RT-PCR master mix and PCR cycling parameters was used: 
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Standard Taq reaction buffer (10x) 5µl 
Deoxynucleotide solution mix (10mM) 1µl 
Forward primer (10µM)  1µl 
Reverse primer (10µM)  1µl 
DNA template      1ng 
Taq DNA polymerase  0.2µl 
Nuclease-free water       to a total of 50µl 
  
1 minutes at 95ºC 
30 seconds at 95ºC 
 45 seconds at 60ºC     30 cycles 
 45 seconds at 72ºC 
5 minutes at 72ºC 
 Hold at 4ºC 
 
2.3.5 SYBR Green qPCR 
Synthesised cDNA was quantitated as a surrogate for mRNA using SYBR Green 
qPCR (Applied Biosystems, Warrington, UK). All qPCR primers were ordered from 
Sigma-Aldrich and were designed to span exon boundaries to eliminate genomic 
DNA amplicons. Other primer design criteria included being 21-24 nucleotides in 
length, approximately 50-60% GC content and having a melting temperature (Tm) 
variation between forward and reverse primers of less than 2ºC. Primer efficiencies 
were calculated for each set of primers using a dilution curve of the target amplicon. 
The cycle threshold (Ct) values that were generated for each serial dilution was 
plotted on a logarithmic scale. A linear regression curve was then calculated using 
these data points and the slope of the trend line calculated.  
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Primer sets were only used if they produced an efficiency of between 90-100%. 
Dissociation curves were analysed following qPCR amplification to check that only a 
single target amplicon was generated and there was an absence of multiple 
amplification products.   
For absolute quantification of gene expression, product amplification standards for 
each qPCR target gene were produced. These standards were created by 
amplifying the target gene of interest using 1µl of wildtype cDNA for 30 cycles of 
PCR amplification. The PCR reaction was then electrophoresed on an agarose gel, 
visualised on a UV gel imaging system and the product band extracted using a Gel 
Extraction Kit (Qiagen) to isolate DNA as per manufacturer’s instructions. Serial 
dilutions of gel purified PCR product ranging from 10‾3 to 10‾7 was produced with 
which to obtain a qPCR standard amplification curve which allowed quantification of 
test sample gene expression. For gene expression analysis, qPCR primers were 
first validated using serially diluted wildtype cDNA at a range of 10-3 to 10-6. This 
was done to check for the absence of primer dimers which could distort the gene 
expression quantification reading.  
For all qPCR reactions, GAPDH was used as a housekeeping gene control with 
which to normalise gene expression to the fold expression change of the gene of 
interest. GAPDH levels as assessed by the Ct were seen to be unchanged 
throughout test samples. SYBR Green qPCR was carried out by mixing 5µl of SYBR 
Green Mastermix (Applied Biosystems) with 1µl of template cDNA. Working stock 
10µM solution forward and reverse primers was then added along with 0.2µl of 
Roxlow (Applied Biosystems) to normalise the fluorescent signal and made up to a 
total reaction volume of 10µl. qPCR reactions were carried out in triplicate in 96 well 
PCR plates.  
65 
 
PCR reactions for each primer set containing no reverse transcriptase (noRT) 
controls were carried out to check for DNA contamination in the RNA samples. 
Further no template controls (NTC) were carried out by omitting template cDNA to 
check for additional nucleic acid contamination and for primer dimer formation in 
SYBR Green qPCR reactions. Three biological repeats were carried out for each 
validation experiment which consisted of assessing experiments using cells from 
different passage numbers. Three technical replicates of target gene amplification 
were carried out for each biological repeat. The SYBR Green qPCR reaction 
programme cycle was as follows: 
 3 minutes at 95ºC 
20 seconds at 95ºC 
 20 seconds at 57ºC     40 cycles 
 20 seconds at 72ºC 
 Hold at 4ºC 
 
Table 1: PCR primer sequences  
PCR primer sequences used to assess gene expression. Forward and reverse 5’-3’ 
sequences are displayed along with the corresponding PCR product size.  PCR primer 
efficiencies are also displayed which were calculated using a dilution curve of the target 
amplicon. Primer sets were only used if they produced an efficiency of between 90-100%. 
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2.4 Protein Expression Analysis 
2.4.1 Protein Extraction  
Protein was extracted from cell lysates by firstly pelleting cells following incubation 
with 0.25% Trypsin at 37⁰C until cells detached from the culture flask surface. 
Pelleted cells were washed three times with ice cold PBS. Cell pellets were 
resuspended with 1x RIPA buffer (1x PBS, 1% NP40, 0.5% sodium deoxycholate, 
0.1% SDS) (Cell Signalling, Hitchin, UK) to lyse cell pellets and allow the isolation of 
cytoplasmic, nuclear and membrane-bound proteins. RIPA buffer was supplemented 
with a protease inhibitor cocktail (Roche, Welwyn Garden City, UK) to prevent 
protein degradation. Cell lysate was then pelleted by centrifugation at 4500xg for ten 
minutes. Protein containing supernatant was removed and stored at -80⁰C.  
 
2.4.2 Protein Concentration Quantification 
A colorimetric protein assay was used to quantitatively measure the total protein 
concentration in test samples (Bio-Rad, Watford, UK). The Bio-Rad protein assay is 
based on the Bradford dye-binding principle and test samples compared to known 
protein standard [244]. Protein concentration was determined using a 96 well plate 
microplate protein assay. Protein standards ranging from 0, 0.25, 0.5, 1, 2, 4 and 
8µg BSA per well were produced as a reference with which to determine protein 
levels in samples. One-part Bio-Rad protein assay reagent was then diluted in dH20 
giving a 1:5 dilution and 195µl added to each well. To each well containing the 
protein assay reagent, 5µl of standard was added along with 5µl of test sample. The 
plate was then read for absorbance at 595nm wavelength using a 
spectrophotometer (Promega GloMax® Multi+). 
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2.4.3 SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Equal concentrations of quantified protein samples were prepared by mixing with 2x 
Laemmli buffer (4% SDS, 0.1M Tris pH 8.9, 2mM EDTA, 0.1% bromophenol blue 
and 20% glycerol) and boiled for 10 minutes at 95⁰C. Samples were centrifuged at 
4500xg for five minutes and 20µl was loaded into individual wells of pre-cast sodium 
dodecyl sulphate (SDS) polyacrylamide gels (Invitrogen). Novex pre-stained protein 
standards (Invitrogen) were used to determine protein sample size and relative 
mobility. Protein gels were usually run at 150V for one hour at 200mA or until 
appropriate migration through the gel was achieved.  
 
2.4.4 Western Blotting 
SDS PAGE gel, PVDF transfer membrane (Thermo Scientific) and filter paper were 
equilibrated in 1x transfer buffer (for 1L of 10x: 24g Tris base and 90g glycine was 
dissolved in dH20). SDS PAGE gel was placed over the PVDF transfer membrane in 
between two pieces of filter paper to keep the gel and membrane wet in a semi-dry 
blotter. Proteins were then transferred to the membrane for 40 minutes at 15V. Once 
proteins have been transferred, the PVDF membrane was blocked with PBS 
containing 5% skimmed milk powder for one hour. PVDF membrane was then 
washed in PBS containing 0.1% Tween-20 (PBS-T). Primary antibody incubation 
was then carried out in PBS-T with 5% skimmed milk powder on a rocking platform 
overnight at 4⁰C using antibody dilutions according to manufacturer’s instructions. 
Antibodies used in western blotting and the appropriate dilutions can be found in the 
following table:  
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Table 2: Western blot antibodies 
Primary and corresponding secondary antibodies used in Western blot analysis of protein 
levels. Appropriate dilutions in PBS-T for each primary and secondary antibody are 
displayed along with supplier and catalogue numbers. 
 
 
2.4.5 Immunocytochemistry (ICC) 
Cells were first washed three times with PBS before being fixed with 4% 
paraformaldehyde (PFA) (Electron Microscopy Sciences, Hatfield, US) for one hour 
at room temperature. Samples were then washed three times with PBS and 
subsequently blocked and permeabilised in PBS containing 1% BSA (Sigma), 0.2% 
Triton X-100 (Sigma). Primary antibody incubations were then carried out on a 
rocking platform overnight at 4⁰C. Cells were then washed three times with PBS 
followed by the addition of a corresponding fluorescent Alexa Fluor (Invitrogen) 
secondary antibody for two hours on a rocking platform at room temperature under 
aluminium foil to prevent exposure to light. Cells were washed three times with PBS 
to remove traces of secondary antibody and then stored under foil at 4⁰C until 
visualisation. Secondary only antibody controls were also carried out with no primary 
antibody to check for background fluorescence. Antibodies used in ICC and the 
appropriate dilutions can be found in the following table:  
Antibody Supplier and Catalogue Number Dilution 
Human Nodal R and D Systems #MAB1315 1:1000 
Human Cripto R and D Systems #AF145 1:1000 
Secondary Alexa Fluor anti-goat 488 Thermo Fisher #A-11055 1:2000 
Secondary Alexa Fluor anti-mouse 594 Thermo Fisher #A-11005 1:2000 
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Antibody Supplier and Catalogue Number Dilution 
Primary CYP1A1 
Santa Cruz Biotechnology  
#sc-25304 
1:100 
Primary CYP1A2 
Santa Cruz Biotechnology 
#sc-53241 
1:100 
Primary CYP3A4 
Santa Cruz Biotechnology 
#sc-27639 
1:100 
Primary SOX17 
R and D Systems #AF 
1924 
1:1000 
Primary FOXA2 
R and D Systems  
#AF2400 
1:1000 
Secondary Alexa Fluor anti-goat 488 
Thermo Fisher 
#A-11055 
1:2000 
Secondary Alexa Fluor anti-mouse 594 
Thermo Fisher 
#A-11005 
1:2000 
Table 3: Antibodies used in ICC staining 
Primary and corresponding secondary antibodies used in ICC staining. Appropriate dilutions 
in for each primary and secondary antibody are displayed along with supplier and catalogue 
numbers. 
 
2.4.6 Flow cytometry 
Cells undergoing flow cytometry were prepared by removing DMEM-complete media 
and washing cells twice with PBS. Cells were then incubated with 0.25% Trypsin at 
37⁰C until cells detached from the culture flask surface. Trypsin was neutralised with 
the addition of DMEM-complete at a 2:1 ratio of serum containing media to trypsin to 
neutralise enzymatic activity before pelleting cells at 300xg for five minutes. Cell 
pellets were then washed three times with PBS before being resuspended in 1ml 
PBS. Samples were run on LSRFortessa flow cytometer (BD) using FACSDiva 
software. Live cells were identified from the sample data by forward scatter (FSC) 
and side scatter (SSC) profile. Background autofluorescence was then calibrated 
and gated using non-transfected cells. Data was subsequently analysed using 
FlowJo version 7.6.4 (Treestar, Oregon, US).  
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2.5 Fluorescent and Luminescent Assays 
2.5.1 EROD Assay for CYP1A1/A2 Activity 
The fluorescent ethoxyresorufin-O-deethylase (EROD) assay was used to quantify 
levels of CYP1A1/A2. Cells were first washed with assay medium consisting of 
William’s E media (Lonza) containing 10µg/ml insulin (Invitrogen), 0.1µM 
Hydrocortisone (Stem Cell Technologies), 2mM L-glutamine and 1% P/S. 20µM of 
7-ethoxyresorufin (0.2% final concentration DMSO) diluted in assay media was then 
added and incubated for two hours at 37ºC. Following incubation with 7-
ethoxyresorufin, EROD assay media was removed and transferred to NUC96ft 
plates (Nunc) and liberated resorufin was analysed for excitation at 560nm and 
emission at 590nm wavelength on a GloMax 96 well plate reader (Promega).   
2.5.2 p450Glo Assay for CYP3A4 Activity 
CYP3A4 activity in HLCs was quantified using the luminescent p450Glo assay kit 
(Promega). Cells were washed with assay media consisting of William’s E media 
containing 10µg/ml insulin (Invitrogen), 0.1µM Hydrocortisone (Stem Cell 
Technologies), 2mM L-glutamine and 1% P/S before being incubated with luciferin 
IPA (1:1000) in assay medium. Cells were incubated for sixty minutes at 37ºC. 
Supernatant was then removed and transferred to white walled NUC96fw plates 
(Nunc) and 50µl of detection reagent was added and left to incubate for twenty 
minutes at room temperature. Luminescence readings were then taken with an 
integration time of 500ms on a GloMax® Multi+ 96 well plate reader.  
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2.5.3 Luciferase Assay using Luciferin  
Cells were washed three times with PBS followed by the addition of 300μl of 
luciferase lysis buffer ((0.65% NP40, 10mM Tris (pH 8.0), 1mM EDTA (pH 8.0) and 
150mM NaCl)). Lysis buffer was left at room temperature for five minutes to lyse 
cells. To completely lyse cell samples, three freeze/thaw cycles at -80ºC were 
carried to ensure complete lysis. Samples were then centrifuged for two minutes at 
4500xg to precipitate nuclei and cellular debris. Samples were then stored at -80ºC 
or direct quantitation carried out immediately. In a 96 well white walled plate, 20µl of 
cell lysate was mixed with 20µl of luciferase buffer B ((50mM Tris Phosphate (pH 
7.8), 2mM DTT, 2mM EDTA, 2% Triton X-100, 16mM MgCl2 being added to 3ml 
glycerol, 80 µl 100mM ATP (Sigma) and 2ml of 10% BSA)). Luciferase reactions 
were performed in biological triplicate repeats using cells from different passage 
numbers.  
A background reading was taken for ten seconds before the injection of luciferin to 
test samples, which was then subtracted from actual readings after luciferin 
administration. This is particularly importance if luciferase levels are low and the 
gain adjustment, or sensitivity, of the machine is high. 40µl of 3mM luciferin was 
injected to each test well to give a final concentration of 1.5mM. Bradford assays 
were carried out to determine protein concentrations (see Methods 2.4.2) as a 
method to normalise luciferase readings to account for cell numbers between test 
samples.  
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2.5.4 NanoLuc Secreted Luciferase Assays  
NanoLuc (Nluc) secreted luciferase assays were used to give a real-time readout of 
reporter activation on a day-on-day basis in living cells. Cells were transduced with 
the Nluc luciferase constructs at a concentration of 20MOI as described previously. 
Cells transduced with Nluc luciferase containing lentiviral vectors were allowed to 
condition culture media for 24 hours before media samples being taken. As a control 
for cell number between cell samples, secreted Vargula luciferase (Vluc) was 
utilised as an alternative to lysing cells and normalising to Bradford protein assays.  
In a 96 well white bottomed plate, 20µl of cell lysate was mixed with 20µl of 
luciferase buffer B (containing no ATP) to make luciferase reaction buffer in a final 
volume of 40µl in each well. A background reading was taken for ten seconds 
before the injection of coelenterazine and vargulin substrates to test samples, which 
was then subtracted from actual readings after substrate administration. Luciferase 
reactions were performed in biological triplicate repeats using cells from different 
passage numbers. 
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2.6 CombiCult® Hepatocyte Screen 
2.6.1 CombiCult® Growth Factors and Small Bioactive Molecules 
Plasticell Ltd. developed a combinatorial cell culture platform, CombiCult®, for the 
establishment of new stem cell differentiation protocols The CombiCult® platform 
assesses the step-wise application of growth factors and/or small bioactive 
molecules to stem cells to direct differentiation towards cell types of interest. 
Multiplexing of a large range of variable cell culture media combinations can be 
achieved through split-pooling which allows for up to 20,000 possible culture media 
permutations.  
The CombiCult® hepatocyte screen was carried out to identify key differentiation 
inducing factors over a four-stage protocol to mimic in vivo hepatocyte differentiation 
incorporating novel factors with a view to produce more metabolically relevant 
hepatocytes. Each stage of differentiation was designed to mimic DE specification, 
hepatic specification, hepatic progenitor expansion and finally hepatocyte 
maturation.  
At each stage of the differentiation process cell culture media contained 
combinations of three factors consisting of small molecules and growth factors. 
Combinations of growth factors and small molecules at each stage of differentiation 
were added to a hepatocyte basal differentiation (HBM) media consisting of 
William’s E Media (Sigma-Aldrich), 1x B27 (Life Technologies), 1% Sodium 
Pyruvate (Life Technologies), 1% NEAA and 1% P/S was used for the first and 
second stages of the differentiation process. At the third and fourth stage of hepatic 
differentiation, 10µM dexamethasone (Sigma-Aldich) and 0.1µM hydrocortisone 
(Stem Cell Technologies) were added to hepatocyte basal media along with 
combinations of small molecules and growth factors.  
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Growth factors that were used in hepatic differentiation were reconstituted in 
appropriate buffers as per manufacturer’s instructions to a stock concentration of 
100µg/ml and diluted in HBM to appropriate concentrations. Small molecule 
inhibitor/agonists were reconstituted in DMSO to a stock concentration of 10mM and 
subsequently diluted in HBM. The following differentiation inducing factors at the 
concentrations stated were used in the CombiCult® hepatocyte screen: 
 
Hepatocyte differentiation basal media 
100ng/ml Activin A (human recombinant, R and D Systems) 
20ng/ml HGF (human recombinant, R and D Systems) 
10ng/ml FGF4 (human recombinant, R and D Systems) 
2µM BIO (Sigma) 
100nM CITCO (Calbiochem) 
1µM Mysteric Acid (C14-AS) (Calbiochem) 
1µM Hyperforin (Calbiochem) 
100nM Isoproterenol (Calbiochem) 
1µM SR12813 (Calbiochem) 
100µg/ml Linoleic Acid (LAC18:2) (Sigma) 
 
Table 4: CombiCult® Stage 1 - DE Specification 
Factors added in various combinations in hepatocyte differentiation basal media in the first 
stage of the CombiCult® hepatocyte differentiation screen concerned with the specification 
of DE from pluripotent stem cells. Combinations of three differentiation-inducing factors were 
added in each protocol.  
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Hepatocyte differentiation basal media 
10ng/ml VEGF (human recombinant, R and D Systems) 
20ng/ml HGF (human recombinant, R and D Systems) 
25ng/ml WNT5A (human recombinant, R and D Systems) 
2% DMSO (Sigma) 
10µM SB-431542 (Sigma) 
10ng/ml FGF4 (human recombinant, R and D Systems) 
50ng/ml GDF15 (human recombinant, R and D Systems) 
10nM Mysteric Acid (C14-AS) (Sigma) 
1µM Clofibrate (Sigma) 
10µM SMAD3 Inhibitor (SIS3) (Calbiochem) 
 
Table 5: CombiCult® Stage 2 - Hepatic Specification 
Factors added in various combinations in hepatocyte differentiation basal media in the 
second stage of the CombiCult® hepatocyte differentiation screen concerned with 
differentiation towards the hepatic lineage. Combinations of three differentiation-inducing 
factors were added in each protocol.  
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Hepatocyte differentiation basal media (with dexamethasone and hydrocortisone) 
20ng/ml TGFα (human recombinant, R and D Systems)) 
20ng/ml Il6 (human recombinant, R and D Systems) 
10ng/ml BMP7 (human recombinant, Invitrogen) 
1µM Glucagon: (Calbiochem) 
20ng/ml HGF (human recombinant, R and D Systems) 
20ng/ml OSM (human recombinant, R and D Systems) 
1µM All-trans retinoic acid (Calbiochem) 
10ng/ml Growth Hormone (human recombinant, R and D Systems) 
10nM Mysteric Acid (C14-AS) (Sigma) 
100ng/ml Progesterone (Calbiochem) 
 
Table 6:  CombiCult® Stage 3 - Hepatic Progenitor Expansion 
Factors added in various combinations in hepatocyte differentiation basal media in the third 
stage of the CombiCult® hepatocyte differentiation screen concerned with expanding hepatic 
progenitor cells. Combinations of three differentiation-inducing factors were added in each 
protocol.  
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Hepatocyte differentiation basal media (with dexamethasone and hydrocortisone) 
20ng/ml HGF (human recombinant, R and D Systems) 
25ng/ml WNT5A (human recombinant, R and D Systems) 
100ng/ml Progesterone (Calbiochem) 
10µM βEstradiol (Calbiochem) 
10ng/ml Insulin (Invitrogen) 
10ng/ml FGF4 (human recombinant, R and D Systems) 
10ng/ml Growth Hormone (human recombinant, R and D Systems) 
20ng/ml Il6 (human recombinant, R and D Systems) 
20ng/ml OSM (human recombinant, R and D Systems) 
10ng/ml IGF-1 (human recombinant, R and D Systems) 
100nM Glucagon (Calbiochem) 
100nM CITCO (Calbiochem) 
1mg/ml Linoleic Acid (LAC18:2) (Sigma) 
1µM SR12813 (Calbiochem) 
100nM Isoproterenol (Calbiochem) 
1µM TJU103 (Sigma) 
1µM T0901317 (Sigma) 
1µM GW7647 (Sigma) 
1µM Docosahexaenoic Acid (Sigma) 
 
Table 7: CombiCult® Stage 4 - Hepatic Maturation 
Factors added in various combinations in hepatocyte differentiation basal media in the fourth 
and final stage of the CombiCult® hepatocyte differentiation screen concerned with the 
maturation of hepatic cells. Combinations of three differentiation-inducing factors were added 
in each protocol.  
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2.6.2 Four-Stage Hepatocyte Differentiation CombiCult® Screen 
2.6.2.1 Microcarrier Seeding 
During the CombiCult® split-pooling process cells seeded on microcarrier beads 
were maintained in a 37ºC humidified incubator with 5% CO2. At D0, the day before 
the start of a CombiCult® experiment, 600,000 PTC5000 microcarrier beads 
(Plasticell, Stevenage, UK) were sterilised by autoclaving and washed twice with 
PBS before being equilibrated in hESC culture media. Microcarriers were then 
transferred to suspension culture plates (Greiner Bio One) at a concentration of 
4000 beads/well in 2mL of hESC media. Shef-3 hESCs grown in monolayer culture 
were then dissociated through incubation with 0.1µg/ml collagenase I at 37⁰C for 
five minutes. Shef-3 hESC colonies were then cut by mechanical passaging into 
small colony pieces and seeded onto microcarrier beads by adding 1ml of media 
containing 5x105 cells to each well, then left to attach overnight. Viable cells were 
then visualised under a light microscope by staining microcarriers with 1:100 dilution 
neutral red solution (Sigma) for 30 minutes.  
 
2.6.2.2 CombiCult® Split Pooling 
The following day (D1), Shef-3 seeded microcarrier beads were washed, pooled in 
serum free media and split equally into ten tubes. Microcarrier beads in each tube 
were resuspended in the appropriate stage 1 differentiation media and a unique 
species of fluorescent tag added to each media combination tested. The tags used 
in the CombiCult® screen comprised of thirty unique populations of inert fluorescent 
microspheres (Plasticell). Fluorescent tags ranged in size from 1-10 microns with a 
range of ten fluorescent intensities for each size of tag.  
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The fluorescent tags bind to the microcarrier surface during the differentiation 
process. There is very infrequent tag hopping between microcarriers and conditions 
have previously been made to minimise this.  
After five days incubating in stage 1 cell culture media beads were washed with 
hepatocyte basal media to remove excess tags and detached cells. Beads were 
then pooled together followed by splitting again into the next set culture conditions 
as before. This process was subsequently repeated through the desired number of 
culture condition steps to recapitulate the developmental cues specifying mature 
hepatocytes in vivo. Pooling and splitting occurred in this way on D5 and D10 with 
the addition of unique sets of fluorescent tags. On D17, stage 4 differentiation 
protocols were kept in isolation without the addition of fluorescent tags for the last 
stage of hepatocyte differentiation; protocols were not repooled and mixed at the 
end of stage 4. 
 
2.6.2.3 CYP1A1/A2 and CYP3A4 Drug induction  
At the end of hepatic differentiation split-pooling, HLCs on microcarrier beads were 
induced with 10µM omeprazole + 50µM dexamethasone (CYP3A4 inducers) and 
50µM rifampicin (CYP1A1/A2 inducer) diluted in assay media consisting of William’s 
E media containing 10µg/ml insulin (Invitrogen), 0.1µM Hydrocortisone (Stem Cell 
Technologies), 2mM L-glutamine and 1% P/S. Induction was carried out for three 
days with induction media being refreshed every day. As a control, assay media 
containing 0.2% DMSO vehicle control was used to compare levels of CYP1A1/A2 
and CYP3A4 induction to basal levels.  
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2.6.2.4 Microcarrier Immunocytochemistry Staining 
Following end point drug induction or vehicle control treatment, ICC staining was 
carried out. Microcarriers were then washed three times in PBS before being fixed 
with 4% paraformaldehyde (PFA) (Electron Microscopy Sciences) for an hour and 
blocked in 1x PBS containing 1% BSA (Sigma-Aldrich), 0.1% Triton X-100 (Sigma-
Aldrich). Primary antibody incubations for CYP1A1, CYP1A2 and CYP3A4 enzymes 
(Santa Cruz Biotechnology, Dallas, US) was carried out overnight at 4⁰C at 1:100 
dilutions before washing three times and incubating in Alexa Fluor secondary 
antibody (Invitrogen) at 1:1000 dilutions. A secondary only control containing no 
primary antibodies was used to establish levels of background fluorescence.  
 
2.6.2.5 COPAS Sorting 
The COPAS PLUS large particle sorter (Union Biometrica, Holliston, US) is capable 
or sorting large particles, in this case microcarriers seeded with cells, based on size 
and fluorescent intensity utilising two channels allowing for dual staining of 
differentiated HLCs to be analysed. The COPAS sorter is equipped with both a 488 
nm and 561 solid state lasers and green photomultiplier tubes (PMT) 514/23 nm and 
red PMT 615/45 nm optical emission filters. COPAS was utilised to isolate individual 
microcarriers based on fluorescence intensity after ICC staining. Fluorescence 
intensity gating was established firstly by sorting a secondary antibody only 
microcarrier control which gave a measure of background fluorescence intensity 
which was to be omitted. Subsequently, an aliquot of stained microcarrier beads 
from each of the final twenty conditions was pooled to establish a threshold with 
which to identify high levels of CYP1A1/A2 (red) and CYP3A4 (green) fluorescence 
following drug induction across all HLCs.  
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Once threshold gates were established, microcarrier beads from each of the final 
twenty pools were processed in the COPAS large particle sorter and beads which 
exceeded the gated fluorescence intensity threshold were sorted into individual 
wells of a 96 well plate. The COPAS large particle sorter allows the isolation of 
individual microcarriers with HLCs that exceed the established fluorescence gating 
to be isolated in individual wells of a 96 well plate. In this way, the highest 
expressing CYP1A1/A2 and CYP3A4 HLCs can be isolated for cell culture history 
processing.  
 
2.6.2.6 FACS Tag Analysis 
Bound tags on microcarrier surfaces were removed and transferred to individual 
FACS tubes for differentiation history analysis in the FACS Canto II flow cytometer 
(BD) to analyse cell culture history of the most highly expressing HLCs. Three sizes 
of fluorescent tag were used for the first three split-pool procedures at D1, D5 and 
D10 with each sized tag having ten fluorescent intensity graduations.  Individual tags 
were assigned to each media condition at each stage of differentiation allowing 
tracking of unique cell culture history. COPAS isolated beads representing the most 
highly expressing CYP1A1/A2 and CYP3A4 HLCs isolated into individual wells of a 
96 well plate. Prior to fluorescent tag analysis, a reference tag set was used with 
which to establish side and forward scattering gates on the BD FACS Canto II flow 
cytometer to calibrate fluorescence intensity of each specific tag set.  
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2.6.2.7 Ariadne Differentiation Pathway Analysis 
Differentiation histories were deconvoluted and analysed in the Plasticell proprietary 
Ariadne™ bioinformatics software using only microcarriers with three distinct tags 
from stages 1-3 of differentiation i.e. contained full differentiation histories to identify 
clusters of media permutations. The clusters are identified based on the probability 
of any given combination of culture conditions to be present in a positive bead given 
the total number of positive beads and the total number of possible combinations.  
In the CombiCult® hepatocyte screen there were 20,000 possible pathways. From 
this total number of pathways only some returned CYP1A1/A2 and CYP3A4 positive 
beads. From the positive beads, common combinations of media conditions were 
identified, creating differentiation media history clusters. Ranked protocols were 
produced based on linkages between cell culture stages which resulted in the most 
highly expressing CYP1A1/A2 and CYP3A4 HLCs. Differentiation culture history 
clusters were identified when they contain three or more events with near identical 
scattering and fluorescence values.  
 
2.6.3 Statistics 
Quantitative data obtained from gene expression, fluorescent and luminescent 
assays were analysed using GraphPad Prism 6.03 (GraphPad, San Diego, CA). 
Graphs are displayed as representative images of “n number” of experiments as 
detailed per the individual legends. Graphed data are displayed as the arithmetic 
mean ± standard error of the mean (SEM) unless otherwise stated. Statistical 
significance was evaluated by unpaired two-tailed Student’s t-test, or 1- or 2-way 
ANOVA followed by Bonferroni’s post-test for multiple comparisons.  
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A 1-way ANOVA was used if there was a single variable factor between the test 
groups and a 2-way ANOVA was used if there was more than one variable test 
factor. ANOVA analysis was used to determine if there was any significant 
difference between the mean values from two or more test groups compared to the 
control mean in normally distributed samples; the null hypothesis being that there is 
no statistical difference between groups. A Bonferroni’s post-test for multiple 
comparisons was subsequently carried out to assess type I error in groups that had 
been identified as significantly different from an ANOVA statistical test. Data was 
classed as significant when p values were below 0.05. *<0.05, **<0.01, ***<0.001.
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Chapter 3: Investigating Definitive Endoderm 
Specification 
3.1 Introduction 
The efficient production of homogenous populations of DE is a key starting point in 
the differentiation of pluripotent stem cells to hepatocytes. Activin A and Nodal are 
both members of the TGFβ family and share common signalling pathways (Figure 
7A). However, Nodal signalling relies on its signalling co-factor Cripto to bind and 
initiate SMAD signalling whereas Activin A does not and functions independently of 
Cripto [91]. It has been shown that the addition of exogenous recombinant Nodal to 
monolayer cultures of pluripotent stem cells did not specify DE or result in the 
suppression of pluripotency-associated markers [245]. Consequently, Activin A is 
used in an attempt to mimic the process of Nodal signalling which is known to be 
crucial in vivo in the establishment of DE [87] [110] [111] [84] [106] [83]. 
There has been evidence uncovered through genome arrays to show that there are 
significant off-target effects caused by the utilisation of Activin A to induce DE 
specification in vitro (McKay et al., unpublished data) (Figure. 4B, 4C and 4D). 
Expression of the visceral endoderm marker Orthodenticle Homeobox 2 (OTX2) 
(Figure 7C) and mesodermal markers Brachyury (T) and Bone Morphogenetic 
Protein 2 (BMP2) (Figure 7D) were found to be increased upon the exogenous day-
on-day addition of Activin A to pluripotent hESCs over the course of six days 
(McKay et al., unpublished data).  In fact, the working hypothesis from this study is 
that Activin A stimulates the transcriptional upregulation of Nodal which then in turn 
promotes DE specification.  
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The differences in signalling networks between Activin A and Nodal are 
hypothesised to account for the heterogeneous populations of DE produced through 
the exogenous application of Activin A. Work is therefore required to dissect the 
underlying mechanisms involved in Nodal signalling during the specification of DE in 
as a starting point to differentiate towards the hepatic lineage. Studies including that 
of Takenaga et al. (2007) have investigated the role of Nodal signalling in an attempt 
to more efficiently differentiate hESCs to DE [246]. Nodal signalling was regulated in 
transduced hESCs using a tetracycline-on (tet-on) lentiviral system and was found 
that Nodal-related molecules showed the potential to differentiate genetically 
unmanipulated hESCs towards DE and mesoderm. To further address this research 
problem in this thesis, lentiviral vectors to knock down or overexpress Nodal and its 
extracellular co-factor Cripto were utilised. The working hypothesis is that in an 
environment lacking Nodal signalling, i.e. in pluripotent stem cells transduced with a 
Nodal knock down lentiviral vector, there would be a more heterogeneous 
population of DE produced after the six-day differentiation time course. The 
converse would be true for pluripotent stem cell cultures transduced with a Nodal 
overexpression vector. 
Building on the overexpression approach to produce more homogenous populations 
of DE, the ability of Nodal/Cripto proteins to efficiently differentiate hESCs will be 
investigated in different experimental systems. This will be though either the 
production of “feeder-cells” which have been genetically manipulated to overexpress 
secreted Nodal/Cripto proteins or through the production of conditioned media to 
apply to hESCs with a view to differentiation towards DE. The aim of these studies is 
to produce tools with which the profile of DE produced to be examined and 
compared with or without the use of Activin A; using SOX17 and FOXA2 as a 
readout of specified DE cells in future studies.  
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3.2 Aims 
• Validate lentiviral vectors to overexpress or knock down Nodal and/or Cripto.  
• Produce Nodal/Cripto knock down or overexpression transduced cell lines. 
• Compare Nodal/Cripto conditioned media differentiated cells to Activin A 
derived cells for SOX17 and FOXA2.  
• Assess conditioned media approaches to differentiate pluripotent cells to DE. 
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Figure 7: Activin/Nodal signalling in DE specification 
(A) Simplified overview of the similarities and differences in the signalling pathways of the 
TGF- β family members Nodal and Activin A. Nodal signalling relies on Cripto to bind and 
initiate SMAD signalling whereas Activin A does not. (B) Whole transcriptomic analysis of 
day-on-day gene expression modulation following Activin A treatment on feeder free hESCs 
to induce DE specification for a period of six days. (C) Endodermal marker transcriptomic 
analysis showing evidence of off-target gene modulation such as, OTX2 (marker of visceral 
endoderm). (D) Mesodermal marker transcriptomic analysis showing the upregulation of 
Brachyury and BMP2 (mesodermal markers) during Activin A induced DE specification 
(McKay et al., unpublished data). 
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3.3 Results 
3.3.1 Creation of Lentiviral Constructs 
To validate tools with which to investigate the role of Nodal/Cripto signalling during 
in vitro DE specification, lentiviral shRNA knock down and overexpression vectors 
were employed. Knock down and overexpression lentiviral vectors were validated in 
HeLa cells, which have been shown to express both Nodal and Cripto at levels 
appropriate for the analysis of gene modulation to be quantified. 
 
3.3.1.1 Nodal/Cripto Knock Down Lentiviral Vectors 
For gene knock down experiments, eight pGIPZ lentiviral vectors containing different 
shRNA sequences targeting Nodal and Cripto along with a scrambled targeting 
control were obtained from Open Biosystems as bacterial stab cultures. 
Nodal/Cripto shRNA knock down clones included: V2LHS_155453, V2LHS_278899, 
V2LHS_194508, V2LHS_403216, V2LHS_403219, V2LHS_352858, 
V2LHS_352856 and V2LHS_403217. Bacterial stab cultures were streaked onto 
individual ampicillin plates. Individual antibiotic resistant clones were then picked 
after 37⁰C incubation overnight followed by clone amplification before Miniprep DNA 
extractions were carried out (see Methods 2.2.1) (Figure 8). Clones were then 
sequenced to confirm correct Nodal/Cripto sequences. 
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Figure 8: Gel extracted pGIPZ Nodal/Cripto shRNA lentiviral clones (1-8) 
Agarose gel image of the individual pGIPZ shRNA 1-8 knock down clones. DNA extraction 
was carried out on four Cripto (lanes 1-4) and four Nodal (lanes 5-8) shRNA lentiviral 
clones obtained from Open Biosystems in the form of bacterial stab cultures. DNA 
extracted clones were electrophoresed on an agarose gel to check for correct band size of 
12774bp (NODAL) and 12267bp (CRIPTO). L= 1kb DNA Hyperladder. 
 
 
 
 
 
 
 
3.3.1.2 Nodal/Cripto Overexpression Lentiviral Vectors 
Overexpression lentiviral vectors were produced firstly by the excision of Nodal and 
Cripto cDNA from commercially obtained pBluescript and pCR4-Topo vectors 
(Clone IDs: 8327493 and 5286020, Open Biosystems). Restriction digests of 
pBluescript-CRIPTO and pCR4-Topo-NODAL vectors with BamHI:BamHI and 
EcoRI:BamHI (NEB) restriction digests respectively (see Methods 2.2.3). The 
excised Nodal/Cripto cDNA insert fragment was separated from the vector 
backbone through agarose gel electrophoresis and subsequent gel extraction and 
purification using the QIAquick gel extraction kit (Figure 9) (see Methods 2.2.2). The 
excised cDNA was then ligated into the multiple cloning site (MCS) of the pENTR-
1A entry vector (Invitrogen) (Figure 10A-C).  
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This was achieved using complementary restriction sites; BamHI:BamHI and 
BamHI:EcoRI for Nodal and Cripto respectively and gel extraction of digested 
vectors (Figure 9A and C). Ligation was carried out using quick ligase (NEB) as per 
manufacturer’s instructions (see Methods 2.2.4). The use of the pENTR-1A entry 
vector allows the Nodal and Cripto cDNA inserts to be cloned into the delivery vector 
in the correct orientation utilising the LR clonase system (see Methods 2.2.5).  
 
 
 
 
 
 
 
 
 
 
Ligated clones were transformed into competent DH5α E.coli cells (NEB) and 
individual kanamycin resistant clones were picked, DNA extractions carried out 
followed by restriction enzyme digests to identify correct clones and proper insert 
orientation (see Methods 2.2.6).  
A B C D 
 
 
 
 
A 
Figure 9: Construction of pLNT-SFFV-Nodal/Cripto overexpression vectors 
(A) pENTR-1A entry vector digested with EcoRI restriction enzyme. (B) pCR4-Topo-NODAL 
digested with EcoRI restriction enzyme to release the Nodal cDNA insert. (C) pENTR-1A 
entry vector digested with EcoRI:BamHI restriction enzymes. (D) pBluescript-CRIPTO 
digested with EcoRI:BamHI restriction enzymes. Red boxes indicate the correct sized DNA 
bands from each restriction digest which were excised from the agarose gel and carried 
forward to the next stage of cloning. L= 1kb DNA Hyperladder. 
L 
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Clonase recombination was then carried out to shuttle Nodal/Cripto cDNA from 
pENTR-1A entry vector into the pLNT-SFFV-Gateway lentiviral vector (Invitrogen) 
Figure 10D) before transformation into competent Stabl3 E.coli cells (NEB). 
Individual ampicillin antibiotic resistant clones were then picked and sequenced 
using cPPT sequencing primers designed for the pLNT-SFFV-Gateway to check for 
correct insert orientation and Nodal/Cripto cDNA sequence validity.  
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A B 
C D 
pENTR-1A 
2717bp 
pLNT-SFFV-GW 
10,638bp 
pCR4-TOPO-NODAL 
5000bp 
pBluescript-CRIPTO 
3551bp 
Figure 10: Plasmid maps of Nodal/Cripto overexpression lentiviral vectors 
(A) Plasmid map for pBluescript-Cripto (Open Biosystems) with flanking EcoRI:BamHI 
restriction enzyme sites for Cripto excision. (B) pCR4-TOPO-Nodal (Open Biosystems) with 
flanking EcoRI restriction enzyme sites. (C) pENTR-1A subcloning vector where both Nodal 
and Cripto cDNA was ligated into complementary EcoRI restriction sites. (D) Plasmid map of 
the pLNT-SFFV-Gateway expression vector (Invitrogen) into which the Nodal and Cripto 
cDNAs were recombined from the pENTR-1A subcloning vectors (Invitrogen). 
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3.3.2 Validation of Nodal/Cripto Lentiviral Constructs 
HeLa cells, shown to express both Nodal and Cripto (Figure 11B), were transduced 
with pGIPZ knock down lentiviral vectors along with a pGIPZ scrambled target 
control. Puromycin selection was then carried out at a concentration of 1µg/ml for 
one week to produce pure populations of shRNA knock down expressing HeLa 
cells. This was evidenced by eGFP fluorescence merged with phase contrast 
images of transduced cells (Figure 11A). SYBR Green qPCR analysis was then 
carried out to assess absolute levels of Nodal and Cripto knock down in transduced 
cells between the different shRNA clones. SYBR Green qPCR primers were 
designed to span exon-exon junctions for both Nodal and Cripto to eliminate 
genomic DNA amplification and erroneous readings of gene expression. SYBR 
Green qPCR standards with which to compare absolute gene expression values 
were produced by amplifying pGIPZ scramble control transduced HeLa cell cDNA 
with Nodal/Cripto qPCR primers followed by gel purification of the obtained PCR 
product. Serial dilutions from 10‾3 to 10‾7 were produced from gel purified standards. 
GAPDH was used as a housekeeping gene control with which to normalise gene 
expression values. Standard reactions with which to quantify gene expression 
values were carried out in triplicate whilst Nodal/Cripto knock down and 
overexpression samples were analysed through triplicate reactions. Three biological 
repeats consisting of cells from three different passage numbers were carried out for 
each validation experiment. 
It was determined that the most efficient shRNA Nodal knock down vector was sh4 
with a knock down efficiency of 85%-fold change (p=0.05) compared to the wildtype 
control and normalised to GADPH (Figure 11C). Clones sh1, sh5 and sh8 had knock 
down fold change levels of 80% (p=0.05), 70% (p=0.04) and 45% (p=0.12) 
compared to the pGIPZ scramble control.  
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The most efficient shRNA Cripto knock down vector after three biological repeats 
was determined to be sh2 with a knock down efficiency of 80% (p=0.04) (Figure 
11D) compared to pGIPZ scramble control and normalised to GAPDH. Knock down 
clones sh3, sh6 and sh7 were assessed to be 70% (p=0.05), 55% (p=0.11) and 30% 
(p=0.04) respectively.  
Lentiviral overexpression pLNT-SFFV-Nodal/Cripto vectors were also successfully 
transduced into HeLa cells alongside a mock SFFV-eGFP vector containing no 
overexpression cassette to assess transduction efficiency. Through qPCR analysis it 
was shown that pLNT-SFFV-Nodal/Cripto vectors over-expressed Nodal and Cripto 
in HeLa cells above twenty-fold compared to SFFV-eGFP control expression levels 
(p=0.06 and p=0.04 respectively) (Figure 11C-D). The current lack of a selectable 
marker on the overexpression vector hampers a more accurate quantification of 
overexpression levels as the efficiency of transduction cannot be assessed. 
However, as a proof of principle validation of the vectors it can be concluded that the 
constitutive SFFV viral promoter efficiently drives the overexpression of Nodal and 
Cripto in HeLa cells. 
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Figure 11: Validation of knock down and overexpression vectors 
(A) Representative image of HeLa cell transductions with lentiviral pGIPZ knock down 
constructs (4 Nodal and 4 Cripto). Imaging of phase contrast (left) eGFP (middle) and 
merge (right) after one week of puromycin selection to produce pure populations of 
transduced cells. Three biological repeats consisting of cells from three different passage 
numbers were carried out validation.  (B) RT-PCR amplification of pGIPZ scramble control 
HeLa cell cDNA with primers for Nodal and Cripto to assess expression following 20 cycles. 
N = Nodal PCR product, C= Cripto PCR product, L = 1kb DNA Hyperladder. (C, D) qPCR of 
HeLa cells transduced with Nodal knock down and overexpression vectors (C) and Cripto 
Nodal knock down and overexpression vectors (D). Statistical analysis of gene knock down 
was evaluated by a 1-way ANOVA with Bonferroni’s post-test for multiple comparisons. 
Data shown as mean ±SEM of three technical replicates of one representative biological 
repeat. Significance indicated by ***(p<0.001), **(p<0.01), *(p<0.05). 
MERGE 
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3.3.3 Creation of Nodal/Cripto Knock down hESC Lines 
Feeder-free conditioned huES1-OCT4-GFP hESCs were grown on fibronectin 
coated plates in defined media and enzymatically passaged using trypsin/EDTA to 
small colony pieces. Colony pieces were transferred onto new fibronectin coated six 
well cell culture plates and grown to 70% confluence in mTeSR defined pluripotency 
media (Stem Cell Technologies).  
Large scale lentiviral preparations were carried out on the most efficient Nodal and 
Cripto pGIPZ shRNA knock down clones (sh4 and sh2 respectively) along with a 
scrambled pGIPZ vector control. Lentiviral titering was carried out and huES1-
OCT4-GFP cells were transduced at a concentration of 20MOI. The constitutive 
knock down huES1 cell lines that were produced were: sole Nodal knock down, sole 
Cripto knock down, dual Nodal/Cripto knock down and scrambled targeting control. 
Nodal and Cripto knock down lentivirus was produced and concentrated as 
described previously (see Methods 2.1.11) and used to transduce huES1-Oct4-GFP 
cells for 48 hours. The mTeSR culture media was then refreshed every other day for 
a period of seven days. 
After seven days post-transduction, there was no detectable increase in eGFP 
expression resulting from lentiviral integration of the pGIPZ vectors (Figure 12A). 
High levels of eGFP should be detected through florescence microscopy at this 
stage indicating successful incorporation of the lentiviral shRNA knock down 
constructs.  
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Even though no increase in eGFP levels was observed following lentiviral 
transduction, huES1-OCT4-GFP cells were antibiotically selected with 1µg/ml 
puromycin added to cell culture medium to obtain pure populations of transduced 
cells. Preliminary studies using an antibiotic kill curve established that a puromycin 
concentration of 1µg/ml was optimal for hESC selection to allow for quick cell death 
of non-resistant cells whilst not having a visible effect on resistant cell health. 
Selection with 1µg/ml puromycin resulted in near total cell death indicating the lack 
of shRNA lentiviral transduction and expression of the puromycin resistance 
cassette (Figure 12B). 
Transduction of the Nodal/Cripto shRNA lentiviral constructs was also attempted in 
feeder-free conditioned Shef3 hESCs to ascertain hESC line variation in 
transduction potential. Lentiviral preparations were carried out as done previously 
and variable MOI concentrations of shRNA vectors transduced into Shef3 hESCs: 
10MOI, 20MOI, and 50MOI. After seven days post-transduction there was no visible 
eGFP in transduced cells at any of the trialled MOI concentrations and no cells 
survived 1µg/ml puromycin selection (data not shown). This again indicating the lack 
of expression of the resistance cassette and corroborates data obtained through the 
transduction of huES1-OCT4-GFP cells. 
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Figure 12: huES1 OCT4-GFP feeder free knock down cell lines 
(A) huES1 OCT4-GFP cells seven days post-transduction with Nodal/Cripto knock down 
and scramble control pGIPZ shRNA vectors. (B) pGIPZ shRNA transduced huES1 cells 
following puromycin selection for four days to select for cells containing Nodal/Cripto knock 
down constructs. Antibiotic selection of transduced huES1 OCT4-GFP cells with 1µg/ml 
puromycin resulted in near total cell death indicating the lack of shRNA lentiviral 
transduction and expression of the puromycin resistance cassette.  
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3.3.4 Validation of Nodal/Cripto Over-Expression Conditioned Media 
Following the data collected from validation of the overexpression and knock down 
lentiviral vectors, a new approach was used to differentiate pluripotent stem cells 
efficiently to DE. This was firstly due to the pLNT-SFFV-Nodal/Cripto overexpression 
lentiviral vectors lacking a selectable marker to facilitate accurate and quantitative 
levels of transduction efficiency. It would therefore be difficult to assess transduction 
levels in hESCs and a mock pLNT-SFFV-eGFP transduction would be needed in 
parallel to ascertain lentivirus production through constitutive eGFP expression. 
Secondly, lentiviral integration would limit the future application of DE and the ability 
to differentiate hESCs in a system not requiring lentiviral integration would be 
advantageous.  
To address this research problem, a new system of DE specification from pluripotent 
stem cells was designed. The pLNT-SFFV-Nodal/Cripto vectors encode for the 
corresponding secreted proteins meaning over-expression conditioned media 
containing Nodal and Cripto proteins could be collected, filtered and applied to 
cultures of pluripotent hESCs to promote the efficient differentiation to DE. To 
assess the potential of this new approach, pLNT-SFFV-Nodal/Cripto over-
expression lentivirus was firstly transduced into 293T cells to create “producer cells”. 
Producer 293T cells would be employed to secrete Nodal and Cripto protein into DE 
basal differentiation culture media to produce “conditioned over-expression media” 
(see Methods 2.1.5). Subsequently, this conditioned media containing Nodal and 
Cripto proteins would be added to cultures of hESCs to determine the ability of this 
conditioned media to differentiate the cells efficiently to DE. The ability of the 
conditioned media to specify DE would be compared to that of exogenously added 
Activin A and a differentiation control consisting of basal differentiation media 
without Activin A to evaluate the efficiency and homogeneity (see Methods 2.1.5).   
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To validate the conditioned media concept, levels of both Nodal and Cripto proteins 
in the conditioned media needed to be assessed and quantified. This was achieved 
using a pLNT-SBE-eGFP-luc lentiviral vector created by Juliette Delhove in the 
McKay lab group at WHRI, QMUL. The pLNT-SBE-eGFP-luc lentiviral vector 
contains both luciferase and eGFP elements under the control of a SMAD binding 
element (SBE). Upon the initiation of TGFβ signalling the SBE element will be 
activated and a quantitative readout of increases in signalling from Nodal/Cripto 
proteins through both luciferase activity and eGFP florescence would be obtained, 
allowing assessment of the efficiency of this approach.  
The pLNT-SBE-eGFP-luc lentivirus was first transduced into 293T cells to create 
“reporter cells” that give both a visual indication of the initiation of TGFβ signalling 
through eGFP florescence and a quantitative readout of activation levels through 
luciferase activity. To test the responsiveness of the pLNT-SBE-eGFP-luc vector 
upon the activation of TGFβ signalling, Activin A was exogenously added to the cell 
culture media of 293T reporter cells. Activin A was used at 0ng/ml (control), 
50ng/ml, 100mg/ml and 200ng/ml for a period of six days, with media refreshed 
every day. Following Activin A treatment the levels of TGFβ signalling activation as 
determined through the pLNT-SBE-eGFP-luc reporter was assessed by eGFP 
fluorescence (Figure 13A) and quantitative luciferase assays (Figure 13B).   
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It was found that the pLNT-SBE-eGFP-luc transduced 293T reporter cells were 
responsive to the exogenous addition of Activin A in a dose dependant manor. 
eGFP fluorescence levels were seen to be present at background levels at 0ng/ml 
(control) indicating basal levels of TGFβ signalling in 293T reporter cells followed by 
a significant increase in eGFP fluorescence upon the exogenous addition of Activin 
A (Figure 13A). It was seen that the addition of 50ng/ml, 100ng/ml and 200ng/ml 
increased reporter activation by 45, 55 and 60-fold over control (0ng/ml) respectively 
as assessed through luciferase assays (p<0.001) (Figure 13B).  
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Figure 13: Validation of the pLNT-SBE-eGFP-luc reporter through 
exogenous Activin A addition to reporter cells 
(A) Low levels of background eGFP fluorescence were observed in 293T pLNT-SBE-
eGFP-luc reporter cells in control cells (no Activin A addition). A significant increase in 
fluorescence was observed through the addition of Activin A after five days of treatment. 
Levels of eGFP fluorescence were observed to be similar in 50ng/ml, 100ng/ml and 
200ng/ml. (B) Luciferase assays quantitatively showed that there was an increased 
luciferase reporter activity in a dose dependant manner upon addition of Activin A at 
50ng/ml, 100ng/ml and 200ng/ml respectively. Luciferase fold change was measured in 
comparison to reporter cells without the addition of Activin A. Data are shown at the mean 
±SEM from three biological replicates (n=3). Statistical significance was calculated using 
a 1-way ANOVA with Bonferroni’s post-test for multiple comparisons. Significance 
indicated by *** (p<0.001), ** (p<0.01), * (p<0.05). The pLNT-SBE-eGFP-luc lentiviral 
vector was created by Juliette Delhove in the McKay lab group at the WHRI, QMUL. 
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After validation of the pLNT-SBE-eGFP-luc reporter system to assess levels of 
TGFβ signalling upon the addition of Activin A, it was possible to quantitatively 
measure inceases in SBE reporter levels from secreted Nodal and Cripto proteins 
present in conditioned media. To produce Nodal/Cripto overexpression media, 293T 
cells were transduced with the pLNT-SFFV-Nodal/Cripto lentiviral vectors to create 
“producer cells”. As the pLNT-SFFV-Nodal/Cripto vector doesn’t contain a 
selectable marker to assess levels of transduction, a lentivirus containing an SFFV-
eGFP cassette was transduced in parallel into separate populations of 293T cells 
and found to be ~70% expressed in populations through GFP+ cells. Following 
successful transduction, conditioned media was produced by adding fresh cell 
culture media and allowing Nodal and Cripto proteins to be secreted for a period of 
24 hours. Subsequently, conditioned media was harvested from the producer cells 
and filtered followed by the addition to 293T reporter cells measure TGFβ signalling 
increases. Conditioned media was applied to reporter cells using the same 
production method for six days with media being refreshed each day. As a control, 
conditioned media was collected from SFFV-eGFP transduced 293T cells 
(containing no Nodal/Cripto proteins) and applied to reporter cells in the same 
manner.   
It was found through luciferase assays that sole Cripto conditioned media exhibited 
SBE-eGFP-luc reporter activation at levels comparable to control conditioned media 
produced from SFFV-eGFP cells (Figure 14B). However, Nodal conditioned media 
induced reporter activation six-fold over control (p<0.05) as assessed through 
luciferase activity and exhibited eGFP levels in corroboration with quantitate 
analysis (Figure 14A). It was not possible to assess the levels of combined Nodal 
and Cripto conditioned media on SBE reporter activation due to experimental 
problems and time constraints but would be an avenue of future investigation.  
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Figure 14: Validation of Nodal/Cripto conditioned media  
(A) eGFP fluorescence levels upon TGFβ signalling activation from 293T producer cells 
following six days of treatment with either control (0ng/ml Activin A), Nodal conditioned 
media or Cripto conditioned media. (B) Quantification of pLNT-SBE-eGFP-luc reporter 
activation upon the addition of Nodal and Cripto conditioned media after six days of 
treatment. Data are shown at the mean ±SEM from three biological replicates (n=3). 
Statistical significance was calculated using a 1-way ANOVA with Bonferroni’s post-test for 
multiple comparisons. Significance indicated by *** (p<0.001), ** (p<0.01), * (p<0.05). The 
pLNT-SBE-eGFP-luc lentiviral vector was created by Juliette Delhove in the McKay lab 
group at the WHRI, QMUL. 
 
 
 
106 
 
3.3.5 Differentiation of hESCs with Nodal/Cripto Conditioned Media  
Following the validation of the overexpression media system using the pLNT-SBE-
eGFP-luc reporter construct, Nodal/Cripto conditioned media was collected from 
Nodal/Cripto overexpression 293T producer cells and sequentially added day-on-
day to feeder free conditioned Shef-3 hESCs for five days. Combinations of 
conditioned media used to assess DE specification included: sole Nodal 
overexpression media, sole Cripto overexpression media, combined Nodal and 
Cripto overexpression media, 100ng/ml Activin A and 0ng/ml Activin A 
(unconditioned basal media only). Combined Nodal and Cripto conditioned media 
was used at a 1:1 ratio which resulted in a 50% reduction in concentration when 
compared to sole application of Nodal or Cripto.  
Feeder free conditioned Shef-3 hESCs were transduced with the lentiviral reporter 
constructs pLNT-SBE-eGFP-Nluc and pLNT-Vluc-eGFP-Nluc at 20MOI. The pLNT-
SBE-eGFP-Nluc and pLNT-Vluc-eGFP-Nluc lentiviral vectors were created by 
Juliette Delhove in the McKay lab group at the WHRI, QMUL. Secreted Nluc 
lentiviral reporters were used as opposed to the pLNT-SBE-eGFP-luc reporter to 
better understand the day-on-day TGFβ temporal signalling changes, underlying DE 
specification from pluripotent stem cells over five days of differentiation (Figure 
15A). As the Nluc luciferase is secreted into the culture media, samples can be 
taken daily and reporter activity can therefore be monitored in addition to eGFP 
florescence in real time without lysing cells (see Methods 2.5.4). 
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The secreted Vargula luciferin (Vluc) served as a control to normalise cell numbers 
between the different wells of the experiment. This was opposed to carrying out 
Bradford assays which requires the lysing of cells to collect total protein in traditional 
luciferase assays. Culture media samples of Nluc conditioned media were taken 
precisely every 24 hours and assessed for secreted luciferase on the GloMax® 
Multi+ (Promega) machine; allowing for a measure of signalling activity to be 
quantified (Figure 15B).  
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Figure 15: Shef3 differentiation with Nodal/Cripto conditioned media 
(A) Schematic diagram of the pLNT-SBE-eGFP-Nluc lentiviral reporter vector used to assess 
levels of TGFβ signalling during DE specification. The pLNT-SBE-eGFP-Nluc and pLNT-
Vluc-eGFP-Nluc (control) lentiviral vectors were created by Juliette Delhove in the McKay 
lab group at the WHRI, QMUL. (B) Nluc secreted luciferase assays showing SBE reporter 
activity in relative fluorescent units (RFU) over five days of DE differentiation normalised to 
Vluc. Sole Nodal, sole Cripto and combined Nodal + Cripto conditioned media, 100ng/ml 
Activin A (+ Activin A) and basal media containing no Activin A (- Activin A) are displayed 
over the five days of differentiation. Line graphs were created from the average of three 
biological repeats (n=3) with three technical repeats carried out for each biological repeat. 
Error bars were calculated for each time point using the ±SEM. Statistical analysis using a 1-
way ANOVA gave a significance value of p=0.632 indicating no significant difference 
between control and conditioned media reporter activity.  
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Upon transduction of Shef3 hESCs with the pLNT-SBE-eGFP-Nluc reporter, very 
low levels of eGFP were visualised at 20MOI. Over the course of the differentiation 
experiment, it was found that there was no significant change in the levels of Nluc 
lentiviral reporter activity compared to the control over the five days of treatment 
following normalisation to account for cell numbers with Vluc (p=0.632).  
Differentiated cells at the day five-time point were subsequently fixed with 4% PFA 
and stained by ICC for SOX17, a robust marker of DE, which is widely used to 
assess the populations of DE cells produced (Figure 16).  Primary antibody 
incubations were carried out at 1:1000 dilution using a SOX17 primary antibody and 
secondary antibody incubation at 1:2000 dilution using Alexa Fluor anti-mouse 594 
(see Methods 2.4.5). It was seen that there were exclusively SOX17+ cells in the 
0ng/ml Activin A (basal media only) condition group however, the number of positive 
cells was seen to be at very low numbers. It was also observed that cells produced 
through the withdrawal of Activin A displayed different cell morphology to those of 
cells differentiated with either overexpression conditioned media or through the 
addition of Activin A at 100ng/ml. Overexpression conditioned media differentiated 
cells were seen to stain strongly for SOX17, indicating DE cells were specified 
through this approach. Comparative SOX17+ levels were seen between sole Nodal, 
sole Cripto and combined Nodal/Cripto conditioned media. Cell morphology in 
conditioned media and +100ng/ml Activin A groups closely resembled that of DE; 
possessing “cobble stone-like” cell morphology. 
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Figure 16: ICC staining of conditioned media differentiated cells 
SOX17+ ICC staining of cells differentiated through the addition of conditioned media to 
feeder free Shef-3 hESCs for five days. (A) 0ng/ml Activin A (basal media only), (B) 
100ng/ml Activin A, (C) sole Nodal conditioned media, (D) sole Cripto conditioned media 
and (E) combined Nodal and Cripto conditioned media. ICC staining images are from one 
biological replicate at x20 magnification. 
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3.3.6 Differentiation of hESCs with Nodal/Cripto Overexpression MEFs 
Following the differentiation of hESCs to SOX17+ cells utilising overexpression 
conditioned media, the possibility of using Nodal/Cripto transgenic overexpression 
MEF feeder lines to efficiently specify cells expressing DE markers was explored. To 
create the MEF overexpression lines, pLNT-SFFV-Nodal/Cripto vectors was 
transduced into CD1 MEFs at passage 1 post-isolation at 20MOI. As a measure of 
transduction efficiency, a mock pLNT-SFFV-eGFP lentivirus was transduced side-
by-side with overexpression constructs into separate populations of MEFs. This was 
done as the pLNT-SFFV-Nodal/Cripto overexpression vectors lack a marker to 
assess transduction (Figure 17A). It was assessed through the mock pLNT-SFFV-
eGFP transduction that eGFP+ cell expression was approximately 50%. 
Overexpression MEFs were subsequently expanded to passage 3 to create stocks 
and inactivated with 100µg/ml mitomycin C to create Nodal/Cripto overexpression 
feeder cells.  
To validate the ability of the overexpression MEFs to induce TGFβ signalling 
through the secretion of Nodal/Cripto protein into the culture media, the pLNT-SBE-
eGFP-luc reporter was used to quantify increases in reporter activity. 
Overexpression MEF cell lines that were created included sole Nodal, sole Cripto 
and combined Nodal/Cripto. Nodal/Cripto overexpression MEFs conditioned culture 
media for a period of 24 hours before being added to reporter 293T cells transduced 
with the pLNT-SBE-eGFP-luc reporter to assess levels of TGFβ signalling activation. 
Nodal/Cripto conditioned media was replaced day-on-day for a period of five days 
before the reporter cells were lysed for luciferase assays (Figure 17B).  
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As a control for this experiment, conditioned media was collected from MEF feeders 
transduced with the pLNT-SFFV-eGFP mock lentivirus and applied to reporter cells 
(no AA). Validation experiments for transgenic overexpression MEFs was carried 
out in biological triplicate with three technical replicates for each sample being 
carried out. 
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Figure 17: Quantification of Nodal/Cripto overexpression MEF feeders 
(A) Phase contrast (left) and eGFP (right) imaging of MEFs transduced in parallel with a 
mock SFFV-eGFP lentiviral vector as a measure of transduction efficiency of the pLNT-
SFFV-Nodal/Cripto overexpression constructs which lack a selectable eGFP marker. (B) 
Levels of Nodal/Cripto overexpression in transgenic MEF feeder cell lines were assessed 
using the pLNT-SBE-eGFP-luc reporter 293T system. Conditioned media produced from 
overexpression MEFs was added day-on-day to reporter cells for a period of five days and 
compared to conditioned media from MEF feeders transduced with the pLNT-SFFV-eGFP. 
Reporter cells were then lysed for quantitative luciferase assays. Statistical analysis of 
reporter activation was evaluated by a 1-way ANOVA with Bonferroni’s post-test for multiple 
comparisons. Data is shown as mean ±SEM of three biological repeats. Significance 
indicated by *** (p<0.001), ** (p<0.01), * (p<0.05). RFU = raw fluorescent units. 
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It was found that there was no significant difference in SBE reporter levels between 
control conditioned media produced from SFFV-eGFP MEFs and reporter cells 
treated with conditioned media produced from sole Nodal and sole Cripto MEFs. 
However, there was found to be a significant increase in TGFβ reporter activity, 
through the activation of the SBE reporter element, with combined Nodal and Cripto 
conditioned media (p<0.001). An increase of approximately four-fold was quantified 
through luciferase assays above control conditioned media treated reporter cells. 
This result contrasted the inductive potential of sole Nodal activation of the SBE 
response element seen in conditioned media collected from 293T producer cells 
(Figure 14). This could be in part due to the cocktail of secreted factors produced 
from MEF feeder cells which masked a DE inducing effect of secreted Nodal/Cripto 
proteins.  
Following assessment of Nodal/Cripto overexpression levels in transgenic MEF 
feeders, inactivated MEFs were plated onto 0.1% gelatin coated 12 well plates at 
70,000 cells/well 24 hours prior to Shef3 hESC seeding. Feeder free conditioned 
Shef3 hESCs cultured in mTeSR were dissociated into single cells using Accutase® 
and replated onto transgenic overexpression MEFs at 70,000 cells/well in mTeSR 
pluripotency media. Feeder free conditioned Shef3 hESCs were used in this 
experiment due to problems with contamination in feeder-conditioned Shef3 hESCs 
and time constraints. The following day, cell culture media was changed to basal 
differentiation media (see Methods 2.1.5). In addition to using Nodal/Cripto 
overexpression MEFs to differentiate Shef3 hESCs to DE, inactivated MEFs 
transduced with SFFV-eGFP were used as control feeder cells. Shef3 hESCs were 
plated onto either inactivated SFFV-eGFP MEFs in basal media or basal media with 
the addition of 100ng/ml Activin A. Basal culture media was refreshed every 48 
hours in all cell lines to allow for transgenic overexpression MEFs to condition the 
media for a total of five days.  
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Following five days of differentiation, cells were fixed with 4% PFA and stained by 
ICC for SOX17. In addition, FOXA2 ICC staining was also carried out on replicate 
wells as the presence of SOX17+ and FOXA2+ cells are used in combination as 
robust markers of DE (Figure 18).  Primary antibody incubations were carried out at 
1:1000 dilution using SOX17 and FOXA2 primary antibodies and secondary 
antibody incubations at 1:2000 dilution using Alexa Fluor anti-mouse 594 (see 
Methods 2.4.5).  
Strong FOXA2+ ICC staining was found in all treatment conditions at comparable 
levels except for Cripto overexpression MEF feeders which were found to exhibit 
lower levels of FOXA2+ cells (Figure 18A). Cell morphology was also seen to be 
consistent in all treatment protocols including that of SFFV-eGFP conditioned 
culture media (containing no added DE inducing factors). In addition, the confluency 
of the differentiated cells was seen to be at comparative levels across treatments 
and replicate wells for each condition.  
Levels of ICC staining for SOX17+ cells was seen to be at lower levels in both the 
100ng/ml Activin A and SFFV-eGFP conditioned media (no AA) than was seen in 
FOXA2 ICC staining. Levels of SOX17+ cells were seen to be higher in the 
100ng/ml Activin A treatment compared to SFFV-eGFP conditioned culture media 
containing no added DE inducing factors (Figure 18B). This result was expected 
however, there was predicted to be a larger difference in levels of both SOX17+ and 
FOXA2+ cells between these treatments as Activin A is routinely used to specify DE 
from pluripotent hESCs. One explanation for this result in both the SOX17 and 
FOXA2 staining of control cells could be that the MEF feeder cells secrete a cocktail 
of growth factors which could be masking the inductive effects of the conditioned 
media and the 100ng/ml Activin A treatment, through the secretion of TGFβ into 
culture media.  
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Cell morphology in SOX17+ cells was seen to be consistent in both SFFV-eGFP 
conditioned media, 100ng/ml Activin A and dual Nodal/Cripto overexpression 
conditions and maintained consistent with cell morphology seen in FOXA2+ cells. 
However, differences in cell morphology were seen in both sole Nodal and sole 
Cripto treatments. In sole Cripto overexpression cells, there was large amounts of 
SOX17+ cells however, the cell morphology was seen to be particularly distinct from 
other treatments; SOX17+ cells were seen to be “cobble-like” in appearance. It is of 
note that the differentiated cell morphology in the sole Cripto overexpression MEFs 
largely resembled the that of cells produced in the basal media only (0ng/ml Activin 
A) of the 293T producer cell conditioned media experiment (Figure 16). 
Differentiated cells produced through sole Nodal overexpression conditioned media 
were seen to be found in defined tightly-packed cell clusters with distinct gaps 
between SOX17+ cell clusters.  
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Figure 18: DE cells produced utilising transgenic overexpression MEF feeders 
(A) ICC staining for FOXA2+ cells on transgenic MEFs in the different treatment groups at 
day five of differentiation. (B) ICC staining of SOX17+ cells on transgenic overexpression 
MEFs of the different treatment groups at day five of differentiation. ICC staining images are 
from one biological repeat at x20 magnification.  
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3.4 Discussion 
As DE cells give rise to the hepatic lineage as well as other cell lineages of 
therapeutic interest including pancreatic cells, the ability to efficiently specify DE 
cells from human pluripotent stem cells is an attractive approach that has yet to be 
realised [87] [247]. Using different methodologies including the use of shRNA 
knockdown and lentiviral overexpression in both a MEF feeder and feeder-free 
differentiation systems, human pluripotent stem cells were subjected to DE 
differentiation methods in comparison to Activin A.  
 
3.4.1 Investigating DE Specification with shRNA Lentiviral Knock Down 
The validation of lentiviral shRNA knock down vectors were trialled to validate tools 
with a view to dissect DE specification and in particular the role of Nodal and its 
extra-cellular signalling co-factor Cripto. Previous studies have shown that the 
addition of exogenous recombinant Nodal to monolayer cultures of pluripotent stem 
cells resulted in a lack of differentiation and continued maintenance of pluripotency 
markers as assessed through qPCR and undifferentiated colony morphology [245]. 
Activin A is routinely used to mimic Nodal signalling specify DE in vitro [248] [148] 
[83] [249]. The use of Activin A in place of recombinant Nodal in DE differentiation 
protocols is therefore due to Activin A exhibiting greater activity than currently 
available recombinant human Nodal proteins. However, the off-target gene 
activation caused by the addition of exogenous Activin A maybe deleterious to 
producing homogenous populations of DE (McKay et al. unpublished data).  
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There has been evidence provided by Chen et al. (2013) that the use of 
recombinant Nodal protein at much increased concentrations promotes mES cells to 
differentiate to more mature and functional insulin-producing cells [250]. Levels of 
Nodal protein added to mES cells to elicit this response were twenty-fold increased 
over levels of Activin A that is typically used to specify DE in vitro. Therefore, 
analysis of DE populations in different Nodal/Cripto expression environments would 
provide a valuable insight into the underlying signalling mechanisms. 
Gene expression knock down was validated in HeLa cells, a cell line that was shown 
to have an intact TGFβ signalling pathway and was shown express both Nodal and 
Cripto at levels that permitted the assessment of shRNA knockdown. Through this 
validation, a range of knockdown efficiencies was obtained across the eight 
Nodal/Cripto clones. However, the use of pGIPZ lentiviral shRNA vectors to carry 
out gene knock down studies in pluripotent stem cells was not successful in this 
project. Efficient lentiviral transduction in both huES1-OCT4-GFP and Shef3 hESCs 
could not be obtained over a variety of MOI concentrations and over multiple 
biological replicates using different batches of titred shRNA lentivirus; including the 
use of both freshly produced lentiviral particles and cryopreserved samples. 
Lentiviral vectors utilising the CMV promoter driving shRNA knock down of 
Nodal/Cripto could not be expressed in Shef3 hESCs. The lack of expression in both 
the pGIPZ Nodal and Cripto shRNA lentiviral vectors suggests the problem is with 
the CMV promoter driving knock down expression.  
A previous study by Norrman et al. (2010) compared a number of viral promoters 
and showed that that the CMV viral promoter is rapidly silenced  in transduced 
hESCs [251]. Other studies have also shown that the CMV promoter was down 
regulated in transduced hESCs when compared to other viral promoters including 
EF1α and PGK [252] [253].  
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Expression levels between the promoters in these studies as assessed through 
eGFP florescence was seen to be the lowest in hESCs transduced with CMV-
containing lentiviral vectors. Liew et al. (2007) were unable to obtain successfully 
transduced hESCs when a CMV promoter containing vector was used to transfect 
hESCs [254]. Transfection of hESCs with four different viral promoter containing 
vectors corroborated other studies and further showed that the CMV promoter is not 
the most appropriate choice for gene expression studies in hESCs. Taken together, 
these studies show the variation in strength of expression and in transduction 
efficiency between different viral promoters and highlight the need for appropriate 
promoters to be used when transducing particular cell types. This idea is further 
strengthened by findings in this thesis that very high levels of lentiviral transduction 
was obtained in the validation phase where HeLa cells were transduced 
successfully with the knock down constructs and efficient gene expression 
knockdown was achieved.  
 
3.4.2 Differentiation to DE with Nodal/Cripto Conditioned Media 
After the unsuccessful transduction of Shef3 hESCs with the pGIPZ lentiviral 
Nodal/Cripto shRNA knockdown constructs, a new approach was undertaken with 
which to differentiate pluripotent stem cells to DE. The pLNT-SFFV-NODAL-luc and 
pLNT-SFFV-CRIPTO-luc lentiviral vectors encode secreted Nodal/Cripto proteins 
which were utilised as a method of DE specification using Nodal/Cripto conditioned 
media. This approach was first validated with the use of the pLNT-SBE-eGFP-luc 
293T reporter system. The reporter system validated the proof of principle of using 
the conditioned media approach to increase signal levels of the TGFβ pathway and 
consequently was applied to specify DE from pluripotent hESCs.  
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The Nodal/Cripto conditioned media approach was trialled alongside the use of 
100ng/ml Activin A, typically used to specify DE from pluripotent stem cells [87], 
[110] [111] [84] [106] [83] as well as a pluripotent stem cells exposed to basal media 
without the addition of DE differentiation inducing factors.  
Shef3 hESCs were transduced with the pLNT-SBE-eGFP-Nluc reporter to allow 
changes in TGFβ signalling to be quantitatively assessed at day-on-day intervals. 
Following transduction of the pLNT-SBE-eGFP-Nluc lentiviral reporter very low 
levels of eGFP were visualised at 20MOI. Over the course of the differentiation 
experiment, it was found that there was no significant change in the levels of Nluc 
lentiviral reporter activity over the five days of treatment. This either indicates that 
there were very low levels of lentiviral transduction, possibly accounted for by an 
erroneous p24 assay detecting non-viable lentiviral particles. The second possibility 
is that the Nluc lentiviral reporter is not sensitive to changing TGFβ levels. It was 
seen from the quantitative Nluc analysis that there were no distinct changes in 
pLNT-SBE-eGFP-Nluc reporter activity between the +100ng/ml Activin A and 0ng/ml 
Activin A (basal media only) groups. The addition of Activin A should have increased 
the Nluc reporter activity as seen in the pLNT-SBE-eGFP-luc reporter validation. 
pLNT-SBE-eGFP-Nluc reporter was not previously tested in 293T reporter cells like 
the pLNT-SBE-eGFP-luc secreted luciferase reporter which was shown to be 
responsive and provide a quantitative measure of change. Further investigation is 
therefore needed to validate the pLNT-SBE-eGFP-Nluc and assess the suitability of 
this reporter to be applied in the investigation of TGFβ signalling analysis. 
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After five days of differentiation, with conditioned Nodal/Cripto media combinations 
being applied day-on-day, it was found that cells stained positive for the DE marker 
SOX17. Comparisons between the SOX17+ levels seen between sole Nodal, sole 
Cripto and combined Nodal/Cripto were seen to be comparative between media 
combinations. This was unexpected as sole Nodal conditioned media was seen to 
significantly upregulate SBE-JDG-luc reporter activity compared to sole Cripto 
conditioned media when the approach was first validated. However, it was found in 
this experiment that pluripotent stem cells differentiated without the application of 
DE inducing factors (basal differentiation media only) to SOX17+ cells. 
Differentiated cells from this treatment were present at very low numbers but were 
almost exclusively SOX17+. It was further observed that cells produced through the 
withdrawal of Activin A displayed different cell morphology to those of cells 
differentiated with either overexpression conditioned media or through the addition 
of Activin A at 100ng/ml. This could be due to batches of Nodal/Cripto conditioned 
media containing low levels of the proteins and further investigation would include 
batch testing conditioned media using the pLNT-SBE-eGFP-luc reporter before the 
application to pluripotent stem cell cultures for DE differentiation.  
The use of conditioned media to differentiate human stem cells has been 
investigated previously using conditioned media from chondrocytes which showed 
the ability to successfully differentiate Mesenchymal Stem Cells (MSCs) to 
chondrocytes  [255]. Further studies have shown the potential of specific 
conditioned medias to drive the differentiation of stem cells to osteogenic lineages 
utilising MSC conditioned media [256]. The application of conditioned media to 
differentiate pluripotent stem cells to cell types of interest is therefore an interesting 
proposition to induce lineage specification in a feeder-free environment.  
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The use of quantitative methods of analysis such as qPCR would better assess the 
levels of DE specification through the gene expression analysis of markers including 
SOX17, FOXA2 and CXCR4 amongst others. This could be compared to gene 
expression analysis of DE cells produced using 100ng/ml Activin A. A further 
optimisation of the current system that could be applied to future experiments would 
be to concentrate the Nodal/Cripto conditioned media. Currently, Nodal and Cripto 
conditioned media is combined at a 1:1 ratio which reduces the concentration of 
Nodal and Cripto in the overall media by 50% when compared to sole conditioned 
media. This would make comparisons of the DE differentiation potential of 
conditioned media test groups to Activin A more consistent between treatment 
groups. 
 
3.4.3 Differentiation to DE with Nodal/Cripto Overexpression MEFs 
The use of Nodal/Cripto transgenic overexpression MEFs was investigated as a 
potential feeder-based method to efficiently differentiate hESCs to DE through the 
secretion of combinations of Nodal/Cripto proteins into culture media. This was 
investigated as an alternative strategy to specify DE cells as opposed to utilising 
conditioned media from 293T Nodal/Cripto producer cells which was carried out in a 
feeder-free environment. The ability of transgenic Nodal/Cripto overexpression MEF 
feeder cells to specify DE was assessed against the use of mock transduced MEFs 
containing a selectable marker with or without the addition of 100ng/ml Activin A.  
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From initial validation of the ability of Nodal/Cripto transgenic MEF overexpression 
media, it was found that levels of SBE-eGFP-luc activity in 293T reporter cells was 
less pronounced than those achieved in Nodal/Cripto 293T producer cells (Figure 17 
and Figure 14). This result could account for the differences in results obtained 
through both approaches in terms of SOX17+ cells. As 293T cells are more readily 
transduced than MEFs, it could be that a near pure population of 293T producers 
was obtained compared to the MEF feeder cells which would exhibit a lower 
transduction efficiency (assessed to be ~50%). This would enable higher 
concentrations of Nodal/Cripto DE inducing proteins to be secreted into the 
conditioned culture media from the 293T producer cells.  
The lack of a selectable marker, either eGFP or an antibiotic resistance cassette, in 
the pLNT-SFFV-NODAL-luc and pLNT-SFFV-CRIPTO-luc lentiviral overexpression 
constructs prevents an accurate quantification of transduction efficiency, which 
would need to be incorporated in future validation and DE specification experiments. 
The incorporation of an antibiotic resistance cassette, for example puromycin, would 
allow a pure population of both 293T and MEF feeder producer cells to be 
established with which to carry out DE specification experiments more accurately as 
opposed to relying on mock parallel transductions with a lentivirus containing a 
eGFP element. In this way, effects of overexpression MEFs could be more tightly 
controlled between experiments and the levels of Nodal/Cripto proteins in the 
conditioned media to be standardised. This approach would address the potential 
problem of the loss of transgene expression during passaging of the MEF 
overexpression feeder cells to P3 to obtain sufficient cells to conduct the conditioned 
media experiments. Further advantages include allowing transduced MEFs to be 
distinguished from ICC stained SOX17+/FOXA2+ cells for dual colour imaging. This 
could also have a use in assessing the levels of transgenic MEFs remaining in 
culture wells over the process of DE specification.  
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As the hESCs proliferate and differentiate MEF feeders are pushed outwards of the 
expanding colonies of hESCs; resulting in MEFs undergoing apoptosis and 
detaching from the surface of the cell culture wells. Consequently, there would be 
lower numbers of transgenic overexpression MEFs secreting variable 
concentrations of Nodal and Cripto proteins into cell culture media. This could be a 
possible reason for the disparity in previous literature and the assumed experimental 
outcome in contrast to the levels of SOX17+ and FOXA2+ staining following DE 
differentiation using Nodal/Cripto transgenic MEF feeder cells in this thesis. It was 
expected that the hESCs treated with basal differentiation media collected from 
SFFV-eGFP MEFs with no added DE inducing factors would produce much reduced 
levels of SOX17+ and FOXA2+ cells in comparison to the use of 100ng/ml Activin A, 
which is routinely used to specify DE. The lack of a significant increase in SOX17+ 
and FOXA2+ DE cells was particularly surprising between differentiated cells on 
SFFV-eGFP MEFs supplemented with 100ng/ml Activin A and cells differentiated 
cells that had been exposed to basal media only without DE inducing factors. 
Possible explanations for this outcome could be due to MEF feeder cells secreting 
and undefined cocktail of growth factors into the cell culture media. This allows for 
the possibility that some of these secreted growth factors, including TGFβ family 
members, could compensate for the lack of Activin A and promote the specification 
of DE.  
Before the seeding of hESCs in the feeder-based DE differentiation system, 
mitomycin c was added to inactivate the Nodal/Cripto overexpression MEFs to 
prevent feeder cell overgrowth. Mitomycin C is routinely used as a method to arrest 
feeder cell growth in the culture of different cell types including hESCs [257] [258] 
[259] [260]. Potential effects of mitomycin c on the levels of Nodal/Cripto proteins 
secreted into conditioned media was not studied in this thesis.  
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It has however been previously shown that mitomycin c can increase GFP trans-
gene expression in human glioma cells which have been infected with Adeno-
Associated Virus Type II (AAV) [261]. This observation was further validated in vivo 
and showed that mitomycin c increases AAV transgene expression in mice. 
Consequently, mitomycin c treatment wasn’t thought to decrease lentiviral transgene 
expression in the MEF overexpression experimental system and consequently the 
amount of Nodal/Cripto protein secreted. Future experiments using the feeder-
based DE differentiation system could assess possible effects of both active and 
inactivated Nodal/Cripto secreting MEFs on SBE reporter activation to verify there 
are no negative impacts through the utilisation of mitomycin c in this experimental 
system.  
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Chapter 4: CombiCult® Hepatic Differentiation Screen 
4.1 Introduction 
4.1.1 CombiCult® Differentiation Matrix Design 
Directed differentiation of pluripotent stem cells to cell types of interest has been 
traditionally a process of trial and error which is both time consuming and expensive. 
CombiCult® is a combinatorial cell culture platform that allows the multiplexing of a 
large range of differentiation protocols to be carried out simultaneously – greatly 
reducing the time taken to identify key factors that can be utilized in defined 
protocols [237]. The CombiCult® platform has previously been used to successfully 
identify and optimise protocols to differentiate a number of cell types including 
osteoblasts [238] and haematopoietic progenitor cells [239].  
There is an outstanding requirement in the biotechnology industry for an 
inexhaustible supply of hepatocyte-like cells (HLCs) to be used in regenerative 
medicine to help to repair, augment or replace damaged tissues and with which to 
perform early-stage drug toxicity screens [124] [125]. There is a need for 
hepatocytes to carry out drug safety testing and this is compounded by the fact that 
isolated primary hepatocytes quickly lose their proliferative potential when cultured 
in vitro and dedifferentiate; losing their functional activity [126]. Liver 
hepatocarcinoma cell lines such as HepG2, Huh7 and HepaRG have been used 
previously as hepatocyte models with which to study drug metabolism and conduct 
toxicological assays however, the results have varied in reproducibility and are not 
directly translational to humans [124] [128] [129] [130].  
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To date, in vitro hepatic differentiation protocols have produced HLCs assessed to 
show some degree of functional capability albeit at significantly lower levels than 
seen in isolated primary hepatocytes. [111] [99] [107] [106]. These results taken 
together suggest that the HLCs derived so far resemble immature, foetal 
hepatocytes. As the process of hepatic differentiation and subsequent maturation 
has yet to be fully recapitulated in vitro to produce metabolically relevant HLCs, 
combinations of differentiation-inducing factors need to be assessed and compared 
to the current best models. 
A CombiCult® split-pool screen was designed to identify novel protocols for the 
efficient differentiation of hESCs to mature, metabolically relevant hepatocytes that 
outperform current hepatocyte in vitro models. CombiCult® maturation screens 
carried out on hepatic progenitor cells by Dr Jey Jeyakumar of Plasticell Ltd. gave 
insights into candidates involved in the maturation stages of hepatocyte 
differentiation. Taking previous studies and CombiCult® screen candidates, a new 
hepatocyte differentiation CombiCult® matrix was designed. I conducted a literature 
review to identify components that have been shown to play an important role during 
the different stages of hepatogenesis; that is, DE specification, hepatic specification, 
hepatoblast expansion and hepatic maturation. Previous knowledge of in vivo liver 
development and the growth factors and signalling mechanisms involved was 
utilized and applied to in vitro hepatocyte differentiation (Figure 19). The new screen 
further incorporated small bioactive molecules wherever possible to replace growth 
factors along the key developmental stages of hepatocyte differentiation from 
pluripotent hESCs (see Methods 2.6.1). The use of small bioactive molecules has 
many advantages over the use of growth factors and is important for the future 
industrial application to differentiate pluripotent stem cells to HLCs to reduce costs 
and increase reproducibility [136]. 
 
 
 
130 
 
4.2 Aims 
• Validate a CYP450 ICC assay for hepatic maturation in derived HLCs. 
• Design and conduct a CombiCult® screen to identify novel factors for the 
optimal hepatic differentiation of pluripotent stem cells to HLCs. 
• Isolate top CombiCult® hepatic differentiation protocols for further analysis. 
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Figure 19: Targetting of regulatory mechanisms to produce more mature HLCs 
The mechanisms involved in hepatic specification and maturation were targeted with small 
bioactive molecules and growth factors. The factors used had either previously been 
identified as being important in vivo or were predicted to have a potential inductive effect in 
vitro with a view to more efficiently differentiate HLCs from pluripotent stem cells. 
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4.3 Results 
4.3.1 Validation of End Point Readout for Hepatocyte Differentiation 
For identification and isolation of differentiated HLCs cultured on microcarriers an 
endpoint readout assay for their maturity and metabolic induction potential was 
developed by Dr Jey Jeyakumaer of Plasticell Ltd. Immunocytochemistry (ICC) was 
used to stain for two key members of the CYP450 family of metabolic enzymes, 
CYP1A1/A2 and CYP3A4, which are key players in xenobiotic drug metabolism and 
therefore a robust marker of the levels of hepatocyte maturity in differentiated HLCs. 
ICC staining for mature hepatic markers would be used in conjunction with the 
COPAS large particle sorter to separate out ‘hits’, differentiated HLCs present on the 
microcarrier surface expressing both CYP1A1/A2 and CYP3A4, from non-hepatic 
cells lacking the expression of these markers. CYP1A1/A2 and CYP3A4 enzymes in 
differentiated HLCs were induced through the addition of drug cocktails. CYP1A1/A2 
was induced with the addition of 10µM omeprazole and 50µM dexamethasone 
whilst CYP3A4 was induced with the addition of 50µM rifampicin. Microcarriers can 
therefore be induced solely or dual induced. The levels of CYP1A1/A2 and CYP3A4 
induction upon drug addition was compared to uninduced HLCs.  
CYP1A1/A2 and CYP3A4 induction assays to detect mature HLCs were first 
validated on two cell lines. Firstly, on HepaRG cells, a hepatocarcinoma cell line 
serving as an in vitro hepatocyte model [129] [262] [129]. HepaRG cells exhibit 
some characteristics of primary hepatocytes, such as, metabolic induction; albeit at 
levels that are vastly lower than in primary hepatocytes. Validation was also carried 
out on HepG2 cells, another in vitro hepatocarcinoma model cell line which lacks the 
capacity to be significantly induced with omeprazole and rifampicin (Figure 20).  
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HepaRG cells were maintained on collagen I coated plates in Lonza HBM basal 
media supplemented with Lonza SingleQuots whilst HepG2 cells were maintained in 
DMEM-complete media (See Methods 2.1.2 and 2.1.4). HepG2 and HepaRG cells 
were grown in monolayer culture before being enzymatically dissociated to single 
cells were counted on a haemocytometer before seeding at a density of 100 cells 
per microcarrier bead. HepG2 and HepaRG cells and microcarrier beads were then 
mixed and cell attachment was achieved through overnight incubation at 37⁰C. 
Viable attached cells were then visualised under a light microscope by staining 
microcarriers with neutral red solution (Figure 20A and Figure 21A). It was 
determined that 100 cells per bead was the optimal seeding density for the 
validation assay to allow for sufficient cell attachment without microcarriers 
becoming over confluent.  
After cell attachment to microcarrier surfaces the basal culture media was changed 
to Wiliam’s E Media containing 1% sodium pyruvate, 1% P/S, 0.1µM hydrocortisone 
and 10ng/ml insulin. Cells were treated with assay media containing 10µM 
omeprazole + 50µM dexamethasone to induce CYP1A1/A2 or 50µM rifampicin to 
induce CYP3A4. Combined drug treatment to induce both CYP1A1/A2 and CYP3A4 
enzymes was carried out through the addition of 10µM omeprazole, 50µM 
dexamethasone and 50µM rifampicin to assay media. Drug induction was carried 
out for a period of three days, with induction media being refreshed every day. As a 
control, assay media was added containing no CYP1A1/A2 and CYP3A4 inducers 
but containing a 0.2% DMSO vehicle control (uninduced). The hepatic induction 
assay used to test the drug inducibility of CYP450 enzymes in differentiated HLCs 
was designed and previously validated by Dr Jey Jeyakumar of Plasticell Ltd. 
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Figure 20: Validation of CYP1A1/A2 and CYP3A4 induction assays on HepG2 
cell seeded microcarriers 
(A) HepG2 cells seeded onto microcarriers at 70 cells per bead (i-ii) and at 100 cells per 
bead (iii-iv) stained with neutral red to visualise viable cells on the bead surface (x4 
magnification). (B) Uninduced HepG2 cells seeded microcarriers treated with 0.2% DMSO 
vehicle control stained for CYP3A4 (i: green), CYP1A1/A2 (ii: red) and dual CYP3A4 and 
CYP1A1/A2 (iii-iv: green and red). (C) Induced HepG2 cells following three days of drug 
induction stained for CYP3A4 (i: green), CYP1A1/A2 (ii: red) and dual CYP3A4 and 
CYP1A1/A2 (iii-iv: green and red).  
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For ICC staining to assess levels of HLC maturity, microcarriers were washed, fixed 
and stained (see Methods 2.6.2.4). Primary antibody incubations for CYP1A1, 
CYP1A2 and CYP3A4 enzymes were carried out overnight at 4⁰C at 1:100 dilutions. 
Microcarriers were subsequently washed three times with PBS and incubated in 
Alexa Fluor 488 anti-goat (CYP3A4, green) and anti-mouse 594 (CYP1A1/A2, red) 
secondary antibodies at 1:1000 dilutions. A secondary antibody only control was 
used to establish levels of background florescence with which to exclude in 
subsequent analysis of fluorescence intensity. The ICC staining protocol for hepatic 
induction was initially designed and validated by Dr Jey Jeyakumar of Plasticell Ltd.  
As expected, HepG2 cells seeded onto microcarriers showed no visual induction of 
the CYP1A1/A2 or CYP3A4 enzymes upon drug administration for a period of three 
days compared to uninduced 0.2% DMSO vehicle control (Figure 20B and C). In 
contrast, HepaRG cells seeded onto microcarriers showed increased levels of 
CYP1A1/A2 or CYP3A4 enzymes after drug induction compared to uninduced 0.2% 
DMSO vehicle control (Figure 21C and E). This increase in CYP1A1/A2 or CYP3A4 
levels was observed for both individual and combined drug induction but was 
particularly evident during the single induction of CYP3A4 with 50µM rifampicin. It 
was seen that in the dual induced HepaRG seeded microcarriers that there was co-
localisation of staining for CYP1A1/A2 or CYP3A4 (Figure 21E iii.-iv). 
The ability to isolate cells exhibiting high levels of CYP1A1/A2 and CYP3A4 
enzymes is of great importance in identifying the differentiated HLCs with the widest 
spectrum of metabolic activity. This result demonstrates the ability of the 
CYP1A1/A2 and CYP3A4 ICC assay to distinguish between cells exhibiting hepatic 
markers but low levels of metabolic activity from metabolically active HLCs capable 
of being induced upon appropriate drug cocktail treatment.  
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As a result, the validated ICC assay is suitable to use as an end point maturation 
readout to screen for microcarriers containing HLCs at the end of the CombiCult® 
differentiation process.  
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Figure 21: Validation of CYP1A1/A2 and CYP3A4 induction assay on HepaRG 
cell seeded microcarriers 
(A) HepaRG cells seeded onto microcarriers at 100 cells per bead stained with neutral red 
to visualise viable seeded cells on bead surface (x4 magnification). (B) Phase contrast 
image of uninduced 0.2% DMSO vehicle control treated HepaRG cell seeded onto 
microcarriers (x10 magnification). (C) Corresponding uninduced HepaRG seeded 
microcarriers treated with 0.2% DMSO vehicle control stained for CYP3A4 (i: green), 
CYP1A1/A2 (ii: red) and dual CYP3A4 and CYP1A1/A2 (iii and iv: green and red) (x10 
magnification). (D) Phase contrast image of three days post drug induction HepaRG 
seeded beads (x10 magnification). (E) Corresponding three days post drug induction 
HepaRG seeded beads stained for CYP3A4 (i: green), CYP1A1/A2 (ii: red) and dual 
CYP3A4 and CYP1A1/A2 (iii.-iv: green and red) (x10 magnification).  
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4.3.2 CombiCult® Hepatocyte Differentiation Screen 
A four-stage split-pool CombiCult® screen was designed with 10x10x10x20 culture 
media permutations at each of the four split stages respectively, allowing for a 
20,000-multiplexed screen to be carried out. The increased number of media 
permutations in the final fourth step allows for the testing of an increased number of 
possible maturation inducing reagents in the most undefined stage of hepatic 
differentiation. Small bioactive agonists of nuclear hormone receptors as well as 
CYP450 family members were used in an effort to produce more metabolically 
active HLCs.  
 
4.3.3 CombiCult® Matrix Design 
Hepatocyte basal media (HBM) was formulated as a serum free differentiation 
media containing of William’s E Media, B27, Sodium Pyruvate, NEAA and the 
antibiotic P/S (see Methods 2.6.2.1). This basal differentiation media was used for 
the first DE specification stages and in the second stage of hepatic specification. 
During the process of hepatic progenitor expansion and hepatic maturation 10µM 
dexamethasone and 0.1µM hydrocortisone were added to the HBM. The 
differentiation inducing factors at the concentrations stated that were used in the 
CombiCult® hepatocyte screen is detailed in Table 4-7 (See Methods 2.6.1). 
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4.3.4 CombiCult® Hepatocyte Split Pooling 
 
Following validation of the CYP1A1/A2 or CYP3A4 end point induction assays on 
HepaRG seeded microcarriers, Shef-3 cells were grown in monolayer culture on 
MEF feeder layers (Figure 22A) followed by seeding onto 600,000 microcarriers at 
100 cells per bead in small colony pieces (D0) so that each of the 20,000 possible 
conditions is sampled by at least 30 beads (see Methods 2.6.2.1). MEF feeder 
cultured Shef-3 cells were used as opposed to feeder-free conditioned cells for 
consistency with previous hepatic differentiation studies carried out by Dr Jey 
Jeyakumar of Plasticell Ltd. Viable hESC colony pieces were visualised 24 hours 
after seeding using neutral red staining (Figure 22B). Shef-3 seeded microcarriers 
were then pooled together and split through the designed CombiCult® matrix with 
each media condition spiked with unique fluorescent tag. Three sizes of tag were 
used for the first three split-pools: small, medium and large, with each size having 
ten variations for each individual media condition in each stage.  
B A 
x10 
100μm 
Figure 22: Shef-3 hESC seeding onto microcarrier beads 
Representative images of Shef-3 hESCs seeding onto microcarriers (A) Shef-3 hESCs 
grown on MEF feeder layers in monolayer culture followed by manual passaging into small 
colony pieces and seeding at around 100 cells per microcarrier bead. (B) Shef-3 hESCs 
were subsequently stained with neutral red to visualise viable cells on microcarrier beads. 
Images were taken at x4 magnification. 
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At each split stage, an aliquot of seeded microcarriers was removed from the 
CombiCult® experiment to assess efficiency of microcarrier tagging (see Methods 
2.6.2.2). 
Following differentiation in the final split stage, beads were either treated with a 
combined drug cocktail of 10µM omeprazole, 50µM dexamethasone and 50µM 
rifampicin to induce CYP1A1/A2 and CYP3A4 or a 0.2% vehicle control for a period 
of three days as described previously (see Methods 2.6.2.3). Microcarriers were 
then analysed using the validated CYP1A1/A2 and CYP3A4 ICC assay to assess 
the presence of HLCs expressing high levels of CYP1A1/A2 and CYP3A4. Stained 
microcarriers were then sorted using the COPAS large particle sorter for beads 
possessing HLCs expressing both CYP1A1/A2 and CYP3A4 enzymes (Figure 23). 
A gated fluorescence threshold was established through analysis of a population of 
microcarriers representative of all microcarriers across the four stages of 
differentiation so only the microcarrier beads carrying the most highly expressing 
HLCs would be selected through COPAS sorting (Figure 24). This was done by 
collecting a small aliquot of microcarrier beads (termed “all pools”) from all the final 
twenty pools and analysing the CYP1A1/A2 and CYP3A4 intensity profiles in 
COPAS. The fluorescent intensity profiles of the pooled microcarriers stained with 
CYP1A1/A2 and CYP3A4 antibodies, above the background levels of the secondary 
only antibody controls, served to define the gates for sorting positive microcarrier 
beads; those carrying HLCs expressing high levels of both CYP1A1/A2 and 
CYP3A4 from negative ones. Through this method it was seen that distinct 
populations of microcarrier beads could be separated by their fluorescence intensity 
profiles (Figure 23).  
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COPAS sorted 1161 dual-positive microcarriers based on the gating strategy 
described above, these were then taken forward for FACS deconvolution tag 
analysis. CYP1A1/A2 and CYP3A4 fluorescence intensity profiles were seen to vary 
drastically amongst COPAS sorted beads from the twenty final pools owing to 
varying levels of maturation of the HLCs and the ability of sole and combinations of 
factors to induce CYP450 family member activity; shifts in CYP1A1/A2 expression 
were particularly evident amongst microcarriers from different pools.  
FACS analysis showed that around 80% of microcarriers were successfully tagged 
after the first two split pools and displayed defined fluorescent peaks, indicating the 
presence of only one tag present per split stage and therefore provided the ability to 
deconvolute the tag cell culture history (Figure 25). Of the 1161 beads sorted by 
COPAS, complete tagging data was obtained for 512 (40%). These 512 beads were 
further analysed using Ariadne™ (Figure 25). 
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Figure 23: COPAS sorting of beads expressing CYP1A1/A2 and CYP3A4  
Final twenty pools (1-20) isolated from the final stage 4 of differentiation. Top panel: Scatted 
profiling for size gating to exclude doublets and microcarrier bead aggregates so only single 
beads are selected and isolated by COPAS. Bottom panel: CYP1A1/A2 (Y axis) and 
CYP3A4 (X axis) fluorescence intensity profiles of the final 20 culture conditions. Secondary 
antibody (2⁰ Ab control) only controls were used to exclude any background fluorescence to 
setup appropriate gates to capture dual-positive beads. An “all pools” sample from all the 
final 20 differentiation protocols was taken to establish a baseline of fluorescence intensity 
across all the protocols with which to establish a cut off gate. In this way, only the highest 
expressing CYP1A1/A2 CYP3A4 microcarriers were selected from the total population. 
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Figure 24: ICC staining for CYP1A1/A2 and CYP3A4 induced HLCs. 
Representative images of dual drug induced microcarriers from the final stages of the 
CombiCult® differentiation screen. Microcarriers were stained for CYP1A1/A2 (Green) and 
CYP3A4 (Red). Merged overlay images show the dual expression of both CYP1A1/A2 and 
CYP3A4 in HLCs (Yellow) in differentiated HLCs. A pooled sample from all the final 
differentiation protocols was taken to establish a gated fluorescence threshold. This was 
done so only the microcarrier beads carrying the most highly expressing HLCs would be 
selected through COPAS sorting 
CYP3A4 CYP1A1/A2 MERGE PHASE 
x10 
100μm 
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Figure 25: FACS CombiCult® hepatic differentiation screen tag analysis 
After the first two split pooling procedures bead aliquots were taken to check for 
successful tagging. Controls were used consisting of a mixture of all tags to setup voltage 
gates for small tags (top blue), medium tags (middle red) and small tags (bottom green) 
used in the different split-pools (A). The ten different variations for each particular sized 
tag, each emitting at different fluorescence intensity, displaying defined peaks allowing for 
bead cell culture history to be deconvoluted. (B) Example of a microcarrier bead which 
has successfully been tagged in the first two split stages but has no identifying tag present 
for the third stage of differentiation. (C) Example of a microcarrier which has been tagged 
successfully in the first three stages of differentiation showing a single defined peak at 
each stage allowing deconvolution of the complete cell culture history.  
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4.3.5 Ariadne™ Differentiation Pathway Analysis 
CombiCult® Ariadne™ bioinformatics software was used to identify differentiation 
protocols that most commonly produced dual positive CYP1A1/A2 and CYP3A4 
HLCs following dual drug induction. Several strong cell culture linkages were 
established leading to both whole and partial pathways being identified (Figure 26). 
Differentiation history analysis resulted in the identification of 23 top differentiation 
protocols (Table 8). The top 23 protocols were distinguished above the other 
differentiation protocols in the CombiCult® screen as they were in a distinct group 
above the highest set gated threshold from the “all pools” baseline. This threshold 
was chosen as to pick out only the highest expressing CYP1A1/A2 and CYP3A4 
microcarriers with which to carry out further investigation. Due to company 
confidentiality concerning the Ariadne™ software, my FACS tag analysis data was 
inputted into Ariadne™ by Dr Diana Hernandez of Plasticell Ltd. to produce the 
differentiation pathway analysis results. 
In the first split pool stage, the combination of Activin A, FGF4 and HGF was found 
to be the most common starting condition for producing HLCs expressing the 
highest levels of CYP1A1/A2 and CYP3A4. In addition, combinations of Activin A, 
linoleic acid (LAC18:2) and SR12813 as well as Activin A, hyperforin and linoleic 
acid were seen to be associated with the most highly expressing levels of 
CYP1A1/A2 and CYP3A4 as assessed by the ICC readout. Further component 
analysis was then used to account for the frequency of use of the individual factors 
in the first stage of the differentiation. This showed that the use of Activin A in the 
first stage of differentiation was crucial. The majority of beads expressing both 
CYP1A1/A2 and CYP3A4 enzymes were exposed to Activin A initially to induce DE 
from pluripotent hESCs.  
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WNT3A signalling mimicked through the addition of the GSK inhibitor BIO and the 
CAR agonist CITCO were found to be strongly correlated with the use of Activin A in 
the preliminary steps. This analysis further indicates that the combination of Activin 
A, BIO and CITCO was effective in producing HLCs which were dual positive for 
CYP1A1/A2 and CYP3A4 enzymes.  
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Figure 26: Ariadne™ differentiation pathway cluster analysis 
(A) Strongest pathway linkages identified between the four stages of hepatocyte 
differentiation through tagging analysis. The thickest lines correlate to the strongest 
significant linkages between beads travelling through conditions in each step resulting in the 
highest levels of dual CYP1A1/A2 and CYP3A4 activity.  (B) Heat map and (C) dendrogram 
showing cluster analysis indicating grouping of the most efficient media components 
between the four stages of differentiation. Due to company confidentiality concerning the 
Ariadne™ software, my generated FACS tag analysis was inputted into Ariadne™ by Dr 
Diana Hernandez of Plasticell Ltd. to produce the differentiation pathway analysis results. 
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An interesting trend was observed in the second split pool phase of differentiation in 
that SMAD signalling inhibitors were found to be highly associated with producing 
the most dual-positive CYP1A1/A2 and CYP3A4 HLCs. SB-431542, a TGFβ1/Alk7 
inhibitor along with the SMAD3 signal inhibitor SIS3 were found to be present in the 
majority of top differentiation protocols, indicating that TGFβ signalling inhibition 
during this stage is important. Growth factors including HGF, GDF-15, WNT5A and 
VEGF, which are associated with hepatoblast proliferation and expansion upon liver 
injury in vivo, were also found at high frequency. The SR12813, hyperforin and 
CITCO small molecule agonists of CAR nuclear hormone sensor also featured in the 
top differentiation protocols along with the potential ligand of HNF4α, linoleic acid.  
TGFβ signalling, through the addition of the growth factor TGFα, in contrast was 
found to be important in the third phase of hepatocyte differentiation; consistent with 
knowledge that TGFα is upregulated upon liver injury to promote hepatoblast 
proliferation. HGF and the hormone progesterone also featured highly in the top 
differentiation protocols during this stage.  
The final stages of differentiation the CombiCult® differentiation screen was 
dominated by the presence of the hormones progesterone and βestradiol as well as 
the CAR/LXR/PXR nuclear hormone receptor agonists CITCO, SR12813, GW7647, 
T0901317 and docosahexaenoic acid. The combinations of these factors were 
found in the majority of top-ranking protocols during the maturation stages of 
hepatocyte differentiation.  
Component analysis allowed for clusters of differentiation inducing factors to be 
identified in “synthetic pathways”, that is, combining the best media linkages from 
different stages of the differentiation process. Using this process, it was found that 
there was a strong linkage between beads passing through condition two in the first 
stage and condition two in the second stage.  
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This consisted of hESCs firstly being exposed to Activin A, FGF4 and HGF followed 
by HGF, 2% DMSO and the TGFβ inhibitor SB-431542. Significant linkages were 
also found for beads passing firstly through both conditions 8 and 10 in the first split-
pool moving to conditions 5 and 7 in the second differentiation step respectively. 
This corresponded to beads being exposed to Activin A, FGF4 and CITCO followed 
by WNT5a, 2% DMSO and SB-431542 and secondly beads being exposed to a 
GSK3β inhibitor (BIO), isoproterenol and HGF followed by GDF-15, SB-431542 and 
HGF. Between the third and fourth stages of differentiation, there was a strong 
linkage between condition 3 in third differentiation stage and condition 3 in fourth 
stage. This differentiation history corresponded to beads being exposed to HGF, 
OSM and TGFα followed by progesterone, OSM and α βestradiol.   
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PROTOCOL     STAGE 1             STAGE 2               STAGE 3              STAGE 4 
1 Activin A HGF HGF HGF 
 
FGF4 2% DMSO OSM Insulin 
 
HGF SB-431542 TGFα OSM 
2 Activin A HGF HGF Insulin 
 
FGF4 2% DMSO OSM #3722 
 
HGF SB-431542 TGFα GH 
3 Activin A HGF HGF Progesterone 
 
FGF4 2% DMSO OSM SR12813 
 
HGF SB-431542 TGFα CITCO 
4 Activin A HGF HGF #8379 
 
FGF4 2% DMSO OSM #2028 
 
HGF SB-431542 TGFα #5722 
5 Activin A HGF TGFα Insulin 
 
FGF4 2% DMSO BMP7 #3722 
 
HGF SB-431542 HGF GH 
6 Activin A HGF TGFα HGF 
 
FGF4 2% DMSO BMP7 Wnt5A 
 
HGF SB-431542 HGF #2028 
7 Activin A HGF HGF Progesterone 
 
Hyperforin 2% DMSO RA OSM 
 
Linoleic Acid SB-431542 GH βestradiol 
8 Activin A SIS3 HGF Progesterone 
 
Linoleic Acid GDF-15 OSM OSM 
 
SR12813 C14-AS TGFα βestradiol 
9 Activin A SIS3 HGF Progesterone 
 
Hyperforin GDF-15 OSM OSM 
 
Linoleic Acid C14-AS TGFα βestradiol 
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10 Activin A FGF4 Progesterone Progesterone 
 
Hyperforin GDF-15 IL6 #5722 
 
Linoleic Acid C14-AS TGFα CITCO 
11 Activin A Wnt5A Progesterone Progesterone 
 
FGF4 2% DMSO IL6 #5722 
 
CITCO SB-431542 TGFα CITCO 
12 BIO GDF-15 Progesterone Progesterone 
 
Isoproterenol SB-431542 IL6 OSM 
 
HGF HGF TGFα βestradiol 
13 Activin A HGF HGF Progesterone 
 
Linoleic Acid FGF4 OSM OSM 
 
SR12813 SIS3 TGFα βestradiol 
14 Activin A FGF4 HGF HGF 
 
Hyperforin GDF-15 RA Insulin 
 
Linoleic Acid C14-AS GH OSM 
15 Activin A HGF HGF Progesterone 
 
Hyperforin FGF4 RA SR12813 
 
Linoleic Acid SIS3 GH CITCO 
16 Activin A HGF HGF HGF 
 
FGF4 VEGF RA Insulin 
 
HGF Wnt5A GH OSM 
17 Activin A 2% DMSO Glucagon Wnt5A 
 
Linoleic Acid SB-431542 HGF Glucagon 
 
SR12813 HGF Progesterone Progesterone 
18 Activin A HGF Glucagon Linoleic Acid 
 
Hyperforin VEGF HGF SR12813 
 
Linoleic Acid Wnt5A Progesterone CITCO 
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19 Activin A HGF Progesterone HGF 
 
BIO VEGF IL6 #2028 
 
CITCO Wnt5A TGFα OSM 
20 Activin A HGF Progesterone Progesterone 
 
FGF4 VEGF IL6 #5722 
 
HGF Wnt5A TGFα CITCO 
21 Activin A FGF4 Progesterone #8379 
 
Hyperforin GDF-15 IL6 #2028 
 
Linoleic Acid C14-AS TGFα #5722 
22 Activin A Wnt5A TGFα HGF 
 
FGF4 2% DMSO BMP7 Insulin 
 
CITCO SB-431542 HGF OSM 
23 Activin A GDF-15 HGF Progesterone 
 
BIO SB-431542 RA CITCO 
 
Isoproterenol HGF GH βestradiol 
     
Table 8: Top ranking 23 hepatocyte differentiation protocols 
The 23-top ranking hepatic differentiation protocols identified through Plasticell’s Ariadne™ 
software. The best in vitro hepatocyte differentiation protocols were based on the strongest 
pathway linkages between the four stages which produced the highest CYP1A1/A2 and 
CYP3A4 expressing HLCs. Three factor conditions highlighted in red at each stage of the 
differentiation process identify the most commonly present combinations of growth factors 
and small molecules across the final 23 hepatocyte differentiation protocols.  
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4.4 Discussion 
An in vitro end-point assay previously designed by Dr Jey Jeyakumar to detect 
levels of hepatic maturation was successful in the isolation of high CYP1A1/A2 and 
CYP3A4 expressing HLCs in my CombiCult® hepatic screen which utilised novel 
differentiation inducing factors. Through CombiCult® screening of 20,000 culture 
media permutations, 23 new differentiation protocols were identified to be taken 
further for validation in monolayer culture. These protocols featured novel bioactive 
molecules that have not previously been applied to in vitro hepatic differentiation 
protocols.  
These top protocols resulted from 1,161 dual-positive HLCs containing microcarriers 
expressing high levels of both CYP1A1/A2 and CYP3A4 by ICC staining. Of these 
high CYP1A1/A2 and CYP3A4 expressing HLC microcarrier beads, 512 could be 
successfully deconvoluted through FACS tagging analysis and Plasticell’s 
proprietary Ariadne™ bioinformatics software. Through this analysis several 
candidate factors have been identified as being important at crucial stages of 
hepatic differentiation. Novel and previously identified stimulation/inhibition of 
signalling pathways through the addition of small molecules were found to be 
involved in the most effective differentiation protocols. Small bioactive molecules 
were trialled with a view to replace currently used growth factors wherever possible 
to decrease costs and improve reproducibility; this is also important in the future 
industrial application to differentiate pluripotent stem cells to hepatocytes. In 
addition, it was found that some of the observations concerning stimulation/inhibition 
of signalling pathways were consistent with known and previously published in vivo 
signalling mechanisms in mammalian development, but which are not currently 
being applied to in vitro differentiation strategies; future validation is needed to 
identify the best protocols.  
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It is known that TGF-β signalling is critical for the establishment of DE both in vitro 
and in vivo. High levels of Nodal signalling specify DE at the anterior of the primitive 
streak in vivo [246] [87]. The related TGFβ family member Activin A is routinely used 
in vitro as it signals through similar pathways to Nodal [87] [110] [111] [84] [106] 
[83]. As expected, Activin A was present in the first stage of all the top-ranking 
differentiation protocols, commonly in conjunction with WNT/βcatenin signalling in 
the form of GSK-3β inhibitors. GSK3β inhibitors including BIO, 1M and CHIR99021 
have been used previously in combination with Activin A to differentiate pluripotent 
stem cells to DE [121] [99] [83] [263]. This demonstrates that the specification of 
pluripotent cells firstly to DE following in vivo development is crucial to producing 
HLCs with high metabolic activity. Following component analysis, it was found that 
the initial exposure of hESCs to Activin A in the first differentiation stage of the 
CombiCult® screen was required to produce highly expressing duel positive HLCs. 
During the first stage of differentiation, combinations of small molecules and NHR 
agonists were trialled to ascertain if the classical differentiation process from hESCs 
to specify DE and subsequently to the hepatic lineage could be enhanced. One 
factor identified through media component analysis as being important in the early 
stages of differentiation was hyperforin. It is known that hyperforin is a CYP450 
family agonist, specifically CYP3A4 and CYP2C9 [175], as well as being involved in 
the binding and activation of the nuclear hormone sensor PXR which in turn 
regulates CYP450 member activity [264]. Its potential role in the maturation and 
upregulation of CYP450 enzymes is therefore of great interest in producing more 
metabolically functional hepatocytes in vitro.  
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However, the trial of these novel factors which are not typically utilised in the early 
stages of differentiation in culture conditions that lacked Activin A were not involved 
in the production of high expressing CYP1A1/A2 and CYP3A4 HLCs following the 
four-stage differentiation process. This finding highlights the need to firstly specify 
DE as opposed to circumventing the classical four stages of hepatic differentiation.  
In contrast to the key role played by TGFβ signalling in DE specification, during early 
hepatic specification stages, TGFβ signalling has been found to be deleterious to 
hepatocyte proliferation and acts to promote fibrosis upon liver injury in vivo   [265] 
[266] [267] a trend also observed in the CombiCult® screen. Component analysis of 
the most common differentiation pathways revealed the presence of the TGFβ1/Alk7 
inhibitor SB431542 along with the SMAD3 signal inhibitor SIS3 as being present at 
high frequencies in the second phase of differentiation. This temporal change in 
TGFβ signalling levels could be important for the efficient differentiation of 
pluripotent stem cells to hepatocytes and has not previously been addressed 
through in vitro differentiation protocols. 
The CombiCult® platform allows the identification of critical factors involved in the 
manipulation of key signalling pathways during the process of obtaining 
differentiated cell types from pluripotent stem cells. Previous studies into 
differentiated cell types of interest have relied on the trial and error of growth factors 
resulting in increased time and cost in the advancement of understanding in the 
underlying signalling mechanisms. The CombiCult® platform allows for the 
incorporation of small molecule inhibitors/agonists with a view to replace previously 
used growth factors to increase reproducibility and reduce costs.  
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Previous research into the derivation of efficient populations of DE cells with which 
to differentiate mature hepatocytes has been hampered with optimisation of cell 
differentiation protocols, which could have been more efficiently determined using 
the CombiCult® platform. Progress has been made in growth factor derived 
protocols which are increasingly moving towards the replacement with small 
bioactive molecules [234] [235] [236]. Previously published growth factors including 
HGF, FGF4, OSM and IL6 were utilised in the CombiCult® hepatocyte screen and 
found to be present in top differentiation protocols [110] [106] [107] [136] [99]. In 
addition to these growth factors GDF-15, WNT5A, BMP7 and VEGF which are 
associated with hepatoblast proliferation and expansion upon liver injury in vivo 
were found to be present at high frequency in the top differentiation protocols 
identified through CombiCult®; demonstrating the power of the platform to augment 
current knowledge and advance understanding of cellular differentiation. The 
translation of in vivo knowledge to the in vitro differentiation setting has therefore 
been shown to be an important avenue of investigation.  
In conclusion, analysis of the CombiCult® hepatocyte differentiation screen resulted 
in the isolation of 23 top ranking protocols after establishing a threshold to select 
only the most highly expressing dual positive CYP1A1/A2 and CYP3A4 HLCs which 
are now in the process of being further validated. However, the ICC assay is purely 
a qualitative means of assessing levels of CYP450 family activity and quantitative 
means need to be employed alongside ICC readout assays to get an accurate 
readout of hepatocyte maturity which will be addressed through using p450Glo 
(CYP3A4) and EROD (CYP1A1/A2) assays.    
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Chapter 5: CombiCult® Monolayer Validation 
5.1 Introduction 
Following the completion of the four-stage CombiCult® hepatocyte screen the top 
23 differentiation pathways were taken forward to be validated in 2D monolayer 
culture. Combinations of small bioactive inhibitors and agonists were assessed for 
their ability to induce hepatocyte differentiation and promote maturation over the 
four-stages of differentiation. The transition from the 3D bead culture system used in 
CombiCult® platform through to 2D monolayer culture was investigated to identify 
potential challenges involved in the adaptation of cell culture systems including cell 
seeding, passaging of differentiated cells and optimal concentrations of 
differentiation inducing factors. Initial seeding density was investigated as previous 
studies has shown a difference in levels of DE markers present following a 
differentiation time course from pluripotent hESCs [268] [269]. As many of the small 
bioactive molecules and growth factors have not previously been applied in the 
context of pluripotent stem cell differentiation to hepatocytes, it is important to trial 
reagents for adverse effects that could be detrimental to efficient differentiation. It is 
also important to assess whether the top protocols identified through the 
CombiCult® screen also differentiate to produce the most efficient HLCs in 2D 
monolayer culture; a system which lacks some of the cell-cell interactions of 3D 
culture systems [270].  
Imaging analysis was carried out to assess changes in the top 23 protocols as 
differentiation proceeded with which to identify transition points along the four-stage 
process. As a measure of the levels of maturity in derived HLCs produced from the 
top 23 differentiation protocols, ICC staining for CYP1A1, CYP1A2 and CYP3A4 
was used as well as quantitative analysis.  
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Increases in levels of CYP450 family members upon drug induction will give a better 
indication of functional HLC activity and give a better comparison to the current best 
hepatocyte models. HepaRG cells have been shown to possess the ability to be 
induced upon the addition of inducing drugs and the levels of CYP450 family 
upregulation in 2D monolayer differentiated HLCs will be compared [129] [124] 
[129].  
 
5.2 Aims: 
• Transition the top hepatic differentiation protocols from CombiCult® bead-
based platform to 2D monolayer culture. 
• Optimise in vitro differentiation procedure over the 28-day time course. 
• Further assess quantitative levels of hepatic maturity through CYP450 family 
member activity and hepatic marker expression in differentiated HLCs.  
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5.3 Results 
5.3.1 CombiCult® 2D Monolayer Validation  
Shef-3 hESC Seeding (Day 0) 
To be able to more accurately measure initial cell seeding density with which to 
assess the top differentiation protocols, feeder-free cultures of Shef-3 were used as 
opposed to seeding colony pieces from MEF feeder-conditioned cultures. Feeder 
free growth conditioned Shef-3 hESCs were cultured on fibronectin coated tissue 
culture plates in mTeSR pluripotency maintaining culture media. Shef-3 hESCs were 
subsequently dissociated with Accutase® and seeded in mTeSR at a density of 
80,000 cells per well on 24 well plates which were pre-coated with collagen I (D0) 
(Figure 27). The following day, the Shef-3 hESCs were washed three times with 
hepatocyte basal media (HBM) (see Methods 2.6.1) before being subjected to the 
first stage of the differentiation process. Differentiation protocols consisted of HBM 
supplemented with combinations of three growth factors or small molecules 
identified through the CombiCult® hepatocyte differentiation screen.  
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Differentiation Stage 1 (Day 1) 
Following washing Shef-3 hESCs with HBM differentiation media to remove traces 
of pluripotency maintaining mTeSR media, cells were moved into stage 1 of 
differentiation (D1). Stage 1 largely consisted of the addition of Activin A in 
combination with other endoderm inducing factors and small molecule agonists of 
the canonical WNT pathway including BIO which were identified from the 
CombiCult® hepatocyte screen (Table 8). Small molecule agonists of NHRs were 
trialled in an attempt to circumvent the classical four-stage differentiation process 
from pluripotent stem cells to hepatocytes. This was done to more quickly and 
efficiently generate hepatocytes in vitro. Linoleic acid was also included in the first 
stage of differentiation because of its hypothesised role as a ligand for HNF4α and 
the high frequency of differentiation protocols containing linoleic acid exhibiting the 
highest levels of CYP1A1/A2 and CYP3A4 activity.  
x10 
100μm 
Figure 27: Monolayer differentiation Shef-3 hESC seeding (D1) 
Feeder free conditioned Shef-3 hESCs were grown in mTeSR on fibronectin coated dishes 
and then dissociated with Accutase®. Cells were then counted using a haemocytometer 
and seeded at a density of 80,000 cells per well of a 24 well collagen I coated plates (D0). 
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Exposure to stage 1 differentiation media caused a change in cell morphology 
across all protocols exhibiting a loss of distinctive tightly packed, rounded hESC 
colonies with defined edges to cells with a flattened morphology. After five days in 
the first stage of differentiation it was found that there were ten protocols which had 
produced viable cells which then proliferated to confluency (Figure 28). These 
protocols were numbers 1, 2, 3, 4, 5, 6, 7, 11, 16, 20 and 22. It was found that Shef-
3 hESCs exposed to protocols containing linoleic acid, did not survive past two days 
in culture. It was concluded that the type of unconjugated linoleic acid used (Sigma, 
L1376-10MG) was not suitable to be used in monolayer experiments due to high cell 
toxicity. This was surprising as the same unconjugated linoleic acid was used in the 
CombiCult® hepatocyte screen at the same concentration and was involved in 
producing some of the highest expressing HLCs showing variations between 2D and 
3D culture systems. A titration of linoleic acid was conducted to identify a 
concentration that was compatible with maintaining cell viability. However, it was 
found to be highly toxic even at concentrations that were twenty-fold decreased than 
those used in the 3D microcarrier-based CombiCult® hepatocyte differentiation 
screen.  
Protocols consisting mainly of growth factors without the addition of small molecules 
in the first stage of differentiation were seen to produce the most viable 
differentiated cells. The combination of Activin A, HGF and FGF4 was seen to be 
the most effective condition at this stage as the majority of surviving protocols (six 
out of ten) were produced with this media component combination (Figure 28).  
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Figure 28: Monolayer Differentiation Stage 1: Day 5 
Cell culture images of the remaining 11 differentiation protocols at day 5 in stage 1 conditions 
(x10 magnification). Exposure to stage 1 differentiation media caused a change in cell 
morphology across all protocols exhibiting a loss of distinctive tightly packed, rounded hESC 
colonies with defined edges to cells with a flattened morphology. 
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Differentiation Stage 2 (Day 6) 
Cells exposed to protocols 1, 2, 3, 4, 5, 6, 11, 16, 20 and 22 reached 80-100% 
confluency after five days of differentiation in stage 1. At the end of stage 1, cells 
were dissociated to a single cell suspension using Accutase dissociation enzyme 
and replated on new collagen I coated wells at a 1:3 split ratio. Differentiation media 
was then changed to that of stage 2 which is classically associated with the 
expansion of DE. It was found that very low numbers of differentiated cells attached 
following replating suggesting that splitting cells at this stage or replating straight 
into stage 2 media is deleterious to cell survival (Figure 29). A better alternative for 
future experiments would be to split cells later into the differentiation process or to 
split cells into stage 1 differentiation media and change to stage 2 media the 
following day.  
During stage 2 of differentiation it was found that the cells in protocols 1, 2, 3, 4, 5, 
6, and 22 attached following replating and subsequently proliferated more readily 
than cells undergoing protocols 11, 16 and 20. These protocols contained HGF, 2% 
DMSO and SB-431542 (Alk4/5/7 inhibitor). Protocols 1-6 and 22 produced 
differentiated cell types that morphologically resembled endodermal precursors 
exhibiting a “pebble-like” morphology.  
 
 
 
 
 
 
 
 
 
165 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol 1 Protocol 2 
Protocol 3 Protocol 4 
x10 
100μm 
Protocol 5 Protocol 6 
 
 
 
166 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocol 11 Protocol 16 
Protocol 20 Protocol 22 
Figure 29: Monolayer Differentiation stage 2: day 6 
Cell culture images of the remaining 10 differentiation protocols at day 6 in stage 2 
conditions (x10 magnification). Cell cultures exposed to protocols 1, 2, 3, 4, 5, 6, 11, 16, 20 
and 22 reached 80-100% confluency after five days of differentiation and were 
subsequently passaged into stage 2 differentiation medias. Low levels of cell attachment 
were achieved following passaging of cells.  
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Differentiation Stage 2 (Day 9) 
Attached cells continued to proliferate and It was also seen that cell morphology was 
consistent and homogenous between replicate wells of the different differentiation 
protocols (Figure 30). Protocols 1-6, 16, 20 and 22 which survived the replating 
expanded under media conditions containing HGF, 2% DMSO and SB-431542. 
Protocol 11 consisting of WNT5A, 2% DMSO and SB-431542 showed a rapid 
decline in cell number at this point and only small, sparse populations of cells 
remained. Protocols 16 and 20 containing the growth factors HGF, VEGF and 
WNT5A produced sparse clusters of differentiated cells which expanded at a slower 
rate to that of cells produced from protocols 1-6. 
As there were low levels of differentiated cells that attached following passaging the 
confluent cells at the end of the first stage of differentiation, it was decided to 
continue expanding the cell populations across the remaining protocols at the 
beginning of the second stage of differentiation. This was undertaken to obtain a 
usable number of differentiated cells with which to progress to stage 3 as it has 
been observed that proliferation rates decrease towards the end of in vitro 
hepatocyte differentiation protocols. 
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Figure 30: Monolayer differentiation stage 2: day 9 
Cell culture images of the remaining 10 differentiation protocols at day 9 in stage 2 
conditions (x10 magnification). Following passaging at the start of stage 2 of differentiation, 
attached cells continued to proliferate and It was also seen that cell morphology was 
consistent and homogenous between differentiation protocols. 
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 Differentiation Stage 2 (Day 11) 
Cells continued to proliferate in stage 2 differentiation media maintaining an 
endodermal-like morphology (Figure 31). Cell number continued to decline rapidly in 
protocol 11 and this was also accompanied by a sharp decrease in cells numbers in 
protocol 16. This represented cells which were exposed to 2% DMSO, SB-431542 
and WNT5A in protocol 11 and VEGF, HGF and WNT5A in protocol 16. Protocols 1-
6, 20 and 22 continued to proliferate with uniform cell morphology that was 
consistent between replicate wells of each protocol.   
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Figure 31: Monolayer differentiation stage 2: day 11 
Cell culture images of the remaining 10 differentiation protocols at day 11 in stage 2 
conditions (x10 magnification). Protocols 1-6, 20 and 22 continued to proliferate with 
uniform cell morphology however protocols 11 and 16 showed a sharp decline in cell 
numbers. 
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Differentiation Stage 2 (Day 13) 
Through previously published research articles regarding hepatocyte differentiation 
and taking into account knowledge of in vitro primary hepatocyte culture, it is known 
that upon maturation stages that proliferation rates sharply decline. With low levels 
of cell attachment following stage 1 of differentiation, it was decided that the best 
approach was to continue to expand DE populations in stage 2 differentiation media 
that had been designed from the CombiCult® screen to promote proliferation of DE 
and hepatic progenitors. Stage 2 of differentiation was initially planned for five days 
however, this was extended by an extra three days to increase the population of 
differentiated cells. Cells reached sufficient numbers to start stage 3 of hepatic 
differentiation at day 13.  
At this stage of the differentiation process there was two morphologically distinct 
populations of cells which were present in all protocols (Figure 32). The first type 
was observed to be rounded and display pebble-like in morphology. It was further 
seen that this cell type was clustered together in distinct regions of the culture wells. 
The second distinct population were found to be elongated and typically surrounded 
the outside of the clusters of pebble-like cells.  
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Figure 32: Monolayer Differentiation stage 2: day 13 
Cell culture images of the remaining 10 differentiation protocols at day 13 in stage 2 
conditions (x10 magnification). Due to low levels of cell attachment at the onset of stage 2 
of differentiation it was decided to continue to expand DE populations at this stage to 
increase cell numbers. The planned time in stage 2 of differentiation media was therefore 
increased from five to eight days.  
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Differentiation Stage 3 (Day 14) 
Stage 3 of differentiation was designed with a view to commit DE cells to a hepatic 
fate. Consequently, factors including TGFα and BMP7 were used as it has been 
seen in vivo to promote the expansion of hepatic progenitors upon hepatectomy. 
Cells exposed to stage 3 differentiation media were seen to undergo further 
changes in cell morphology (Figure 33). Cells were seen to cluster together whereas 
previously cells were more dispersed throughout the tissue culture wells. Cell 
numbers were seen to be decreased across all differentiation protocols after one 
day in stage 3 differentiation media. This could correspond to cells either committing 
to a hepatic fate or undergoing apoptosis due to not being able to be supported in 
stage 3 differentiation media. Protocols 16 and 20 suffered the most cell death and 
numbers of cells were seen to be very low after only two days in stage 3 
differentiation media containing HGF, RA and GH and Progesterone, IL6 and TGFα 
respectively.  
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Figure 33: Monolayer differentiation stage 3: day 14 
Cell culture images of the remaining 9 differentiation protocols at day 14 in stage 3 
conditions (x10 magnification). After increasing the time spent in stage 2 of differentiation 
to expand cell populations, stage 3 of differentiation was initiated with a view to commit DE 
cells to a hepatic fate. 
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Differentiation Stage 3 (Day 20) 
Protocols 1-6 and 22 continued to survive in stage 3 differentiation media after 
twenty days of differentiation. Levels of cell proliferation were seen to be further 
decreased upon progression through stage 3 of differentiation in accordance with 
expectations. Protocols 16 and 20 continued to decline in cell numbers and 
proliferation of existing attached cells until only a very few viable cells remained at 
day 24 of differentiation. As cells progressed through stage 3 of differentiation, cell 
morphology was seen to noticeably change in that cobble-like cells which emerged 
during the DE specification/expansion stages were replaced with elongated cells 
across all remaining protocols (1-6 and 22) (Figure 34).   
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Figure 34: Monolayer differentiation stage 3: day 20 
Cell culture images of the remaining 7 differentiation protocols at day 20 in stage 3 
conditions (x10 magnification). Levels of cell proliferation in the surviving seven protocols 
were seen to be decreased in stage 3; typically concerned with hepatic specification. 
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Differentiation Stage 4 (Day 23) 
Stage 4 of differentiation was concerned with the onset of hepatic maturation and 
combinations of small molecule agonists and anti-apoptotic factors including 
dexamethasone were added to hepatic basal media. Cell morphology remained 
consistent in most protocols trough the transition from stage 3 into stage 4 with the 
exception of protocols 4 and 22 (Figure 35). Protocol 4 contained combinations of 
small bioactive agonists targeting members of the NHR family as well as agonists of 
particular CYP450 family members. Protocol 22 consisted of a combination of HGF, 
insulin and OSM. As predicted, levels of cell proliferation were decreased following 
the onset of stage 4 and there was no visible level of cell expansion. As stage 4 
progressed there was increased amounts of apoptosis and cell numbers continued 
to decline day-on-day until there were very few amounts of cells remaining at day 4 
of stage 4 which formed isolated clusters.  
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Figure 35: Monolayer differentiation stage 4: day 23 
Cell culture images of the remaining 7 differentiation protocols at day 23 in stage 4 
conditions (x10 magnification). The transition to stage 4 of the differentiation process 
concerned the onset of hepatic maturation and accordingly included small bioactive 
molecules identified through the CombiCult® screen. Cell proliferation was seen to cease 
during stage 4 in line with expectations and cell morphology remained largely similar 
across the surviving protocols except for protocols 4 and 22.  
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Differentiation Stage 4 (Day 28) 
Cells in protocols 4 and 22 continued to show a flattened appearance and at day 28 
of stage 4 this was also seen in protocols 3 and 5 containing progesterone, 
SR12813 (PXR agonist) and CITCO (CAR agonist) and Insulin, Docosahexaenoic 
Acid (DHA) and GH respectively (Figure 36). Cell numbers continued to decline day-
on-day until day 30 when there was a significant event resulting in cells in all 
protocols undergoing apoptosis. Consequently, hepatic maturation analysis through 
ICC staining for CYP3A4 and CYP1A1/A2 and PCR for key hepatic markers was not 
possible at the end of the hepatic differentiation process.   
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Figure 36: Monolayer differentiation stage 4: day 28 
Cell culture images of the remaining 7 differentiation protocols at day 28 in stage 4 
conditions (x10 magnification). Cells produced through protocols 4 and 22 continued to show 
a flattened appearance at day 28 and this was also seen in protocols 3 and 5. Cell numbers 
in all protocols continued to decline day-on-day until day 30 of stage 4 when there was a 
significant event resulting in cells in all protocols undergoing apoptosis. 
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5.3.2 Optimised 2D CombiCult® Monolayer Validation  
Shef-3 hESC Seeding (Day 0) 
Following completion of the initial monolayer validation experiment the six protocols 
with particularly interesting combinations of growth factors and small molecules 
were studied further under optimised conditions; that being protocols 1, 6, 7, 10, 21 
and 22. The three major obstacles that were identified in the initial monolayer 
validation study was firstly passaging of the differentiated cells on day 6 following 
the completion of stage 1, the toxicity of linoleic acid in the first stage of 
differentiation and the mass apoptosis of differentiated cells at the end of the fourth 
stage of differentiation. To address these issues feeder free conditioned Shef-3 
hESCs were seeded on collagen I coated plates at a density of 0.3x106 cells per well 
of a 12 well plate. This density was determined to be the optimal cell number 
through carrying out titrations of Shef-3 hESC seeding densities followed by 
differentiation to assess confluency levels after set time intervals. Using the 
determined 0.3x106 optimal well seeding density allows for the four-stage 
differentiation process to be completed without the need to passage the cells and 
associated risk of low levels of cell attachment, as was seen in the first monolayer 
validation experiment. The optimal density was also determined to seed sufficient 
cells for analysis following the decrease in cell proliferation in the final stages of 
hepatic differentiation. On day 0, Shef-3 hESCs were dissociated with accutase and 
seeded 16 hours before the start of the first stage of differentiation at 0.3x106 cells 
per well of a 12 well plate (Figure 37). 
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The second optimisation step from the first monolayer validation experiment was to 
use a new BSA-conjugated linoleic acid (Sigma #L9530-5ML) which was found to be 
far less toxic to cells. Titration experiments were carried out over a range of 
concentrations and it was found that BSA-conjugated linoleic acid had no discernible 
increase in levels of cell death or stress. 
 
Differentiation Stage 1 (Day 3) 
Exposure of Shef-3 hESCs to stage 1 media combinations induced the 
differentiation of pluripotent stem cell colonies. Differentiated cell morphology across 
differentiation protocols was seen to be similar at day three, likely due to Activin A 
being present in all differentiation protocols inducing DE specification (Figure 38). At 
day 3, differentiation of hESC was initially observed from the periphery of the 
colonies whilst the centre of the colony maintained a more pluripotent-like 
morphology. Differentiated cells were seen to proliferate rapidly at equivalent levels 
across all six protocols at day 3. 
X10  
100μm 
Figure 37: Optimised monolayer differentiation seeding (D1) 
Shef-3 hESCs seeded at a density of 0.3x106 cells/well on collagen I coated 12-well plates 
(D0). Hepatic differentiation in stage 1 media was started 24 hours later (D1).   
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Figure 38: Optimised monolayer differentiation stage 1: day 3  
Cell culture images of the top six selected differentiation protocols at day 3 in stage 1 
conditions (x20 magnification). Upon differentiation cell morphology was seen to be 
changed at the edges of stem cell colonies. The morphology of differentiated cells was 
observed to be consistent across all the six CombiCult®-derived protocols.  
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Differentiation Stage 1 (Day 5) 
Differentiated cells continued to proliferate at equivalent levels between the different 
protocols to the end of stage 1 of hepatic differentiation upon reaching the last day 
in stage 1 differentiation media (Figure 39). Cell morphology at this stage was also 
seen to be consistent across the six differentiation protocols. The majority of 
differentiated cells displayed flattened endodermal-like cell morphology after DE 
specification from pluripotent hESCs. Differentiated cells reached a confluency level 
of approximately 50-60% at the end of the first stage of differentiation across all six 
differentiation protocols. This level of confluence was determined to be ideal for 
hepatic differentiation as cells from the previous monolayer validation protocols were 
seen to proliferate at a lower level at the end of the second stage of the 
differentiation process and then display very low levels of proliferation upon hepatic 
maturation steps. 
 
 
 
 
 
 
 
 
 
 
 
 
189 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39: Optimised monolayer differentiation stage 1: day 5 
Cell culture images of the top six selected differentiation protocols at day 5 in stage 1 
conditions (x20 magnification). Levels of cell proliferation was seen to be consistent across 
all six CombiCult®-derived protocols displaying similar cell morphology at the end of the first 
stage of differentiation from pluripotent stem cells.  
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Differentiation Stage 2 (Day 7)  
Stage 2 of differentiation was largely concerned with TGF-β signal inhibition after it 
was seen that the small molecules SB-431542 (Alk 4/5/7 inhibitor) and SIS3 
(specific SMAD3 inhibitor) featured highly in the most efficient protocols identified 
through the initial CombiCult® screen. TGF-β signal inhibition is known to be 
important for DE proliferation and hepatoblast formation in vivo but has not yet been 
applied to the in vitro differentiation of HLCs. To further push hepatic differentiation, 
HGF and FGF4 were added in conjunction with WNT5A and GDF-15 which are 
elevated in vivo upon liver injury to proliferate hepatic progenitor populations. After 
two days in stage 2 differentiation media, cell morphology remained largely similar to 
that of cells seen at the end of stage 1 although round, flat and compacted cells 
started to emerge in protocol 1 (highlighted in Figure 40).  Levels of cell proliferation 
was also seen to be consistant between all protocols. 
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Figure 40: Optimised monolayer differentiation stage 2: day 7 
Cell culture images of the top six selected differentiation protocols at day 7 in stage 2 
conditions (x20 magnification). Levels of cell proliferation was seen to be similar across all 
six CombiCult®-derived protocols. Differentiated cell morphology was also seen to be 
consistent across protocols although round, flat and compacted cells started to emerge in 
protocol 1 (highlighted in red).  
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Differentiation Stage 3 (Day 11)  
Stage 3 of differentiation consisted of growth factors that have been seen in vivo to 
expand the pool of hepatic progenitors through promoting proliferation upon liver 
injury. These included HGF, TGFα, BMP7 and Il6. At this stage of differentiation, 
there was a notable change in cell morphology particularly in protocol 1 (highlighted 
in Figure 41). Alongside the addition of growth factors promoting proliferation, 
progesterone was added to protocol 10 and 21 in an attempt to promote hepatic 
maturation as it had been found to be present at high frequency in the CombiCult® 
screen in stages 3 and 4 (Figure 41). 
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Figure 41: Optimised monolayer differentiation stage 3: day 13 
Cell culture images of the top six selected differentiation protocols at day 13 in stage 3 
conditions (x20 magnification). At this stage of differentiation process the most notable 
change in differentiated cell morphology was observed in protocol 1 (highlighted in red).  
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Differentiation Stage 4 (Day 24)  
Levels of proliferation were seen to be drastically reduced in all protocols upon the 
transition to stage 4 of differentiation following the withdrawal of hepatic proliferation 
factors to an emphasis of pushing terminal differentiation. This was consistant with 
findings from the initial monolayer differentiation study and further conforms to 
published literature. Cell morphology in all CombiCult® derived protocols remained 
largely similar after the transition from stage 3 to stage 4 of differentiation (Figure 
42). 
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Figure 42: Optimised monolayer differentiation stage 4: day 24 
Cell culture images of the top six selected differentiation protocols at day 24 in stage 4 
conditions (x20 magnification). In the final stage of differentiation cell proliferation was seen 
to be greatly reduced in all six tested protocols. Cell morphology was also seen to be 
largely similar throughout the protocols.  
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5.3.3 RT-PCR Analysis of Hepatic Differentiation  
After completion of the four-stage monolayer differentiation process on D28 cell 
samples were treated in triplicate with both omeprazole and rifampicin. Cell samples 
were also treated with 0.1% DMSO vehicle control (uninduced) (see Methods 
2.6.2.3). Induction was carried out for a period of three days, with media refreshed 
every day. Cells were lysed and RNA was isolated for gene expression analysis 
using PCR. HepaRG cells were also plated in monolayer culture and samples were 
treated in the same way as the differentiated HLCs. Following induction drug 
treatment or 0.1% vehicle control, RNA was collected for RT-PCR for both induced 
and uninduced HLCs (see Methods 2.3.4). However, there were problems with the 
RNA extraction of the induced drug treated wells of differentiated HLCs which 
resulted in very low yields of RNA being obtained. Because of this differentiated 
HLCs treated with inducer drugs were not able to be analysed for gene expression. 
Uninduced samples were compared to HepaRG cells through RT-PCR to measure 
basal levels of CYP1A1/A2 as an assessment of hepatic maturation. RT-PCR was 
carried out for 30 cycles and PCR products analysed on a 2% agarose gel GAPDH 
was used as a housekeeping gene to normalise gene expression (see Methods 
2.3.4).  
It was found that all HLCs produced through the differentiation protocols and 
HepaRG cells expressed Albumin, the highest levels been seen in uninduced 
HepaRG cells (Figure 43). Albumin expression levels between the HLCs 
differentiated from the CombiCult® derived protocols was seen to be comparable. 
Albumin is expressed in hepatic cells at an early stage at low levels and then 
subsequently increased to maximum levels in mature adult hepatocytes.  
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The presence of albumin is an indicator that the differentiated cells produced 
through the CombiCult® derived protocols are in fact hepatocyte-like.  CYP1A1 was 
shown to be upregulated through the addition of inducer drugs in the HepaRG cells 
compared to uninduced HepaRG cells. This confirms that the inducer drugs do 
indeed upregulate CYP1A1 in monolayer cultures and can be used as a readout 
assay for hepatic maturity in both gene expression analysis and ICC staining in the 
CombiCult® platform. CYP1A1 levels in the CombiCult® derived protocols were 
seen to be at the comparable levels to those seen in the uninduced HepaRG cells 
indicating a base level of expression between differentiated HLCs and uninduced 
HepaRG cells. CYP1A2 was seen to be most strongly expressed in protocol 1 and 
was shown to be at higher levels than in HepaRG cells. Protocols 6, 21 and 22 were 
seen to display comparable levels of CYP1A2 expression compared to HepaRG 
cells. In addition, α1AT was found to be strongly expressed in protocol 1 and to a 
lesser extent in protocols 6, 7,10 and 22 along with induced HepaRG cells.  
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Figure 43: RT-PCR analysis of hepatic markers in differentiated HLCs 
RT-PCR reactions were carried out on RNA extracted from differentiated HLCs that were 
treated with 0.1% DMSO vehicle control (uninduced) for three days. Differentiated HLCs 
were compared to HepaRG cells that had either been induced of treated with 0.1% DMSO 
vehicle control. RT-PCR reactions were carried out for 30 cycles and visualised on a 2% 
agarose gel. L = 100bp DNA ladder, 1-22 = CombiCult®-derived protocol number, H- = 
uninduced HepaRG, H+ = induced HepaRG, -RT = no reverse transcriptase control, W = 
water control. Results are representative of n=3 biological repeats.  
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5.3.4 ICC Analysis of Drug Induced HLCs 
After completion of the four-stage monolayer differentiation process on day 24 
differentiated HLCs were dual stained with primary antibodies for the CYP450 family 
members CYP1A1, CYP1A2 and CYP3A4. Secondary antibody incubations were 
carried out using Alexa Fluor 488 anti-goat (CYP3A4, green) and anti-mouse 594 
(CYP1A1/A2, red) antibodies (Invitrogen) at 1:1000 dilutions (see Methods 2.4.5). 
Cells were also stained with DAPI for nuclear visualisation (Figure 44). This ICC 
assay had previously been utilised as a measurement of hepatocyte maturity in the 
CombiCult® platform.  
Image J (National Institutes of Health, Maryland, US) was used to count DAPI 
positive staining in uninduced differentiated HLCs to give total cell numbers present 
at the end of monolayer differentiation. This was further carried out for cells staining 
positive for CYP1A1/A2 and CYP3A4 in the six protocols tested. CYP1A1/A2 and 
CYP3A4 positive cells were found in all hepatocyte monolayer differentiation 
protocols at similar numbers and florescence intensities apart from protocol 22 
which displayed lower numbers of CYP1A1/A2 and CYP3A4 positive cells. It was 
calculated that approximate numbers of CYP1A1/A2 positive cells in protocol 1 was 
20%, 17% in protocol 6, 30% in protocol 7, 21% in protocol 10, 30% in protocol 21 
and 3% in protocol 22. CYP3A4 positive staining was calculated to be 27% of cells 
in protocol 1, 20% in protocol 6, 27% in protocol 7, 17% in protocol 10, 30% in 
protocol 21 and 3% in protocol 22. It was seen that CYP3A4 and CYP1A1/A2 
staining mostly co-localised in the differentiated HLCs analysed through ICC.   
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Figure 44: ICC Staining for CYP1A1/A2 and CYP3A4 in Differentiated HLCs 
Differentiated HLCs were stained for the CYP450 family members CYP1A1, CYP1A2 and 
CYP3A4. Corresponding secondary antibody incubations were carried out using Alexa Fluor 
anti-goat 488 (CYP3A4, green) and Alexa Fluor anti-mouse 594 (CYP1A1/A2, red) 
antibodies (Invitrogen). Cells were further stained with DAPI for nuclear visualisation (blue).  
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5.3.5 Quantitative Analysis of CYP450 Functional Levels 
Along with gene expression and ICC analysis, differentiated HLCs were assessed 
for hepatic maturation using both the quantitative luminescent p450Glo (Promega) 
and fluorescent EROD quantitative assays for CYP3A4 and CYP1A1/A2 activity 
respectively. These assays were utilised to assess levels of CYP1A1/A2 and 
CYP3A4 activity upon drug induction. 
Following completion of the differentiation protocols, cells were either treated with 
combined omeprazole and rifampicin/dexamethasone to induce CYP1A1/A2 and 
CYP3A4 expression respectively or with assay media containing 0.1% DMSO as a 
vehicle control. Induction was carried out for a period of three days with media being 
refreshed every day. Induction assays were conducted in biological triplicate repeats 
with three technical replicates carried out for each test sample (see Methods 2.5.2 
and 2.5.1).  
5.3.5.1 CYP3A4 Induction Analysis in Monolayer Differentiated HLCs 
CYP3A4 activity as assessed by the p450Glo assay was found to be increased 
upon drug addition in comparison to 0.1% DMSO treated control cells (Figure 45). 
Induction levels of 1.52 (p<0.05), 1.32 (p<0.05), 1.54 (p<0.01), 1.85 (p<0.001), 1.94 
(p<0.001) and 1.74 (p<0.001) were obtained for protocols 1, 6, 7, 10, 21 and 22 
respectively. The biggest relative fold increase in CYP3A4 activity between control 
and drug treated samples was found to be in protocol 21 which contained a 
combination of two small molecule agonists and a fatty acid precursor in the final 
stage of hepatic maturation. These factors were GW7647 (PPARα agonist), 
T0901317 (LXR agonist) and docosahexaenoic acid (fatty acid precursor).  
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Protocol 21 also contained novel in vitro hepatic differentiation factors in early 
stages including linoleic acid which is a proposed HNF4α ligand and hyperforin 
which has been shown to upregulate CYP3A4. In stage 3 of differentiation 
progesterone and TGFα were also incorporated because of the in vivo role in 
hepatoblast expansion upon liver injury.  
 
 
 
 
 
Figure 45: CYP3A4 induction in monolayer differentiated HLCs 
The difference between induced versus uninduced CYP34A levels in monolayer 
differentiated HLCs was quantified using a p450Glo assay. Luciferase units (LU) per protocol 
were measured and statistical analysis calculated by a Student’s t-test. Significance is 
indicated by *** (p<0.001), ** (p<0.01), * (p<0.05). Data are shown as mean ± SD of n=3 
biological repeats. 
 
5.3.5.2 CYP1A1/A2 Induction Analysis 
CYP1A1/A2 levels were seen to be consistent in HLCs produced from CombiCult® 
derived protocols (Figure 46). At the end of hepatic differentiation, HLCs were 
treated with rifampicin to induce CYP1A1/A2 and an EROD assay carried out to 
quantify differences between protocols.  
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Unfortunately, due to cell culture infection, uninduced HLCs were lost and could not 
be compared to induced HLCs that had been treated with rifampicin for a measure 
of CYP1A1/A2 levels. Levels of CYP1A1/A2 in induced HLCs were compared to 
assess differences between the six CombiCult®-derived protocols.  
It was found that there was a small but significant difference between CYP1A1/A2 
levels in protocol 1 compared to those present in HLCs derived from the other 
protocols (p<0.05). There was also a small but significant difference between 
increased levels of CYP1A1/A2 in protocol 21 compared to those quantified in 
protocol 6 (p<0.05).  
 
 
 
 
 
 
Figure 46: CYP1A1/A2 levels in CombiCult® derived HLCs 
CYP1A1/A2 activity measured in raw fluorescence units (RFU) following omeprazole drug 
induction was assessed by an EROD assay.  Differences between CYP1A1/A2 activity in the 
HLCs produced from the CombiCult® derived protocols were evaluated by a 1-way ANOVA 
with Bonferroni’s post-test for multiple comparisons. Data is shown as mean ±SEM of n=3 
biological repeats. Significance indicated by *** (p<0.001), ** (p<0.01), * (p<0.05).  
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5.4 Discussion 
The promise to differentiate unlimited amounts of hepatocytes from pluripotent stem 
cells with which to carry out in vitro drug toxicity screens and metabolic assays has 
yet to be realised with currently derived HLCs displaying low levels of metabolic 
activity compared to primary hepatocytes [111] [106] [136]. The aim of the 
monolayer validation experiments was to translate protocols containing novel factors 
identified through the CombiCult® hepatocyte screen from a 3D system to 
monolayer culture. Factors that have been shown to play an important role in 
hepatocyte differentiation and maturation in vivo were incorporated into the 
CombiCult® screen and some of these factors were indeed found to be highly 
involved in producing HLCs with the highest levels of CYP450 family activity as 
assessed through ICC staining. 
Previous studies to direct pluripotent stem cells towards the hepatic lineage have 
relied on the addition of recombinant growth factors including Activin A and WNT3A 
during the initial stages, FGF4, BMP4 and HGF during the early hepatic 
specification and OSM and during the latter stages of differentiation [185] [99] [106] 
[112] [148] [136]. Studies into targeted differentiation have increasingly focused on 
the replacement of recombinant growth factors with small molecule 
inhibitors/agonists to specifically target signalling pathways to direct differentiation to 
cell types of interest. Siller et al. (2015) incorporated the use of small molecules in 
the absence of recombinant growth factors to differentiate pluripotent stem cells to 
hepatocytes through the targeting of key hepatic regulators [235]. During the initial 
stages of differentiation the small molecule agonist CHIR99021 was used to mimic 
WNT/βcatenin signalling was used to specify DE as previous studies have 
highlighted the importance of WNT signalling during DE specification [121] [122].  
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Importantly for the hypothesis that Nodal is the driver of DE specification, Nodal 
expression was seen in this study to be upregulated after four hours using 
CHIR99021 [121]. Another study by Lickert et al. (2013) showed the regulation of 
SOX17 expression through the use of small molecule GSK3β inhibitors, mimicking 
WNT3A signalling, demonstrating important avenues of investigation to differentiate 
efficient populations of DE [271].  
There is a need for a better understanding of different culture combinations at each 
stage of differentiation, therefore future screens could be carried out in larger scale. 
This would be accompanied with the incorporation of time point analysis through 
qPCR and ICC staining to gain a more in-depth knowledge as to the effect of culture 
permutations on key hepatic regulators. This is particularly important as factors 
incorporated into the hepatic differentiation screen could potentially have negative 
regulatory effects and negate the hepatic maturation properties of factors used in 
combination.  
A key finding from the monolayer validation studies was that specific linoleic acids 
have toxicities and are not applicable for use during in vitro differentiation protocols. 
Form the first monolayer validation experiment it was found that linoleic acid, which 
was previously used in the CombiCult® screen (Sigma #L1376), was toxic to hESCs 
in monolayer culture. Investigation into addressing this problem led to the use of a 
BSA-conjugated linoleic acid (Sigma #L9530) which was shown to have no visible 
levels of cell toxicity or stress when applied to cells in the first stage of 
differentiation. The toxicity of linoleic acid has previously been investigated on 
different cell types including in vitro cell lines derived from the haematopoietic 
lineage. Cury-Boaventura et al. (2004) showed that the addition of linoleic acid to 
haematopoietic-derived cells promoted both apoptosis and cell stress [272].  
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Therefore, the selection of appropriate conjugated forms of linoleic acid and other 
differentiation promoting factors must be carefully investigated as the transition from 
3D to 2D monolayer culture systems could yield different results.  
Another important consideration identified through conducting the initial monolayer 
validation was appropriate initial seeding densities of pluripotent stem cells. Seeding 
densities were shown to be a critical factor in the survival of differentiated cells at 
the end of the first stage of differentiation. Enzymatic passaging at these early 
stages was seen to be deleterious to cell survival and continuation of the protocols. 
It was necessary to expand cell populations in stage 2 of differentiation to obtain 
sufficient cell numbers to proceed with differentiation and this extended cell culture 
could lead to the senescence and apoptosis seen in later stages of hepatic 
differentiation. It was seen that the rates of cell proliferation decreased as the 
differentiation protocols entered the third stage of differentiation and further declined 
during the hepatic maturation stage. The longer that the differentiating cells were in 
culture the bigger the decline in cell numbers was observed. Therefore, more quickly 
and efficiently differentiating hepatic progenitor cells to mature HLCs would be very 
advantageous. It has been shown by Huh et al. (2004) that decreased rates of 
hepatic proliferation corresponded with a decrease in HGF concentrations [273] 
[274] [275]. Observations of reduced rates of proliferation could be addressed using 
proliferation promoting factors at later stages of differentiation, such as HGF, before 
finally changing culture conditions to switch towards terminal differentiation of HLCs. 
Activators of the constitutive androstane receptor (CAR) have been shown to be 
transient inducers of hepatocyte proliferation [276]. In this study the small bioactive 
molecule CITCO was used as previous studies had identified the ability of CITCO to 
upregulate CAR [228].  
 
 
 
209 
 
This could be further investigated in future studies for its potential to induce hepatic 
proliferation at the later stages of the monolayer protocols.  
A possibility in the future application of in vitro derived HLCs to drug 
toxicity/metabolic screens could be the identification of targetable proliferation 
inducing regulators with small bioactive molecules [228]. This would allow progenitor 
cell populations to be expanded without the senescence and apoptosis that is seen 
with transition to the final stages of differentiation for extended periods. Hepatic 
progenitor cells could be identified and isolated through the expression of key 
markers and then taken forward to hepatic maturation stages through the addition of 
small molecule agonists of the NHR and CYP450 family. It has been shown that 
HepaRG cell cultures can maintain levels of metabolic enzymes in culture for a 
period of 14 days and future investigation would apply the same tests to 
CombiCult® derived HLCs [133]. Another avenue of investigation that could be used 
to circumvent the senescence of hepatic cells in the third stages of differentiation 
could be to shorten the differentiation time course. In addition, the matrix used to 
differentiate cells plays an important role in recapitulating conditions in vivo. 
Collagen I was used as a basement matrix for monolayer hepatic differentiation 
studies but Cameron et al. (2015) has shown that Laminin promotes the proliferation 
of hepatic cells in vitro and therefore could be investigated along with the 
incorporation of proliferation-inducing small bioactive molecules [277].   
HepaRG and hepatocellular carcinoma (HCC) cells have been previously used as a 
model for functional hepatocytes including the induction of CYP1A1/A2 and CYP3A4 
and are currently used to study the effects of drugs in vitro [133] [124] [129] [278]. 
There is however batch-to-batch variability of HepaRG cells which have been shown 
to produce differing levels of inducibility upon the addition of drugs [121].  
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In this study, batch-to-batch variability of CYP3A4 was seen to vary amongst 
HepaRG cell lines however, reproducibility within cell lines was seen to be 
consistent [279]. Members of the CYP450 family have been successfully induced 
through the use of drugs including rifampicin to induce CYP3A4 [129] [280] [281].  
However, it was found that the expression fold-increases of induction in the CYP450 
family members was greatly increased using 3D culture systems compared to 
monolayer cultures.  
In the study carried out by Guillouzo et al. (2007) it was found that there was an 
approximate two-fold induction in CYP3A4 mRNA levels in monolayer culture upon 
the addition of rifampicin compared to HCC cells without the addition of the inducing 
drug [129]. This however was much reduced than the effect seen when the HCC 
cells were cultured in a 3D culture system which displayed much higher basal levels 
of CYP3A4 mRNA and significantly greater levels of fold-induction in response to 
rifampicin treatment. In the RT-PCR carried out to assess hepatic maturity in the 
CombiCult®-derived HLCs, it was found that similar basal levels of CYP1A1/A2 
were present in HLCs compared to uninduced HepaRG cells. In fact, protocol 1 was 
seen to display the highest levels of basal CYP1A2 compared to other protocols and 
HepaRG cells. Unfortunately, it was not possible to assess the levels of CYP1A1/A2 
upon drug induction in this assay and future experiments would be concerned with 
addressing this to determine comparative levels to HepaRG cells. To better 
understand and assess the potential of the CombiCult® differentiated HLCs to be 
induced upon drug addition, future studies would incorporate the use of quantitative 
qPCR as opposed to the semi-quantitative RT-PCR to examine mature hepatic 
markers that are characteristic of hepatocytes.  
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In addition, further expansion of the number of hepatic markers including other 
members of the CYP450 family that are expressed early in development and lost 
during the transition to mature hepatocytes, such as CYP3A7 and conversely in the 
case of CYP2C9 would be a good indication of CombiCult®-derived HLC potential 
[282].   
Comparisons between drug induction levels in control and treated cells revealed low 
but significant levels of CYP3A4 induction (approximately 1.5-2-fold) across the six 
differentiation protocols (p<0.05) in the p450Glo assay. As novel factors were 
involved during the process of hepatic differentiation, optimal concentrations have 
yet to be determined for some small bioactive molecules which could have a 
significant effect on hepatic maturation. The comparative levels of HepaRG CYP3A4 
rifampicin inducibility have been quantified at differing levels in previous studies. 
Approximate levels from 2-40-fold increase in CYP3A4 levels have been seen in 
studies assessing the addition of rifampicin to HepaRG cultures [281] [124]. 
Therefore, it is important to optimise the culture conditions and titrations of 
differentiation and maturation inducing factors so the true potential of the 
CombiCult®-derived HLCs can be compared to the HepaRG model. CombiCult® is 
a powerful tool for identifying key factors in the differentiation process but their 
transition to monolayer culture needs to be optimised.  
Even though relatively low but significant levels of CYP3A4 drug induction were 
quantified in the CombiCult® derived HLCs, the incorporation of the differentiated 
HLCs into drug toxicity assays would be a useful study to determine if they could 
serve as a better model than the current in vitro model cell line, HepaRG cells. 
HepaRG cells have been shown to be able to predict drug toxicity in previous 
studies alongside human hepatocytes but have been seem to express much lower 
levels of drug transporters [283].  
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The hepatocarcinoma cell line Huh-7 has also been assessed for a role in drug 
toxicity assays and was seen to be more suitable in this application than HepaRG 
cells [281]. Future work would incorporate HepaRG, primary hepatocytes and other 
in vitro cell lines into metabolic/toxicity assays to better assess the CombiCult® 
derived HLCs in comparison with the current best models for drug toxicity and 
metabolism. CYP1A1/A2 levels were seen to be consistent in HLCs produced from 
CombiCult®-derived protocols at the end of hepatic differentiation following drug 
induction with rifampicin and assessment in the EROD assay. A small but significant 
difference between CYP1A1/A2 levels in protocol 1 was observed compared to 
those present in HLCs derived from the other protocols (p<0.05). There was also a 
small but significant difference between increased levels of CYP1A1/A2 in protocol 
21 compared to those quantified in protocol 6 (p<0.05). Previous studies have 
shown that HepaRG cells can be treated with omeprazole or other appropriate drugs 
to induce CYP1A1/A2 [124]. Gerets et al. (2012) quantified the increase in CYP1A1 
levels of approximately two-fold [124] whilst Garcia-Canton et al. (2013) found 
CYP1A1 and CYP1A2 were significantly increased following drug induction [284]. To 
fully examine the CYP1A1/A2 fold-increases upon drug induction in future work, the 
CombiCult®-derived HLCs would be compared alongside HepaRG cells. This would 
expand upon the quantified basal levels of CYP1A1/A2 in the CombiCult-derived 
HLCs assessed in this study.  
Siller et al. (2015) investigated a small molecule approach to the differentiation of 
pluripotent stem cells to functional HLCs [235]. Growth factors were replaced in this 
study with small molecule alternatives to increase reproducibility. Quantitative 
assays to assess basal CYP1A1/A2 and CYP3A4 levels and further increases upon 
drug induction with omeprazole (CYP1A1/A2) and rifampicin (CYP3A4) was carried 
out and compared between growth factor-derived HLCs and small molecule-derived 
HLCs.  
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It was shown in growth factor derived HLCs that a two-fold increase in CYP1A2 
levels was achieved following drug induction in conjunction with a three-fold 
increase in CYP3A4. In comparison, small molecule-derived HLCs exhibited a two-
fold increase in CYP1A2 levels and a two-fold increase in CYP3A4. Levels of 
CYP3A4 induction following drug treatment compares to similar levels of induction 
obtained from CombiCult®-derived HLCs in this thesis. Hay et al. (2008) 
differentiated hESCs to HLCs using a growth factor approach and showed that the 
differentiated HLCs expressed Albumin in the latter stages of differentiation 
however, CYP3A4 levels were seen to be comparable to those quantified in fetal 
liver and below levels seen in adult hepatocytes [285]. Further assessment of 
CYP3A4 induction levels following rifampicin drug treatment resulted in a two-fold 
increase in CYP3A4. Song et al. (2009) demonstrated an approximate two-fold 
increase in CYP450 family member activity upon drug treatment in three iPSC-
derived HLC lines [107]. This was compared to significantly higher basal and drug 
induced levels of P450 family members present in adult primary hepatocytes. Taken 
together these results suggest similar levels of maturation as assessed through 
CYP1A1/A2 and CYP3A4 levels were achieved in CombiCult®-derived HLCs as 
seen in currently published in vitro differentiation protocols.  
Following the correction and optimisation of issues arising from the two monolayer 
validation studies, including cell seeding density and toxicity of differentiation 
factors, assessment of the other top differentiation protocols identified through the 
CombiCult® hepatic screen need to be carried out. This will give a better 
understanding of the levels of hepatic maturity that can be obtained through the 
differentiation protocols. As many of the differentiation protocols contain factors of 
interest that have yet to be utilised during in vitro hepatic differentiation, it is 
important to fully determine their application to producing metabolically relevant 
HLCs.    
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Chapter 6: Hepatic Reporter Constructs 
6.1 Introduction 
To aid the identification and development of novel hepatic differentiation protocols 
through the utilisation of Plasticell’s CombiCult® platform, a higher throughput 
method of assessing hepatic differentiation is needed. This was aimed to improve 
upon the current ICC maturation readout assay of staining for members of the 
CYP450 family to move the workflow towards a higher throughput platform. To 
address this current need, fluorescent lentiviral reporters were designed to allow 
monitoring of hepatic differentiation in real-time and allow for analysis of populations 
of differentiated cells throughout the CombiCult® split-pooling process. Utilising 
fluorescent lentiviral reporters is also advantageous as it doesn’t require HLCs to be 
sacrificed for ICC analysis and opens the possibility for further analysis of 
maturation on living cells. Differentiated HLCs obtained after the split-pooling 
process could be put through hepatocyte maturation screens using combinations of 
small bioactive molecules with an aim to produce more metabolically relevant 
hepatocytes.  
To assess the targeted effects of small bioactive molecules on signalling pathways, 
lentiviral vectors were created. Designed lentiviral vectors contained liver-specific 
fluorescence for CombiCult® real-time readouts of maturation and a luciferase 
reporter for accurate titration of small bioactive molecules in 2D monolayer 
validation studies. This was firstly investigated to identify ligands for potential 
hepatic master regulators and secondly to determine optimum differentiation factor 
concentrations with which to manipulate specific signalling pathways.  
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Small molecule concentrations were derived for the CombiCult® screen from 
previously published protocols or through informed assessment of levels during in 
vivo differentiation. However, as many of these molecules have not previously been 
utilised in the in vitro differentiation of pluripotent stem cells, translation of 
efficacious concentrations was made difficult and a balance between desired activity 
and toxicity had to be made. To effectively differentiate pluripotent stem cells to 
hepatocytes, optimum concentrations of small bioactive molecules that have an 
important role during the in vitro hepatic differentiation need to be determined in 
vitro. To this end optimum concentrations of small bioactive molecules to activate 
key signalling pathways in hepatic maturation luciferase reporter constructs were 
utilised. Luciferase enzymes catalyse their specific substrates in a reaction that 
produces light as a by-product which has previously been utilised an alternative 
means for the quantification of relative protein expression during in vivo studies 
[286]. This makes luciferase reporters a powerful tool and thus the application of 
luciferase as a reporter gene has been widely exploited in the study of promoter 
activity during in vitro studies [287].  
 
6.2 Aims 
• To create a hepatic reporter applicable to the CombiCult® platform to 
replace ICC staining as a readout for mature HLCs. 
• To validate hepatic reporters for the in vitro titration of hepatic maturation 
inducing factors identified through CombiCult®. 
• Identify optimal concentration ranges for small molecule agonists for in vitro 
studies of HLC maturation. 
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6.3 Results 
6.3.1 Development of Liver-Specific Fluorescent Reporters 
6.3.1.1 CombiCult® Hepatic Reporter Construct 
A truncated version of the alpha-1-antitrypsin (α1AT) promoter was used as a liver-
specific reporter in the context of hESC differentiation to hepatocytes as α1AT has 
been shown to be mainly synthesised in hepatocytes [288]. The serum trypsin 
inhibitor α1AT is expressed outside of the liver, such as in lung where it is involved 
in protecting tissues from enzymes of inflammatory cells, but is considered to be 
specifically expressed in hepatocytes in the context of hESC differentiation to the 
hepatic lineage [288]. The truncated promoter is designed to maintain the core 
transcriptional activity of the endogenous promoter but it is significantly shorter to 
aid lentiviral integration [289]. The α1AT promoter has been characterised 
previously in both in vitro and in vivo studies and shown to direct stable gene 
expression in liver cells [290] [291] [292] [293]. A constitutively active spleen focus 
forming virus (SFFV) viral promoter was used to drive the expression of eGFP to 
allow for a visible selection marker of successfully transduced cells (Figure 47A). 
The α1AT truncated promoter was placed upstream of DsRed to drive expression 
upon hepatic lineage differentiation from pluripotent stem cells (Figure 47B).  
The lentiviral pLNT-SFFV-eGFP backbone was first linearised through digestion of a 
unique EcoRI restriction. The α1AT-DsRed insert was removed from the pcDNA3.1-
α1AT-DsRed plasmid through digestion with a PmeI restriction enzyme to produce a 
blunt ended fragment.   
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Before being ligated into the lentiviral backbone the EcoRI site was blunt ended 
through Klenow DNA polymerase to remove the sticky end overhangs left behind 
through EcoRI digestion. Blunt ended ligation was then carried out to produce the 
pLNT-SFFV-eGFP- α1AT-DsRed lentiviral reporter (Figure 47C) followed by 
restriction digests of obtained clones to check for correct insert incorporation and 
orientation (Figure 47D).  
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Figure 47: Creation of pLNT-SFFV-eGFP-α1AT CombiCult® hepatic reporter  
(A) Plasmid map of pLNT-SFFV-eGFP lentiviral backbone. (B) Plasmid map of pcDNA3.1-
α1AT-DsRed. (C) Plasmid map of completed pLNT-SFFV-eGFP-α1AT-DsRed liver reporter 
construct following ligatin of α1AT-DsRed into the lentiviral backbone. (D) Restriction digest 
of pLNT-SFFV-eGFP-α1AT-DsRed to check for correct clones containing the α1AT-DsRed 
insert. Lane 1 = 1kb DNA Hyperladder (Invitrogen). Lane 2 = Restriction digested of pLNT-
SFFV-eGFP lentiviral backbone with EcoRI before blunt ending. Lane 3 = Restriction digest 
of pLNT-SFFV-eGFP-α1AT-DsRed with correct orientation insert α1AT-DsRed following 
blunt end ligation. Lane 4 = 100bp DNA ladder (Invitrogen). 
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To validate the liver-specific reporter construct, the in vitro hepatocarcinoma cell 
lines Huh7 and HepG2 were used. The Huh7 and HepG2 cell lines are commonly 
used as in vitro hepatocyte models although both exhibit low levels of metabolic 
activity and inductive potential upon drug treatment whilst also serving as inferior 
models for hepatotoxicity compared to primary hepatocytes. The transformed 
fibroblast cell line NIH-3T3 was used as a non-hepatic control to test the specificity 
of the liver-specific α1AT promoter. Transfection of the pLNT-SFFV-eGFP-α1AT-
DsRed plasmid into hepatic and NIH-3T3 fibroblast cell lines was carried out using 
PEI (see Methods 2.1.10). pLNT-SFFV-eGFP-α1AT-DsRed lentivirus was produced 
in 293T cells and titred using a p24 assay (see Methods 2.1.11 and 2.1.12). Titred 
lentivirus was transduced into cell lines in three biological repeats at a concentration 
of 20 MOI for a period of two days in fresh DMEM-complete culture media before 
being refreshed with standard media every two days. Assessment of fluorescence 
intensity levels for both transfected and transduced cells was carried out on day five 
post lentiviral application.  
It was found that upon transfection of the pLNT-SFFV-eGFP-α1AT-DsRed reporter 
construct, successfully transfected cells expressed both eGFP and DsRed, owing to 
HepG2 and Huh7 cells expressing α1AT (Figure 48A). In the fibroblast NIH-3T3 cell 
line, successful transfection was observed through eGFP fluorescence coupled with 
the lack of DsRed expression, owing to the integrity of the α1AT promoter and lack 
of α1AT expression in non-hepatic cells. However, upon lentiviral production and 
transduction of the hepatic reporter construct into Huh7 and HepG2 cells, there were 
much lower levels of DsRed expression visible compared to levels seen in 
transfected cells (Figure 48B). This was observed despite comparable levels of 
eGFP fluorescence between the transfected and transduced cells.  
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Figure 48: Validation of pLNT-SFFV-eGFP-α1AT-DsRed Reporter Construct 
(A) Transfection of the pLNT-SFFV-eGFP-α1AT-DsRed hepatic reporter construct into Huh7, 
HepG2 and control fibroblast NIH-3T3 cell lines showing both eGFP and DsRed expression. 
(B) Lentiviral transduction of pLNT-SFFV-eGFP-α1AT-DsRed into Huh7, HepG2 and NIH-
3T3 cells showing eGFP but very low levels of DsRed. Images are representative of n=3 
biological repeats. 
 
The expression of eGFP, driven by SFFV promoter, and DsRed, driven by the 
endogenous α1AT promoter, in transduced Huh7 cells was also assessed by flow 
cytometry (Figure 49). 66.8% of transduced Huh7 cells expressed eGFP (Figure 
49C) whilst 0.3% were DsRed-positive. (Figure 49B). Only 0.1% of the transduced 
population of Huh7 cells were found to be double-positive for both eGFP and DsRed 
(Figure 49D). This result correlates with fluorescence microscopy results of visible 
levels of both eGFP and DsRed in transduced Huh7 cells.  
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SFFV-eGFP/α1AT-DsRed double positive cells would indicate successfully 
transduced cells expressing DsRed driven by the α1AT promoter in Huh7 cells. 
 
 
Figure 49: Flow cytometry analysis of the CombiCult® hepatic reporter  
Huh7 cells were transduced with the pLNT-SFFV-eGFP-α1AT-DsRed hepatic reporter 
construct and fluorescence was quantified by flow cytometry. (A) Live cells were selected on 
the basis of forward scatter (FSC) and side scatter (SSC) (P1), with subsequent gating on 
(B) α1AT-DsRed+ cells (gate P2), and (C) SFFV-eGFP+ cells (gate P4). (D) Double positive 
α1AT-DsRed+SFFV-eGFP+ Huh7 cells are gated in P3. Note: Fluorescence gates were 
established to exclude background levels of fluorescence in wildtype Huh7 cells, which was 
subsequently removed from the analysis. 
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Further investigation was carried out to assess the reasons for low levels of DsRed 
expression of the liver-specific reporter construct into hepatic cells Huh7 and HepG2 
cells upon lentiviral transduction. Methods trialled to increase the levels of DsRed 
expression upon lentiviral transduction included testing the hypothesis that the low 
levels of DsRed expression could be due to low levels of α1AT in the in vitro liver 
carcinoma Huh7 and HepG2 cell lines. This was addressed by the transient 
treatment of both Huh7 and HepG2 cells with DMEM-complete media containing 2% 
DMSO to terminally differentiate the hepatocarcinoma cell lines. It has been 
previously reported that transient 2% DMSO treatment for a period of three days 
increases the levels of liver-specific markers including α1AT in Huh7 cells [161]. 
This is due to DMSO being a HDAC inhibitor and forcing the unspecific 
differentiation of cells through the ability to disrupt the function of histone 
deacetylases. However, it was found that after transient 2% DMSO treatment of 
both Huh7 and HepG2 cells following the same previously published protocol [161], 
no increase in the levels of DsRed fluorescence was observed (Figure 50A). This 
result was further validated using an alternative HDAC inhibitor, valproic acid (VPA), 
which also had no effect (Figure 50B).  
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Figure 50: Effect of HDAC inhibitors on CombiCult® hepatic reporter activity 
(A) Huh7 cells transduced with pLNT-SFFV-eGFP-α1AT-DsRed following three days of 
treatment with 2% DMSO to increase the expression of hepatic markers including α1AT. (B) 
Huh7 cells transduced with pLNT-SFFV-eGFP-α1AT-DsRed following treatment with a 
different HDAC inhibitor, VPA. Images are representative of three biological repeats. 
 
6.3.1.2 pLNT- α1AT-DsRed Hepatic Reporter Construct 
The next optimisation step in addressing the issue of low levels of α1AT-DsRed 
expression upon lentiviral transduction of the pLNT-SFFV-eGFP-α1AT-DsRed 
reporter construct consisted of removing the constitutive SFFV-eGFP selection 
element of the reporter construct. This was done to ascertain whether the strong 
SFFV viral promoter was interfering with the comparatively weaker truncated α1AT 
promoter driving DsRed expression.  
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To produce the optimised reporter construct after initial validation, the SFFV-eGFP 
element was removed from the lentiviral backbone by carrying out a MluI restriction 
digest. Vector backbone containing only the α1AT-DsRed hepatic reporter was then 
religated and transformed into competent E. coli followed by growing on ampicillin 
resistant plates (see Methods 2.2.3, 2.2.4 and 2.2.6). Extracted DNA was checked 
on a 1% agarose gel for correct clones lacking the SFFV-eGFP element. This 
produced a liver-specific reporter construct containing only the α1AT-DsRed hepatic 
reporter element with no selectable marker for transduction efficiency. Lentivirus for 
the pLNT-α1AT-DsRed construct was produced in 293T cells and subsequently 
transduced into Huh7 cells in three biological repeats (see Methods 2.1.11). It was 
found that there was more DsRed expression upon the removal of the SFFV-eGFP 
element compared to the very low expression levels seen in the previous reporter 
construct containing SFFV-eGFP selectable marker (Figure 51A).  
DsRed expression levels driven by the α1AT promoter in pLNT-α1AT-DsRed 
transduced Huh7 cells were quantified through FACS analysis (see Methods 2.4.6). 
Fluorescence gates were established to ascertain levels of background auto-
fluorescence in wildtype Huh7 cells before analysis of DsRed expression in pLNT-
α1AT-DsRed transduced Huh7 cells. 29.8% of transduced Huh7 cells were positive 
for DsRed expression (Figure 51B). This compares to 0.3% of cells positive for sole 
DsRed expression and 0.1% of cells that were dual positive for eGFP and DsRed in 
Huh7 cells transduced with the.pLNT-SFFV-eGFP-α1AT-DsRed reporter construct 
(Figure 51C).  
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Figure 51: Validation of Optimised α1AT Liver-Specific Reporter Construct 
(A) Transduction of optimised pLNT-α1AT-DsRed liver-specific construct (no SFFV-eGFP) 
into Huh7 showing significantly increased levels of DsRed expression. (B) Quantification of 
DsRed expression levels transduced Huh7 cells as determined by flow cytometry showing 
29.8% of total cells expressing DsRed (gate P2). (C) Comparative quantified fluorescence in 
transduced Huh7 cells. *(left) Huh7 cells transduced with the pLNT-SFFV-eGFP- α1AT-
DsRedhepatic reporter expressing sole positive eGFP (+GFP), sole positive DsRed 
(+DsRed) and dual positive eGFP and-DsRed (+dual). **(right) Huh7 cells transduced with 
the optimised pLNT-α1AT-DsRed reporter expressing positive DsRed (+DsRed). Presented 
data is from n=3 biological repeats.  
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6.3.1.3 pLNT-HNF4α-eGFP-Luc Hepatic Reporter Construct 
HNF4α is known to be key hepatic regulator and is involved in many hepatic 
processes including the specification of hepatic progenitor cells from pluripotent 
stem cells [294] [171] [191]. The importance of HNF4α has been demonstrated by 
the fact that the forced expression is enough to trans-differentiate fibroblasts to 
HLCs with some measure of functional ability [295]. HNF4α is therefore of interest 
through targeting with small bioactive molecules could be employed as a strategy for 
producing more metabolically relevant hepatocytes. Linoleic acid has been 
proposed as a potential ligand for HNF4α and was therefore trialled as a potential 
inducer to produce more metabolically relevant HLCs. DMSO treatment is routinely 
used during in vitro culture to terminally differentiate HepaRG hepatocarcinoma cells 
and also used in hepatic differentiation protocols in hepatic specification stages 
along with other HDAC inhibitors such as sodium butyrate [133] [131] [296] [132] 
[297].  
A lentiviral reporter construct was created to address this hypothesis which 
consisted of a synthetic promoter made up of eight serial HNF4α minimal binding 
elements driving the expression of a minimal promoter (Figure 52A). The pLNT-
HNF4α-eGFP-luc lentiviral vector was created by Juliette Delhove in the McKay lab 
group at the WHRI, QMUL. The HNF4α promoter drives both eGFP fluorescence in 
pluripotent stem cell lines to monitor real-time differentiation to hepatic cells in the 
CombiCult® platform (Figure 52B) whilst the firefly luciferase allows for accurate 
quantification of HNF4α inducing factors (Figure 52C). HepaRG cells were 
transduced in three biological repeats with the pLNT-HNF4α-eGFP-luc lentiviral 
reporter at 20 MOI for two days and then media changed until the appearance of 
eGFP fluorescence indicating HepaRG cells expressing HNF4α (see Methods 
2.1.13).  
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HepaRG cells were then treated for five days with assay media consisting of HBM 
(see Methods 2.6.1) containing either linoleic acid, 2% DMSO, linoleic acid + 2% 
DMSO or a control consisting of assay media. The ability of linoleic acid to increase 
expression of HNF4α was compared to and used in combination with 2% DMSO 
treatment in pLNT-HNF4α-eGFP-luc transduced HepaRG reporter cells. Following 
HepaRG treatment with either sole or dual inducer conditions, cells were first 
visualised for eGFP fluorescence driven by the from the HNF4α promoter. Levels of 
fluorescence from the reporter construct were assessed in comparison to control 
treated HepaRG cells. Subsequently, cells were lysed to carry out luciferase assays 
to quantitatively assess the levels of HNF4α induction (see Methods 2.5.3). After 
five days of treatment, it was seen that there were increased levels of eGFP 
fluorescence in HepaRG reporter cells treated with either linoleic acid alone or 
combined linoleic acid with 2% DMSO (Figure 52B). Levels of eGFP fluorescence 
between control cells and 2% DMSO treated reporter cells was observed to be at 
comparative levels. It was found through luciferase assays that sole linoleic acid 
treatment increased HNF4α reporter activity. An increase in reporter activation of 
three-fold (p<0.001) was observed as assessed through luciferase activity (Figure 
52C). This data provides evidence for linoleic acid being a ligand for HNF4α and 
therefore can be used in the production of more mature HLCs upon differentiation 
from pluripotent hESCs. In contrast, the treatment of HepaRG cells with 2% DMSO 
was found to not significantly upregulate HNF4α reporter activity and was in fact 
shown to negatively influence the inductive potential of linoleic acid when used in 
combination (p<0.01). In addition, HepaRG cell morphology was seen to be 
changed upon the treatment of 2% DMSO with cells displaying a sparser, rounded 
morphology indicative of cell stress and apoptosis (Figure 52B).  
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Visualised levels of background auto-fluorescence were also found to be increased 
upon treatment with 2% DMSO which could also be taken as being correlated with 
an increase in apoptosis and cell stress. 
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Figure 52: Linoleic Acid induction of HNF4α Reporter Construct   
(A) pLNT-HNF4α-eGFP-luc lentiviral reporter construct overview demonstrating key 
elements. (B) Phase contrast and eGFP fluorescence images of lentiviral transduction 
of HepaRG cells with the pLNT-HNF4α-eGFP-luc reporter construct followed by either 
2% DMSO, linoleic acid, combined 2% DMSO + linoleic acid or control. (C) Luciferase 
assay to measure HNF4α reporter activity upon test treatment in comparison to levels 
of HNF4α activity in control HepaRG cells. Data are shown as mean ± SEM of 3 
repeats and differences in reporter activity versus control were determined by 1-way 
ANOVA with Bonferoni’s post-test and significance indicated by *** (p<0.001) and ** 
(p<0.01). The pLNT-HNF4α-eGFP-luc lentiviral vector was created by Juliette Delhove 
in the McKay lab group at the WHRI, QMUL. 
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6.3.1.4 pLNT-LXR-eGFP-Luc Hepatic Reporter Construct 
The transcription factor activated LXR reporter was constructed with a view to test 
the inductive ability of small bioactive molecules on NHRs with a view to upregulate 
CYP450 family members and produce more metabolically active HLCs. The reporter 
construct consisted of a synthetic promoter made up of eight serial LXR minimal 
binding elements driving the expression of a minimal promoter (Figure 53A). The 
pLNT-LXR-eGFP-luc lentiviral vector was created by Juliette Delhove in the McKay 
lab group at the WHRI, QMUL. Like the HNF4α reporter construct, the LXR 
promoter drives both eGFP fluorescence for incorporation in pluripotent stem cell 
lines to monitor real-time differentiation to hepatic cells in the CombiCult® platform 
(Figure 53B) whilst the firefly luciferase allows for accurate quantification of LXR 
inducing factors (Figure 53C). The targeting of NHR family members to increase the 
metabolic activity of HLCs differentiated from pluripotent stem cells is a key strategy 
in the application to drug toxicity screens. Factors involved in the upregulation of the 
NHRs during the CombiCult® screen included CITCO and T0901317 however their 
optimum concentrations during monolayer in vitro hepatic differentiation from 
pluripotent stem cells and in particular during the stages of hepatic maturation 
stages has not yet been determined.  
To assess optimal concentrations of hepatic maturation inducing agonists, LXR 
reporter cells were produced using the pLNT-LXR-eGFP-luc lentiviral vector. This 
involved the transducing of HepaRG cells with the pLNT-LXR-eGFP-luc lentiviral 
vector at a 20 MOI concentration for two days and then media changed until the 
appearance of eGFP fluorescence indicating HepaRG cells expressing LXR. LXR 
reporter transduced HepaRG cells were then subjected to treatment with increasing 
concentrations of the T0901317 small molecule agonist to increase LXR expression.  
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Concentrations of 0.1µM, 1µM and 10µM was used to determine the inductive effect 
on the LXR reporter construct in HepaRG cells and therefore determine the optimum 
concentration with which to increase LXR and consequently produce the most 
metabolically relevant HLCs in vitro. T0901317 small molecule agonist containing 
media was refreshed day on day for a period of seven days (Figure 53B). The 
induction period of seven days was used to recapitulate the final stage of the 
CombiCult® differentiation screen which in turn was designed to improve on current 
in vitro differentiation strategies.  
The small bioactive molecule T0901317 was shown to increase levels of LXR 
reporter activity by six-fold compared to levels of reporter activity wildtype at 1µM 
concentration (p<0.001) (Figure 53C). The 1µM concentration was seen to exhibit 
the highest levels of LXR reporter activation as assessed by luciferase assay in the 
HepaRG reporter cells. It was found that 0.1µM concentrations of T0901317 did not 
significantly increase levels of luciferase reporter activation in reporter HepaRG cells 
whilst increasing the concentration to 10µM was seen to be increase reporter activity 
by four-fold (p<0.001) compared to the control. This data demonstrates that 
increasing the concentration of T0901317 from 1µM to 10µM does not further 
increase LXR reporter activity. 
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Figure 53: T0901317 Induction of LXR Reporter Construct   
(A) pLNT-LXR-eGFP-luc lentiviral reporter construct overview demonstrating key elements. 
(B) Lentiviral transduction of HepaRG cells with the pLNT-LXR-eGFP-luc reporter 
construct followed by increasing concentrations of the small bioactive T0901317 agonist at 
0.1µM, 1µM and 10µM for a period of seven days. (C) Luciferase assay to quantitatively 
measure LXR reporter activity in relative fluorescent units (RFU) upon small molecule 
agonist treatment for seven days. Data are shown as mean ± SEM of n repeats and 
differences in reporter activity versus control were determined by 1-way ANOVA with 
Bonferoni’s post-test and significance indicated by *** (p<0.001). The pLNT-LXR-eGFP-luc 
lentiviral vector was created by Juliette Delhove in the McKay lab group at the WHRI, 
QMUL. 
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6.4 Discussion 
6.4.1 Development of Liver-Specific Fluorescent Reporters 
Work completed has tested liver-specific reporter constructs containing a truncated 
α1AT promoter driving the red fluorescent reporter gene DsRed and a second 
constitutive expression cassette where the green fluorescent eGFP gene is 
expressed from the strong constitutive SFFV gene promoter. We predicted that 
transduced stem cells would fluoresce green but when differentiated to hepatocytes 
the cells would maintain eGFP fluoresce and also DsRed due to hepatic cells 
expressing α1AT. It was found that this initial construct was unsuitable for use in 
high-throughput hepatocyte differentiation screens due to problems with SFFV-
eGFP interference, resulting in very low levels of DsRed fluorescence upon viral 
transduction into in vitro liver cell lines. In initial transfection experiments, all 
transfected cell lines tested fluoresced green and only hepatic cell lines fluoresced 
red showing that the truncated α1AT promoter was specifically expressed in hepatic 
cell lines and not in non-hepatic control cell lines. However, lentiviral transductions 
of the same hepatic reporter construct showed no or very low levels of expression of 
the α1AT-DsRed reporter although the SFFV-eGFP reporter was fully functional. 
Various approaches were undertaken to resolve the anomaly between transfection 
and lentiviral transduction including selectively deleting each expression construct 
from the parental plasmid. It was found that α1AT-DsRed conditional expression 
could be rectified through removal of a SFFV-eGFP selectable marker. This allowed 
for high levels of DsRed fluorescence driven by the α1AT promoter to be obtained 
and quantified through FACS analysis in lentivirus transduced Huh7 cells.  
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Problems with co-expressing two gene cistrons in lentiviral vectors have been 
previously documented in which the IRES-eGFP cassette has been found to 
interfere with the translation of other cDNAs [298]. It has further been found that 
there is a much reduced expression of the second gene in these bicistronic vectors 
[299] [272]. The SFFV-eGFP and α1AT-DsRed are expressed in the same direction 
in the pLNT-SFFV-eGFP-α1AT-DsRed reporter construct and this has been shown 
to cause problems with the efficient expression of both gene cistrons in previously 
published studies. In line with this previous research, high expression from the CMV 
promoter driving eGFP expression was quantified whilst in contrast very low levels 
of DsRed expression were driven by the α1AT. An alternative strategy could be to 
express the eGFP and DsRed in opposite directions as this has been shown to 
allow for both cistrons to be successfully expressed at comparative levels [233]. The 
bidirectional expression approach could potentially remove the problem of promoter 
interference from organising the SFFV-eGFP and α1AT-DsRed cassettes in the 
same orientation.  
Future work into producing hepatic reporter constructs could be concerned with 
incorporating alternative selectable marker such as a puromycin resistance gene. 
This can be used to select pure populations of transduced cells to be used in high-
throughput differentiation screens from pluripotent stem cells to hepatocytes.  
However, for this to be realised the problem of promoter interference during the co-
expression of two cistrons in the same direction would have to be addressed either 
through a bidirectional vector or through the utilisation of insulator sequences to 
shield from promoter interference [204] [300]. Antibiotic resistance genes rather than 
a fluorescence selectable marker may be more appropriate as fluorescence can 
only be selected through FACS.  
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This however could be overcome with the use of feeder-free growth conditioned 
pluripotent cells which can be enzymatically passaged to single cells and 
subsequently be recovered for replating after FACS purification through the use of 
ROCK inhibitor, which prevents apoptosis in single pluripotent cells [301].  
If this construct proves efficacious we will compare a number of hepatic promoters 
replacing the truncated α1AT promoter with other relevant hepatic gene promoters. 
This could be done to encompass different hepatic cell markers involved in the early 
expansion stages and in hepatocyte maturation. Early hepatic markers such as 
FOXA2 and SOX17 along with mature hepatic markers such as CYP450 family 
members, both key to hepatocyte gene regulation and maturation, would provide 
real-time readout of the final and currently largely unknown steps involved in 
producing more functional hepatocytes. Another further direction would be 
concerned with the incorporation of dual reporter elements in the same lentiviral 
construct. This would be especially useful during the early stages of DE specification 
where there is a current lack of specific individual markers and current strategies 
therefore rely on combinations of overlapping markers to distinguish between 
populations of cells such as FOXA2, SOX17 and CXCR4 [77] [103]. Semb and co-
workers have generated hESC lines that contain a GFP knock-in in the first intron of 
the FOXA2 gene which are broadly applicable to assaying DE specification in living 
pluripotent cells [79]; however, such analyses have been restricted to a single hESC 
line. 
In addition to conducting targeted analysis on stage-specific regulators for hepatic 
differentiation, the CombiCult® hepatic differentiation screen identified a number of 
small molecule bioactive molecules as being important during different stages in the 
specification of HLCs from pluripotent hESCs.  
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This included the GSK3β inhibitor BIO, which was incorporated into the first stage of 
differentiation to mimic WNT3A signalling, typically concerned with the specification 
of DE from pluripotent stem cells. BIO has been used previously in vitro to 
differentiate pluripotent stem cells to DE without the exogenous addition of Activin A 
[121]. The activation of the WNT signalling pathway in cooperation with the 
activation of Nodal signalling through the exogenous addition of Activin A has been 
shown to more efficiently generate DE [99] [83] [263]. Other small molecules 
identified as being important in the CombiCult® screen included the TGFβ signalling 
inhibitors SB431542 and the specific SMAD3 signalling antagonist SIS3 during the 
hepatic specification stages of differentiation. It is known that Nodal signalling is 
crucial for DE specification in vivo however there is evidence that the 
downregulation of TGFβ signalling after the formation of DE and early hepatic 
lineage derived cells is important for further differentiation along the hepatic lineage. 
Previous studies have shown that Activin A/TGFβ signalling blocks the 
differentiation to pancreatic whilst promoting hepatic specification [82]. Spagnoli et 
al. (2000) implicated the downregulation of TGFβ signalling as important in the 
progression of bi-potent hepatic precursors to differentiate to mature hepatocytes 
[267]. In this way, TGFβ is important in specifying hepatic cells but the subsequent 
down regulation is important for maturation. The use of real-time readouts from 
lentiviral reporters would therefore give valuable insight into temporal signalling 
changes with a view to recapitulate developmental cues in vitro. 
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6.4.2 HNF4α Reporter Construct 
Luciferase assays have previously been utilised an alternative means for the 
quantification of relative protein expression during in vivo studies [286]. This makes 
luciferase reporters a powerful tool and thus the application of luciferase as a 
reporter gene has been widely exploited in the study of promoter activity during in 
vitro studies [287]. The use of lentiviral constructs containing transcription factor 
activated binding sites which are designed and integrated upstream of a minimal 
promoter to drive the expression of luciferase reporters have been deployed to 
identify ligands for orphan receptors previously [302] [303] [304]. A parental 
lentivirus construct has been created by the McKay lab which allows the shuttling of 
consensus binding sequences through the Gateway system (Invitrogen) allowing for 
multiple signalling pathways to be interrogated using a common parental vector 
containing both eGFP and luciferase as readout assays. The use of luciferase 
reporters also extends to allow for the identification of temporal signalling changes 
over the course of cellular differentiation and serves as a powerful tool for the 
differentiation of pluripotent stem cells to hepatocytes. One example for the 
utilisation of these reporters during hepatic differentiation is in the role of TGFβ 
signalling firstly in the establishment of DE and then the subsequent down regulation 
to allow the maturation of hepatocytes. The identification of the TGFβ signalling 
inhibitors SB431542 and the specific SMAD3 signalling antagonist SIS3 during the 
hepatic specification stages of differentiation in the CombiCult® hepatocyte screen 
is consistent with in vivo knowledge [82] [267]. However, the optimal timings and 
dose for the administration of these small molecule inhibitors could be more 
precisely determined through the use of luciferase reporters which have been 
generated from the parental lentivirus construct through the shuffling of the TGFβ 
signalling consensus binding sequence upstream of a luciferase reporter cassette. 
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HNF4α is a key hepatic regulator and involved in many hepatic processes [171] 
[191]. The importance of HNF4α has been demonstrated by the fact that the forced 
expression is enough to trans-differentiate fibroblasts to HLCs with some measure 
of functional ability [295]. To investigate HNF4α during hepatic maturation, a 
luciferase lentiviral reporter system was used to investigate the potential of linoleic 
acid to upregulate the expression of the nuclear receptor HNF4α in HepaRG cells. 
This was investigated because of the ability of HNF4α to induce the expression of a 
number of the CYP450 family members and therefore presents a target to produce 
more metabolically relevant hepatocytes [217] [176].  
It was shown that unconjugated linoleic acid was highly toxic to hESCs during the 
first stage of differentiation to DE and to HepaRG cultures which resulted in total cell 
death. This corroborates findings by Cury-Boaventura who found that linoleic acid 
displayed toxicity and promoted apoptosis in Raji cells; cells of hematopoietic origin 
[272]. In contrast, linoleic acid conjugated to BSA was found to have no discernible 
toxic effects when used at the same concentration on both hESCs and HepaRG 
cells. Five days of treatment demonstrated the ability of BSA conjugated linoleic acid 
to upregulate HNF4α expression three-fold in HepaRG reporter cells. It was 
observed that there were similar levels of GFP fluorescence between control treated 
HepaRG cells and sole DMSO and combined DMSO + linoleic acid treatment 
groups. A small increase in GFP fluorescence was seen in the sole linoleic acid 
treated HepaRG cells however this was quantified as a significant three-fold 
increase through luciferase assays (p<0.001). This discrepancy could be due to 
higher levels of autofluorescence in the HepaRG cultures that makes distinction 
between control and linoleic acid treatment harder to detect through fluorescence 
imaging but is quantifiable through more sensitive luciferase assays.  
 
 
 
239 
 
This data provides evidence that linoleic acid is indeed a ligand for HNF4α and can 
therefore be used with a view to produce more metabolically relevant HLCs through 
the ability to upregulate xenobiotic drug metabolising enzymes.  
In comparison to the inductive effects of linoleic acid, 2% DMSO treatment was seen 
to have no effect on HNF4α expression and in fact negated the induction of linoleic 
acid when used in combination over five days of treatment. The HDAC inhibitors 
DMSO and sodium butyrate are typically used in the second stage of in vitro hepatic 
differentiation, concerned with the specification of DE to the hepatic lineage and 
early bi-potent hepatic progenitors [99] [133] [131] [296] [132] [297]. This is due to 
the ability of HDAC inhibitors to promote the activation of differentiation inducing 
genes through preventing removal of acetyl groups [83].  
The identification of orphan receptors is important in dissecting signalling 
mechanisms and consequently identifying novel therapeutic targets. Sladek et al. 
(2002) showed that HNF4α targets and upregulates members of the CYP450 family 
of metabolic enzymes and therefore is an important avenue of investigation to 
produce more mature hepatocytes [192]. Another study by Yuan et al. (2009) used 
isolation/mass spectrometry (AIMS) approaches to demonstrate that HNF4α is 
selectively occupied by linoleic acid in mammalian cell however, the exact function 
of the linoleic acid ligand is yet to be fully understood [201]. Utilising agonists of 
hepatic master regulators at an early stage could potentially be used as a strategy to 
more quickly and efficiently differentiate metabolically relevant HLCs from hESCs; 
bypassing the traditional four-stage differentiation process in vitro.  
A future approach could be to utilise a small bioactive molecule agonist to target 
HNF4α in place of linoleic acid. The identification of synthetic HNF4α agonists have 
been utilised previously by Lee et al. (2013) to increase levels of HNF4α with a view 
to increase β-cell replication [305].  
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In addition, phase II NHRs and transporters involved in the elimination of drug 
compounds are also upregulated by HNF4α [217] and the knock down of HNF4α 
has been shown to decrease target genes.  
The next stage of analysis would be to transduce pluripotent hESCs with the HNF4α 
reporter construct and assess the optimal time during hepatic differentiation to 
administer linoleic acid by taking cell lysate samples for luciferase reporter activation 
using the current reporter construct. A future direction of investigation would be to 
incorporate the HNF4α promoter into the secreted Nanoluc lentiviral reporters. As 
well as holding advantages in fluorescence intensity and lower background 
fluorescence levels this new generation of luciferase reporter has the distinct 
advantage of being a naturally secreted form of luciferase allowing for conditioned 
media to be collected as opposed to lysing cells [306]. This would be advantageous 
in the context of this study and in the CombiCult® platform as it allows for the day-
on-day changes in HNF4α to be assessed and give a better understanding as to key 
inducers of master hepatic regulators. Linoleic acid was used in the first stage of 
differentiation during the CombiCult® differentiation screen and therefore could be 
utilised in more efficiently differentiating hESCs to HLCs by the utilisation at different 
stages of differentiation. 
 
 
 
 
 
 
 
 
241 
 
6.4.3 LXR Reporter Construct 
The small bioactive molecule T0901317 was used assess the optimum 
concentration to upregulate LXR reporter activity. This was investigated as LXR and 
other NHRs have a direct effect of the upregulation of members of the CYP450 
family and can be used as a strategy to produce more metabolically relevant 
hepatocytes. It was shown that 1µM concentration T0901317 increased levels of 
LXR activity by six-fold compared to control treated HepaRG cells. It has previously 
been implicated by Mitro et al. (2007) that the small molecule agonist T0901317 also 
has a degree of affinity for another member of the NHR family, the PXR [307]. It was 
shown that T0901317 increases the activity of PXR target genes in addition to 
targets of LXR including CD36, which is involved in metabolism of fatty acids. In 
addition, transcriptomic screening by Chen et al. (2014) showed that the 
overexpression of LXR promoted hepatic maturation of bi-potent HepaRG cell 
cultures [102]. This study suggests that LXR is important in hepatic maturation 
through increasing markers and functions of mature hepatocytes including increased 
metabolic enzyme activity, urea secretion and glycogen metabolism. LXR was also 
been shown to increase the expression of a number of proliferation-associated 
factors including HNF4α. HepaRG cells are routinely used in toxicity studies and are 
normally required to be terminally differentiated in DMSO containing culture media 
for a period of four weeks. However, this same study demonstrated that through the 
overexpression of LXR functional differentiated HLCs could be obtained after seven 
days. This gives rise for the potential of the small bioactive molecule T0901317 to 
be utilised to target and upregulate LXR as opposed to the use of overexpression 
constructs.  
 
 
 
 
242 
 
Transferring this knowledge to the in vitro differentiation of HLCs from pluripotent 
stem cells can be used as a strategy for producing more metabolically relevant 
hepatocytes in future studies. Further to this, LXR is associated with the peroxisome 
proliferator-activated receptor (PPAR) pathway which in turn is implicated in the 
maturation of hepatic cells and tissue and in liver regeneration [308]. The ability of 
T0901317 to induce a wider range of target genes is not shared by more specific 
LXR agonists, such as GW3965. GW3965 was investigated as a maturation 
inducing factor and also identified as being important in the final stage of the 
CombiCult® hepatocyte screen through the ability of GW3965 to induce LXR 
activation [309]. However, the utilisation of T0901317 could be used with a view to 
increase the activity of a wider range of LXR/PXR target genes during the latter 
stages of hepatic differentiation to produce more metabolically functional 
hepatocytes.  
With a view to future hepatic maturation studies, luciferase reporters allow an 
accurate quantification of reporter activity whilst the new generation of secreted Nluc 
lentiviral vectors allow day on day changes in reporter activity to be assessed. 
Therefore, they hold an advantage over traditional luciferase reporters which require 
the lysing of cells at the end of the differentiation process to assess levels of 
reporter induction/inhibition. In this way, day on day changes in master hepatic 
maturation factors can be determined with much greater accuracy and in real-time 
which would allow for a much more in-depth analysis of differentiation.  
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Chapter 7: General Discussion 
7.1 Project Overview 
The findings of this research project have contributed to the overall knowledge and 
understanding of the differentiation of pluripotent stem cells to HLCs. Insights gained 
have helped move towards the goal of achieving the production of metabolically 
relevant hepatocytes for the use in drug toxicity screens. This thesis has 
demonstrated the following findings: 
• CMV promoters are not highly expressed in pluripotent hESCs.  
• Novel factors promote hepatic maturation in vitro. 
• Linoleic acid is a ligand for the HNF4α receptor. 
• Luciferase reporters can be utilised to determine optimum concentrations 
of maturation inducing agonists. 
 
There is a demand from the biotechnology industry for an inexhaustible supply of 
metabolically functional hepatocytes to be used in regenerative medicine to help to 
repair, augment or replace damaged tissues and with which to perform toxicity 
assay screens on early stage drugs. It has been shown in rat models that 
hepatocytes have the capacity to undergo high levels of proliferation following 
hepatectomy [164]. However, isolated primary hepatocytes quickly lose their 
proliferative potential when cultured in vitro and dedifferentiate [310]. The liver-
specific functions of these primary hepatocytes have been seen to be progressively 
lost with extended in vitro culture due to gene expression changes in master hepatic 
regulators [310]. Phenotypic and genotypic variability is also a significant problem 
amongst isolated donor primary hepatocyte samples.  
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Current HLCs produced through the in vitro differentiation rely on the exogenous 
addition of growth factors [111] [145] [136] and so far have yet to show the 
proliferative potential and functional activity of in vivo hepatocytes.  
The in vitro differentiation of pluripotent stem cells to hepatocytes is hampered by 
two major bottlenecks. Firstly, in DE specification from pluripotent stem cells where 
Nodal is known to be the key driver during in vivo mouse development [91] [109]. 
However, it has been shown that the addition of exogenous recombinant Nodal to 
monolayer cultures of pluripotent stem cells resulted in a lack of differentiation and 
no suppression of pluripotent markers as assessed through qPCR and 
undifferentiated colony morphology [245]. Consequently the related TGFβ family 
member Activin A is routinely used to mimic Nodal signalling and differentiate 
human pluripotent stem cells in vitro [87] [110] [111] [84] [145] [83]. However, the 
use of Activin A produces off target gene activation (McKay et al unpublished) in the 
process of DE specification. Investigation into the underlying signalling mechanisms 
is therefore needed with a view to efficiently differentiate pluripotent stem cells to 
homogenous populations of DE.  
The second bottleneck is in the maturation of differentiated cells to metabolically 
relevant hepatocytes. Currently, only foetal-like HLCs have been produced which 
exhibit low levels of metabolic activity and inducibility upon drug administration [111] 
[145] [136]. The maturation of these pluripotent stem cell derived HLCs has so far 
remained elusive and the signalling cues pushing the terminal differentiation of 
hepatocytes in vitro have yet to be fully understood. The ability of pluripotent stem 
cells to give rise to unlimited amounts of cell types of interest makes then an 
extremely attractive proposition.  
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7.1.1 CMV promoters display low transduction and expression in hESCs 
Tools with which to knock down Nodal/Cripto signalling in vitro were assessed using 
lentiviral shRNA vectors. The pGIPZ lentiviral shRNA vector system utilise the CMV 
viral promoter driving shRNA knock down of Nodal/Cripto. However, after extended 
investigation using both the huES1-OCT4-GFP and Shef3 hESC lines successful 
pGIPZ transgene expression could not be obtained at any lentiviral MOI 
concentration trialled. The failure in transgene expression from the pGIPZ lentiviral 
vectors into both huES1-OCT4-eGFP and Shef3 cell lines has hampered the further 
dissection of the role of Nodal/Cripto in DE specification through gene knockdown. 
Other promoters from different lentiviral vectors used in this thesis such as the SFFV 
viral promoter to drive expression of eGFP have been successfully transduced and 
expressed in pluripotent stem cell lines. Taken together, this provides evidence that 
there is a problem with expression of the CMV promoter in human pluripotent stem 
cell lines.  
The use of lentiviral vectors to genetically modify a host genome through delivery of 
transgenes is a powerful tool to dissect signalling mechanisms or drive 
differentiation of stem cells [311]. Lentiviral vectors display high transduction levels 
in a number of cell lines tested however the expression of transgenes has been 
seen to be a problem; particularly in human pluripotent stem cells [110]. A 
mechanism of DNA methylation-mediated silencing has been proposed by Cherry et 
al. (2000) who showed that culture of ES cells transduced with a retroviral vector 
lost expression of GFP driven by a viral promoter. Subsequent treatment with a DNA 
demethylating agent, 5-azadeoxycytidine, was sufficient to reactivate expression of 
GFP. This leads suggests that the expression of transgenes in ES cells is regulated 
in part by methylation-dependant mechanisms [312].   
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A number of previous studies have found the lack of efficient expression of the CMV 
promoter in pluripotent stem cell lines followed by rapid silencing [251] [253] [253] 
[254] [110] [312] corroborating the findings in this thesis. In these studies, alternative 
viral promotes including human elongation factor 1α (EF1α) and phosphoglycerate 
kinase 1 promoter (PGK) were shown to be more highly expressed and maintain 
expression levels for extended periods of cell culture in comparison to CMV 
promoters. This makes them a better option for the use in gene knock down and 
overexpression experiments in human pluripotent stem cell studies. 
Promoter interference has also been hypothesised as a reason for low CMV 
expression levels in pluripotent stem cell lines transduced with dual reporter 
constructs. Luo et al. (2014) proposed that interference between two promoters, 
CMV and EF1α, was responsible for lack of eGFP fluorescence which was driven by 
a CMV promoter [313]. Interestingly, the red fluorescence protein expressed through 
the EF1α promoter in this construct was maintained after eGFP was no longer 
detectable through microscopy in pluripotent cell lines. Promoter interference 
between the PGK promoter driving puromycin resistance in the pGIPZ construct and 
the CMV promoter driving shRNA knockdown could be a reason for the lack of 
detectable eGFP fluorescence in the Nodal/Cripto shRNA knock down lentiviral 
constructs. The findings in this thesis and other studies therefore highlight the 
problems in expression of the CMV viral promoter in hESCs [313]. 
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7.1.2 Nodal/Cripto conditioned media specifies SOX17+ cells 
Conditioned media has previously been utilised to promote the maintenance of 
pluripotency in a feeder-free conditioned human pluripotent cell lines. This has been 
achieved through the collection of conditioned media produced from supportive MEF 
feeder cells and application to feeder-free cells on an appropriate ECM [25] [17] 
[25]. The same approach was used with a view to differentiate pluripotent cells 
through the application of DE inducing factors as opposed to maintaining them in a 
pluripotent state. The approach of using conditioned media to differentiate stem cells 
has been applied previously to oestrogenic and chondrogenic differentiation [314], 
neuronal differentiation [315], cardiac differentiation [316] showing the potential of 
isolating differentiation factors in conditioned media to drive pluripotent stem cell 
differentiation.  
In this thesis, “producer cells” were created to secrete Nodal and Cripto proteins into 
cell culture media which was collected following 24 hours of conditioning and 
subsequently exhibited activation of TGFβ reporter cells. Nodal/Cripto conditioned 
media treatment resulted in SOX17+ cells, a marker of DE, from pluripotent stem 
cells as assessed through ICC staining. Nodal/Cripto conditioned media as well as 
100ng/ml Activin A treatment was seen to produce greater numbers of SOX17+ 
cells over a period of five days against differentiation in basal media with no DE 
inducing factors. It is of note however that even though there were very few cells 
following treatment with basal media containing no DE inducing factors, they were 
almost exclusively SOX17+. Levels of SOX17+ staining as assessed through ICC 
staining was seen to be comparative between sole Nodal, sole Cripto and combined 
Nodal/Cripto conditioned media assessed against the use of 100ng/ml Activin A.  
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The comparative numbers of cells staining positive for SOX17+ was surprising in the 
sole Cripto conditioned media treatments as Cripto is not a direct ligand for the 
activation of TGFβ signalling but is in fact a signalling co-factor of Nodal. This result 
could be evidence of the amplification of existing Nodal signalling through the 
presence of excess Cripto.  Nodal/Cripto conditioned media treatments and the use 
of 100ng/ml Activin A was seen to increase the numbers of SOX17+ cells compared 
to cells treated with media containing additional DE inducing factors. This would be 
expected as the default differentiation pathway of human pluripotent stem cells is 
biased towards the neuroectodermal lineage [245] [19] [83].  
The ability of Nodal/Cripto conditioned media to produce SOX17+ cells 
demonstrates the potential of using the Nodal/Cripto conditioned media approach as 
opposed to Activin A to differentiate pluripotent stem cells to DE in vitro. Further 
investigation is needed to properly characterise the difference in the populations of 
SOX17+ cells produced through conditioned media versus the use of 100ng/ml 
Activin A, which has been shown to activate off target gene expression (McKay et al. 
unpublished). Current DE specification efficiencies through the utilisation of Activin A 
are ~70-85% of the differentiated cell population as assessed through the staining of 
markers such as SOX17 and FOXA2 [148] [83]. Numbers of ICC stained SOX17+ 
cells obtained through Nodal/Cripto conditioned media was seen to be at 
comparable levels to the addition of 100ng/ml Activin A. ICC staining for the co-
localisation of a battery of DE markers including FOXA2 and CXCR4 would allow 
better assessment of the populations of SOX17+ cells seen in this study along with 
qPCR analysis. 
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It has been shown that WNT signalling in collaboration with Activin A more efficiently 
specifies DE cells with higher expression of characteristic markers [99]. Further 
evidence of the importance of WNT signalling was demonstrated by Tahamtini et al. 
(2013) who used the small molecule CHIR99021, a GSK-3β inhibitor mimicking 
WNT signalling activation, to prime pluripotent stem cells which exhibited increased 
numbers of both SOX17 and FOXA2 cells upon DE differentiation using Activin A 
than populations observed without priming [122]. It has been hypothesised through 
previous studies that the targeted activation of WNT signalling through the use of 
small bioactive molecules upregulates the downstream expression of Nodal and this 
is the driver of efficient DE specification in vitro [121]. The use of Nodal/Cripto 
conditioned media with GSK-3β inhibitors is therefore an avenue of investigation to 
potentially amplify the homogenous differentiation of pluripotent stem cells to DE.  
 
7.1.3 Novel factors promote hepatic maturation in vitro 
This project set out to identify novel hepatic maturation inducting factors as well as 
to transfer in vivo knowledge of hepatic specification to in vitro cell culture systems 
to differentiate pluripotent stem cells to metabolically relevant hepatocytes. Through 
the completion of the CombiCult® hepatocyte screen, novel factors were identified 
which promoted differentiation at different stages to the most highly expressing 
CYP1A1/A2 and CYP3A4 HLCs (Figure 54). Following monolayer validation utilising 
CombiCult®-identified factors it was found that the highest levels of CYP3A4 
induction was in protocols containing hepatic differentiation factors which have not 
previously been applied to in vitro protocols.  
 
 
 
250 
 
It was found that small but significant increases in the levels of CYP3A4 family 
induction upon drug administration could be achieved. Although further optimisation 
of the concentrations of small bioactive agonists need to be accurately defined 
which promote optimal activation whilst avoiding toxicity. CYP1A1/A2 levels were 
seen to be consistent across all protocols tested in this study. From observations 
seen in the completion of the CombiCult® hepatocyte screen, novel factors were 
identified including small molecule inhibitors/agonists of pathways known to be 
important along the process of hepatic differentiation. Key factors and conclusions 
from individual stages of CombiCult® differentiation are detailed in the following 
sections: 
7.1.3.1 TGFβ signalling inhibition 
Nodal signalling is critical for establishment of DE during early in vivo development, 
capable of giving rise to both DE and mesoderm [246] [87]. High levels of Nodal 
signalling persist until DE is specified and is subsequently down regulated [87] [88]. 
The down regulation of Nodal signalling is required for the progression to the hepatic 
lineage from specified DE [82] [246]. SB-431542, a TGFβ1/Alk7 inhibitor has been 
used in recent studies to promote hepatic specification and maturation and was 
seen in this thesis to be present in a large majority of top differentiation protocols 
[236]. The specific SMAD3 signal inhibitor SIS3 was also found to be present in the 
majority of top protocols in the second stage of differentiation and consequently 
associated with producing the most dual-positive CYP1A1/A2 and CYP3A4 HLCs. 
This provides further evidence that TGFβ signalling inhibition following the 
establishment of DE populations from pluripotent stem cells in the first stage of 
differentiation is important for the progression to the hepatic lineage during in vitro 
protocols. 
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7.1.3.2 Growth factors 
Growth factors including TGFα were found to be highly prevalent in the protocols 
which produced the highest CYP1A1/A2 and CYP3A4 expressing HLCs. TGFα was 
utilised in the third stage of differentiation concerned with the proliferation of hepatic 
progenitor cells following specification from DE cells. The result that TGFα is 
prevalent in differentiation protocols at this stage of differentiation is in line with 
findings observed through in vivo studies. TGFα has been shown to be involved in 
the promotion of hepatic progenitor cell pool proliferation and expansion in 
cooperation with HGF upon liver injury; it’s proliferative potential has further been 
implicated in hepatocellular carcinoma through overexpression in mice models [317] 
[318] [319].  
7.1.3.3 NHR agonists 
Small molecule agonists of PXR, CAR, LXR and PPARα in the later stages of 
differentiation were found to be present in a large majority of the top 23 CombiCult® 
differentiation protocols. The LXR agonists T0901317 and GW3965, CAR agonist 
CITCO, PXR agonist SR12813 and PPARα agonist GW7647 were all found to be 
present in the top protocols.  
NHRs are known to be key factors in liver metabolism through the regulation of 
members of the CYP450 family. In this way, NHRs are involved in the regulation of 
detoxification and removal of xenobiotic compounds [320] [214]. The ability to target 
NHR induction for maturation and detoxification purposes through the utilisation of 
small bioactive molecules is therefore of interest for the use in drug toxicity screens 
[264] [321] [322]. As a result, current studies are increasingly focussed on the use of 
small molecule inhibitors/agonists of key signalling pathways through the stages of 
hepatic differentiation [235] [234] [236].  
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7.1.3.4 Fatty acids 
Additional factors present in the final stage of the CombiCult® protocols included the 
fatty acid DHA. The effects of DHA has been studied in child patients with non-
alcoholic fatty liver disease (NAFLD) and it was found to promote hepatocyte 
survival and hepatic progenitor cell activation as assessed through the comparison 
of before and after liver biopsies [323]. DHA was found in combination with small 
molecule agonists of NHRs in protocols producing the most highly expressing 
CYP1A1/A2 and CYP3A4 HLCs. Linoleic acid was also identified in a number of top 
CombiCult® protocols during early stages of differentiation. Linoleic acid is a 
proposed ligand for HNF4α [324] [212] which has been shown to be a key in the 
development of the liver [189] [190] [191].  
7.1.3.5 Hormones 
In addition to small bioactive molecules, hormones including progesterone and 
βestradiol, which have not previously been studied in the context of hepatic 
differentiation and maturation in vitro, were identified as potential avenues for further 
investigation to promote hepatic maturation. Progesterone and βestradiol were 
found to be present in 12 out of 23 of the top protocols identified through the 
CombiCult® hepatocyte screen. It is not yet clear the mechanisms by which these 
hormones promote hepatic maturation in the later stages of differentiation but it has 
been shown by Filant et al. (2012) that progesterone upregulates Hgf expression in 
the uterus of sheep and could be a mechanism for hepatic maturation [325].  
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Figure 54: Novel hepatic differentiation factors identified through CombiCult® 
New in vitro differentiation factors were identified through the four stages for hepatic 
specification and maturation utilising the CombiCult® platform. Novel factors are displayed 
below the stage of differentiation which they were found to be prevalent in producing the 
most highly expressing CYP1A1/A2 and CYP3A4 HLCs in the CombiCult® hepatic screen. 
 
7.1.4 Linoleic acid is a ligand for HNF4α 
The identification of orphan receptor ligands is important in dissecting signalling 
mechanisms and consequently identifying novel therapeutic targets with which to 
differentiate cell types of interest. Utilising small bioactive molecules in this thesis 
was aimed to induce the upregulation of key hepatic regulators at different points 
along the differentiation process to more efficiently differentiate metabolically 
relevant HLCs. In other studies it has been shown that HNF4α, a hepatic master 
regulator, plays a key role in the development of the liver [189] [190] [191] [212]. 
Jover et al. (2004) showed that HNF4α regulates a wide variety of liver specific 
factors including members of the CYP450 superfamily of metabolic enzymes 
including CYP3A4 [198].  
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However, the HNF4α ligand has remained largely elusive despite a number of 
proposed candidates including linoleic acid [324] [212]. Due to the key role played 
by HNF4α as a general regulator of members of the CYP450 family, the targeted 
activation of HNF4α can be utilised with a view to producing more metabolically 
active hepatocytes in vitro through the ability of HNF4α to upregulate xenobiotic 
drug metabolising enzymes.   
A luciferase reporter containing a HNF4α synthetic promoter made up of eight serial 
HNF4α minimal binding elements driving the expression of a minimal promoter 
allowed the quantitative analysis of linoleic acid induction of HNF4α. This was 
carried out to address the hypothesis that linoleic acid is a ligand for HNF4α [324]. 
Using this reporter system, it was shown that treatment with BSA-conjugated linoleic 
acid had the ability to upregulate HNF4α activity three-fold in HepaRG cells. This 
outcome provides further evidence that linoleic acid is a ligand for the HNF4α 
receptor and is in line with previous studies suggesting the inductive potential of 
linoleic acid [324]. Future work would be concerned with the optimal time to 
administer linoleic acid. In the CombiCult® screen and subsequent monolayer 
validation linoleic acid was only used in the first stage of differentiation but due to 
the inductive potential on HNF4α activity, the use at later stages of differentiation 
should be investigated.  
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7.2 Future Work 
7.2.1 DE Specification 
The use of lentiviral shRNA vectors driven with different viral promoters could be a 
new direction with which to knock down Nodal/Cripto in hESCs before quantitative 
analysis of DE populations. The CMV containing pGIPZ promoters could not be 
expressed in the pluripotent stem cell lines in this study but the utilisation of different 
viral promoters shown to exhibit superior expression could be addressed. Future 
work concerning the use of Nodal/Cripto overexpression conditioned media would 
primarily concerned with the further validation of the concept through quantitative 
qPCR analysis for the loss of pluripotency-associated markers including OCT4, 
SOX2 and NANOG coupled with the induction of marker sets characteristic of DE 
including SOX17, FOXA2 and CXCR4. Comparisons would be made into the 
differences in gene expression between the use of Nodal/Cripto conditioned media 
and the use of Activin A. Comparative day-on-day changes concerning suppression 
of pluripotency-associated markers coupled with analysing the robustness of DE 
specific gene expression would give a better understanding of the underlying 
signalling mechanisms. A goal of disecting the underlying signalling mechanisms 
would be the replacement of growth factors with potent agonists of the Nodal 
signalling pathway with a view to more efficiently differentiate DE cells.  
Further future DE specification approaches that could be addressed include the 
overexpression of DE inducing factors, including SOX17. Studies in mouse 
embryonal carcinoma cells, which closely mimic epiblast cells, have shown that the 
overexpression of LIM homeobox 1 (Lhx1) promotes differentiation to DE as 
assessed through the presence of the endoderm markers Sox17, FoxA2 and Gata6 
[326].  
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Interestingly, investigation by Hasegawa and Shirayoshi (2015) showed that the 
overexpression of Lhx1 did not result in the induction of markers associated with 
extra-embryonic endoderm including Sox7 and Hnf4α [326].  Other studies carried 
out in mouse pluripotent stem cells demonstrated that the overexpression of Sox17 
promoted the expression of endoderm-specific genes and differentiation towards DE 
[327]. Down regulation of Sox17 in separate studies have demonstrated the 
maintenance of pluripotency markers and the lack of differentiation potential whilst 
forced expression promotes differentiation to endoderm [328].   
In addition to the role of Nodal/Cripto in DE specification, LGR5 is a source of future 
investigation. LGR5 is a marker which was found through transcriptomic analysis to 
be strongly upregulated following six days of DE specification from pluripotent stem 
cells utilising day-on-day addition of Activin A (McKay et al. unpublished). The role 
of LGR5 is therefore of interest in the specification of DE from pluripotent stem cells 
and is a source of future study to more efficiently differentiate DE. LGR5 was first 
identified as a marker of rapidly self-renewing intestinal crypt stem cells [329] and 
subsequently found in self-renewing multipotent stem cells in the stomach [330] and 
hair follicles [331] as well as marker of endodermal progenitor (EP) cells [332]. 
LGR5 has also been shown to be a WNT signalling target so the role of LGR5 in DE 
specification is an interesting prospect [323] [333]. Further to the potential role in DE 
specification, LRG5 has been shown to be upregulated in response to liver injury in 
coordination with the onset of WNT signalling to promote the self-renewal of 
progenitor cells to repopulate damaged tissue [334]. The targeting of LRG5 is 
therefore attractive as WNT signalling is important in both DE specification and in 
hepatic differentiation.  
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The role of WNT signalling during the specification of DE could be further examined 
through the use WNT overexpression conditioned media using lentiviral constructs 
that the McKay lab have already produced.  
 
7.2.2 Hepatic Maturation 
Future investigation of the CombiCult® derived HLCs would include comparisons 
with isolated primary hepatocytes and more in-depth comparisons with HepaRG 
cells. This comparative analysis would follow the optimisation of identified hepatic 
maturation inducing factors to better assess levels of hepatic maturity between 
optimised protocols and the current best models for metabolic assays.  
Following the identification of certain factors at defined stages of differentiation 
including linoleic acid, TGFβ signalling inhibitors, TGFα, progesterone, βestradiol, 
small molecule agonists of the NHRs and CYP450 family members, different media 
permutations would be explored to identify factors that best work in synergy to 
promote hepatic specification and maturation. The utilisation of fluorescent lentiviral 
reporter cell lines produced in this thesis have given a better understanding of 
ligands for hepatic master regulators as well as a platform to determine optimum 
concentrations of small bioactive molecules with which to promote hepatic 
maturation.The use of lentiviral reporters could also be used in future investigations 
to give an accurate quantification of factors promoting the induction of critical 
regulatory processes during hepatic differentiation in vitro. These would include 
small molecule agonists including LXR agonists T0901317 and GW3965, CAR 
agonist CITCO, PXR agonist SR12813 and PPARα agonist GW7647 identified 
through the CombiCult® hepatocyte screen.  
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The use of fluorescent-luciferase reporters could be extended in future work across 
all stages of hepatic differentiation to give better insights into new, novel factors that 
are critical at key checkpoints along this process. This could include the 
incorporation of SOX17 and FOXA2 into a lentivrial reporter construct to better 
assess the effects of small molecule agonists on early in vitro DE specification. 
With the power of the CombiCult® platform to identify new and novel factors that 
promote the differentiation of pluripotent stem cells, hepatic maturation screens 
could be carried out with a much larger scope to incorporate increased numbers of 
potential maturation inducing molecules. This approach could be investigated once 
hepatic progenitor populations are established following stage 3 of differentiation. 
 
7.3 Conclusion 
The CombiCult® technology platform developed by Plasticell has successfully been 
applied to commercially produce “osteoMAX-XF” defined culture media to efficiently 
differentiate osteogenic cells from mesenchymal stem cells (MSCs), demonstrating 
the power and potential of the platform being applied to obtain cell types of interest. 
These osteogenic cells were shown to exhibit superior characteristics than 
previously available protocols. This was achieved through the identification of key 
media components that allow for efficient differentiation in the CombiCult® platform 
[335]. The use of the CombiCult® platform in this project has provided new avenues 
of investigation with new and novel hepatic differentiation/maturation inducing 
factors. Traditionally differentiation protocols have been reliant on trial and error 
experiments utilising growth factors which is both costly and time consuming.  
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Significant progress in the differentiation of pluripotent stem cells to DE and 
subsequently hepatic specification has been made but the CombiCult® platform can 
fast track the isolation of efficient differentiation protocols.  
The aim of this thesis was to investigate the production of metabolically relevant 
hepatocytes and whilst HLCs derived from this project so far haven’t produced large 
changes in CYP450 family member activity upon drug administration, advances in 
the identification of small molecules to direct differentiation have been made. There 
however remains a lack of understanding concerned with the efficient differentiation 
of DE from pluripotent stem cells from which the hepatic lineage is derived. The role 
of Nodal signalling has been well characterised in vivo and future work is ongoing 
into the precise manipulations required to more efficiently generate DE in 
comparison to the use of Activin A. There remain many avenues of investigation into 
identification of new hepatic maturation inducing factors as well as media/matrix 
combinations with which to best differentiate the most metabolically relevant 
hepatocytes. 
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